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Abstract 
 
Obesity is a highly heritable and genetically heterogeneous disorder. Reports have shown 
that the number of obese individuals will project to worldwide high levels in the next 
couple of years.  
 
In this study I tried to identify missing heritability in obesity by looking at extreme 
phenotypes that are likely to be enriched with rare variants. This will improve the power of 
their discovery by identifying the loci that may reveal more rare variants. I employed the 
strategy of using “extreme” sub-groups of obese patients to identify known and novel loci 
for obesity in the population of Saudi Arabia. Two different approaches were used. The 
first was to investigate the contribution of copy number variation (CNV) to obesity in Saudi 
adults/children that have mental retardation, dysmorphic features and obesity or morbid 
obesity: for adults, this was defined as body mass index (BMI) ≥ 30 and ≥ 40 kg.m−2 
respectively; for children, BMI respectively above the 90
th
 and 97
th
 percentiles. The second 
was to look for known and new Mendelian forms of obesity in multiplex consanguineous 
families in children that have extreme obesity (z-BMI above 97
th
 centile). 
 
Genome-wide genotyping was performed using the Affymetrix SNP 6.0 Chip platform 
(AFFYMETRIX, Santa Clara, CA) to discover novel copy number variants using 
PennCNV. I also used a whole exome sequencing in combination with the detection of runs 
of homozygosity (ROH) and linkage analysis to screen for known monogenic and possibly 
novel obesity genes in multiplex Saudi consanguineous families.  
 
Two rare obesity causing CNVs were identified from this study. The first was the known 
chromosome 16p11.2 heterozygous deletion that has been previously shown to be 
associated with obesity. The second is a novel rare homozygous CNV deletion that 
encompasses TRIB3 gene that has been previously associated with diabetes. A chromosome 
16p11.2 duplication was also found within the known chromosome 16p11.2 deletion. This 
duplication helped in narrowing down the obesity-causing region within the chromosome 
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16p11.2 deletion region. Additionally, rare CNV duplication with a size above 500kb were 
found to be slightly enriched (P=0.017) in cases versus controls.  
 
In this study we have also shown the presence of a novel homozygous missense MC4R 
mutation in combination with a heterozygous missense LPIN3 mutation within the same 
family. The carriers of MC4R mutation have developed an extreme obesity phenotype on 
the other hand the carriers of LPIN3 mutation also carried a heterozygous MC4R mutation 
and were found to be lean suggesting a reverse effect of the LPIN3 gene on the 
development of obesity. In another family a heterozygous deletion was found in a possibly 
novel obesity-causing gene CHRNA7. This gene mainly mediates fast signalling 
transmission at synapses and is found particularly in the lateral hypothalamus that regulates 
food appetite.  
 
In summary, this thesis presents multiple novel CNVs and genes that are found as 
promising obesity causing variants. It is hoped that the work from this thesis may 
contribute towards elucidation of the role of CNVs and novel genes in the development of 
obesity. 
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1 Introduction 
 
1.1 Frequency of obesity and how it became a pandemic 
 
In recent decades, obesity has reached epidemic proportions in worldwide populations [1-4]. 
Reports have shown that the number of obese individuals have been projected at a total of 
2.16 billion overweight and 1.12 billion obese by 2030 [1, 4]. Evidence has shown that the 
prevalence of obesity has increased and continues to increase in most developed and 
developing countries. This is naturally a cause of great concern [5].  
 
According to the World Health Organization, the escalating rate of obesity has shown to be 
the most significant contributor to ill health and a major risk factor for different diseases, 
including cardiovascular diseases, pulmonary diseases, metabolic diseases, osteoarticular 
diseases, several of the commonest forms of cancer and for serious psychiatric illness [6]. 
Furthermore, obesity has also been linked to the development of type 2 diabetes (T2D) in 
children [6].  
 
1.2 Morbidity and mortality of obesity 
 
Epidemiological data suggests moderate degrees of overweightness to be associated with 
adverse effects on morbidity and mortality at the population level [7]. It has also been shown 
that obesity during adolescence has important socioeconomic consequences that may affect 
an individual‟s education, marital status and household income [8].  
 
Common obesity has always been viewed as a disease caused by substantial changes in the 
human environment, e.g., an increase in consumption of calorie-rich food and a decrease in 
physical activity [4]. This is especially seen in the industrialised world, were people have 
moved from a calorie poor to a calorie rich environment [9]. The availability of low-cost and 
calorie dense food, along with an increase in sedentary life style, has played a major role in 
the rising adult obesity pandemic [9]. Despite knowing the important effects of 
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environmental factors on obesity, it will still be hard to precisely quantify these factors and 
they are likely to differ to some degree between populations [5].  
 
An evolutionary perspective on the susceptibility of human obesity was introduced by J.V. 
Neil in the 1960s [10]. The thrifty gene hypothesis claims that genes that are predisposed to 
obesity would have had a selective advantage in populations that frequently experienced 
starvation [10]. People that carry these genes in the current calorie rich environment might be 
those that overreact and as a result become extremely obese [11]. Some groups have found 
serious problems with this hypothesis, however, including that this can only be seen in 
certain high risk groups and even in areas where obesity is very common, a large number of 
people remain lean [11, 12]. These differences cannot be explained by lifestyle or economic 
or environmental factors alone, indicating the important role of genetics in the development 
of obesity. 
 
1.3 Physiological basis of obesity  
 
Obesity is caused by a complex physiological system in which the major regulating system is 
the brain. Multiple organ systems also participate in this process, such as circulating signals 
related to the size of fat mass, called adiposity signals. These signals are also integrated with 
signals coming from the gastrointestinal system, which produces satiety signals to control 
energy homeostasis [13, 14]. The hypothalamus functions as a central regulator in this system 
by allowing adiposity, gastrointestinal and satiety signals to enter the brain by receiving input 
from several endocrine hormones, e.g., leptin, ghrelin and peptide YY (PYY) [13, 14]. 
 
Information about energy balance is received through neuronal and hormonal signals that are 
mediated through the arcuate nucleus, which contains two sets of neurons: neuropeptide Y 
(NPY)/agouti-related protein (AGRP) neurons and the pro-opiomelanocortin 
(POMC)/cocaine and amphetamine related transcript (CART) neurons [14, 15]. The 
activation of NPY/AGRP neurons has an orexigenic effect, promoting food intake. On the 
other hand, POMC/CART neurons are seen to have an anorexigenic effect, i.e., decreasing 
food intake. Peripheral endocrine signals exert their effect through long-term and short-term 
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time frames [14, 15]. Insulin has an anorexigenic effect by stimulating the POMC/CART 
neurons and inhibiting the activation of NPY/AGRP neurons [15]. It mainly plays a role in 
the central nervous system as a signal of adiposity over moderate and long time periods. 
Another hormone that has an anorexigenic effect is leptin [16]. Its secretion is proportional to 
adipose tissue stores and it is involved in long-term regulation of adiposity. One of the short-
term regulators of appetite is ghrelin [15]. It is produced in the stomach and duodenum and is 
seen to have an inhibitory effect on the POMC/CART neurons. Ghrelin shows a rise in serum 
levels prior to eating and a decrease after eating. Another mediator is peptide YY, secreted 
from the distal gastrointestinal and has an inhibitory effect on NPY/AGRP neurons, leading 
to a decrease in food intake [15] (Figure 1-1).  
 
The anorexigenic and orexigenic signals are then sent to second order downstream effector 
neurons, which include melanin-concentrating hormone (MCH) and orexin neurons; these 
will also receive modifying inputs from dopamine, serotonin and endocannabinoid signals 
[17]. These effector neurons include Y1 receptor (Y1R) and melanocortin 4 receptor (MC4R) 
[17]. These various inputs will provide the overall balance between food intake and energy 
expenditure.  
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Figure 1-1 The physiological regulation of energy balance. This figure shows a schematic 
summary of the central pathways involved in appetite regulation. Both long-term and short-
term signals from the periphery act on the central nervous system to influence feeding 
behaviour that is mainly regulated by the arcuate nucleus. Two subsets of neurons control 
food intake. The neuropeptide Y (NPY)/agouti-related protein (AGRP) neurons that stimulate 
food intake and pro-opiomelanocortin (POMC)/cocaine and amphetamine related transcript 
(CART) neurons that suppress food intake. Typically, when one of these subsets is activated 
the other is inhibited. These neurons are also responsible for circulating hunger and satiety 
signals such as ghrelin and PYY. They are also signals of long-term energy stores such as 
leptin and insulin.  
Source: Froguel et al. Nature Reveiws Genetics 6,221-234 (2005) 
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1.4 Environmental Factors 
 
There is unequivocal evidence that both heredity and environmental factors are important in 
determining the extent of adiposity in contributing to the obesity phenotype [6, 18] . During 
the last two decades, an overt change in lifestyle and other environmental factors have 
contributed to the phenomenal increase in the prevalence of obesity in developed and many 
developing countries [19, 20]. A decline in physical activity and an abundance of cheap and 
fat-rich foods have been regarded as the two major components of the obesogenic 
environment mainly held responsible for the recent obesity pandemic. In addition, the risk 
factors for development of obesity include age, gender, and ethnicity, amongst others [21]. 
Age-dependent modulation of obesity has been demonstrated both in monogenic and 
polygenic forms. Studies on MC4R mutation carriers indicate an increasing age-dependent 
penetrance (a 23% increase in 40 years) [22]. Several studies show that women are at greater 
risk of developing excessive obesity compared to men [23, 24]. This gender difference has 
been attributed to „female-specific‟ genetic make-up and possibly a stronger effect of genetic 
variants predisposing females rather than males to obesity as demonstrated in monogenic 
MC4R mutation carriers [18, 22]. A differential susceptibility to the obesogenic environment 
has been demonstrated in different ethnic populations [25, 26]. Pima Indians, Pacific 
Islanders and African-and-Hispanic-Americans are more prone to obesity than their 
Caucasian counterparts when living under similar obesogenic conditions [24, 27]. This ethnic 
discrepancy has been partly explained by the controversial „thrifty genes‟ hypothesis, 
postulating that genetic variants predisposing to obesity had had a selective advantage in the 
evolutionary history of populations that frequently experienced famine and starvation [28, 
29]. More recently, though it remains incomplete, evidence has accumulated pointing out that 
the infection by microorganisms, exposure to some pharmaceutical agents, endocrine 
disruptors, sleep deficits and socio-economic and educational levels may also prove to be 
significant contributors to the obesity pandemic [21]. Environmental factors have also been 
shown to influence epigenetic mechanisms, especially during early development; thus, a 
change in the epigenetic regulation of obesity genes could result in obesity [6]. Unlike 
common obesity, monogenic obesity – especially when due to pathogenic mutations 
disrupting the leptin melanocortin pathway – is minimally affected by environmental factors. 
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However, recent evidence indicates that development of obesity, even in those strongly 
genetically predisposed to it, may be affected by the obesogenic environment [22]. 
 
1.5 Heritability of obesity 
 
The pathogenicity of obesity is complex and involves multiple interactions between 
behavioural, environmental, and genetic factors [30, 31]. There is continuing evidence that 
there exists a genetic component that plays an important role in the development of obesity. 
Twin studies of human obesity have shown that the heritability of body mass index (BMI) is 
between 0.5 to 0.8 [32]. It was also shown that the concordance rate between monozygotic 
twin pairs is more than twice that of dizygotic pairs (0.68 vs. 0.28) [33]. The high 
heritability of different obesity measures, e.g., waist circumference and subscapular skinfold 
thickness, highlights that genetics may increase the risk of obesity [34]. Despite exposure to 
an obesogenic environment and its role in the development of obesity, studies have shown 
that this effect is modest, and that obesity is predominantly genetic [34, 35].  
 
1.6  Genetic basis of obesity 
 
In this section, I will provide an overview of monogenic and syndromic forms of obesity. I 
will also have a description of the genetic contribution to complex polygenic obesity, i.e., 
“common obesity”, which is caused by the interaction of multiple genes and the environment.  
 
1.6.1 Monogenic obesity 
 
Monogenic obesity is a term that refers to any number of rare forms of obesity that results 
from mutations of large effect size in an individual or chromosomal gene [36]. Human single 
genetic defects that have led to severe obesity with the absence of developmental delays were 
first described in the mid-1990s [37]. These rare cases of monogenic obesity provided the 
first direct evidence that genetic factors play a considerable role in body weight regulation, 
with initial studies carried out in rodent models.  
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1.6.1.1 Leptin and leptin receptor 
 
In the 1950s, the ob/ob mutant mouse strain was described to exhibit excess adipose tissue 
along with impaired reproductive behaviour and weighing three times more than a normal 
mouse [38]. In 1994, the mutation responsible for positional cloning was used to identify and 
characterise the gene that was mapped to the leptin gene (LEP), and later in its receptor in 
1995 and 1996 [16, 39-41]. Leptin is a hormone produced and secreted by the white 
adipocytes, while its receptor is expressed in the hypothalamus. LEP is also secreted in a 
smaller concentration in other tissues, including brown adipocytes, stomach, placenta, 
skeletal muscles and ovaries [42-45]. It plays a major role for rodents and humans in the 
regulation of food intake, energy balance and body weight [46].  
 
Leptin (LEP) and leptin receptor (LEPR) mutations were both first discovered in 
consanguineous families [37, 47-50], which has led to a deeper understanding of appetite 
control [1, 4, 37, 47, 48, 50, 51]. The mutations in LEP genes were found to include 
homozygous reading frame shift, missense mutations and polymorphisms, which has been 
associated with obesity [37, 47-49, 52-56]. Mode of inheritance for both LEP and LEPR 
genes are found to be autosomal recessive. Some of the associated phenotypes with LEP 
mutations are severe early-onset obesity, extreme hyperphagia, hyperinsulinaemia, 
hypothalamic hypothyroidism, and hypogonadotropic hypogonadism. To date, there are up to 
25 individuals carrying homozygous mutations in the LEP gene that have resulted in 
undetectable levels of blood leptin [37, 47-49, 52-56].  
 
In addition to LEP gene mutations, LEPR homozygous mutations resulting in the skipping of 
exon 16, which produces a truncated protein lacking both the transmembrane and the 
intracellular domains, has shown severe obesity with hyperphagia, delayed or absent puberty, 
reduced insulin-like growth factor levels and growth abnormalities [50, 57, 58]. 
Polymorphisms in LEPR genes have also shown to be associated with obesity in Caucasians 
[59]. It is now clear that obesity is a neuroendocrine disorder in which environmental factors 
and genetic predisposition both have an effect on the development of the disease [60, 61].  
Chapter One: Introduction 
34 
 
1.6.1.2 Leptin-melanocortin pathway genes 
 
Following the studies mentioned above, evidence has revealed the anorectic effects of leptin 
and the integral role of the leptinergic-melanocortinergic pathway on energy homeostasis and 
body weight regulation. Extensive studies have revealed mutations in other genes of the 
leptinergic-melanocortinergic pathway causing monogenic obesity [61-64].  
 
One of these genes is pro-opiomelanocortin (POMC). It is mainly expressed in the arcuate 
nucleus of the hypothalamus and positively regulated by leptin [65]. POMC mainly plays a 
role in feeding behaviour [65]. POMC gene product is cleaved to produce the melanocortin 4 
receptor (MC4R) ligand alpha-melanocyte stimulating hormone (α-MSH) and thus plays a 
role as an integral signal propagator of the leptinergic-melanocortinergic pathway [66]. A 
frame shift mutation in the POMC has been reported to cause a loss of function, associated 
with early-onset obesity, coupled with adrenal insufficiency and red hair pigmentation in 
affected individuals; the mode inheritance in this gene was found to be autosomal recessive 
[65, 67, 68].  
 
Furthermore, a compound heterozygous mutation that causes early-onset obesity has been 
found in the PCSK1 gene, which encodes prohormone convertase 1 (PC1), which is a key 
component in the proteolytic processing of POMC [69, 70] and found to be inherited in an 
autosomal recessive mode. Common nonsynonymous variants in PCSK1 have also been 
shown to increase the risk of development of obesity [71]. Biomedical studies conducted on 
carriers of PCSK1 mutations have shown a reduction of almost 10% in PC1 enzyme secretion 
leading to monogenic early-onset obesity and hyperphagia [69, 72, 73].  
 
The melanocortin receptor (MCR4) plays a role in appetite suppression by controlling leptin 
effects on food intake and body weight. Emanating from the leptin pathway, MC4R is 
believed to produce anorexigenic signals through the paraventricular nucleus of the 
hypothalamus to downstream affecters. Both homozygous and heterozygous mutations in 
MC4R genes have resulted in monogenic obesity [74-77]. Mutations in MC4R genes are the 
most common monogenic disorder resulting in morbid obesity and are thought to account for 
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about 2% of extremely obese adults, and 3-6% of severely obese children [22, 76]. These 
conditions might be inherited in both autosomal dominant or recessive modes.  
One of the effectors of MC4R thought to act both upstream and downstream is SIM1 
homologue of Drosophila melanogaster single-minded (sim), a helix-loop-helix-PAS domain 
transcription factor [78]. It plays an essential role in embryonic neurogenesis and is also 
believed to contribute to maintenance of energy homeostasis [78]. In mice, SIM1 
heterozygosity has led to the development of early-onset obesity, increased linear growth, 
hyperinsulinaemia and hyperleptinemia [79, 80]. Loss-of-function mutations in humans have 
also been shown to result in severe hyperphagia obesity, early-onset obesity, hypotonia, 
developmental delays and short extremities [81, 82].  
 
1.6.2 Syndromic forms of obesity 
 
The above data has shown that the study of genetic syndromes of obesity both in humans and 
mice have provided insight into the underlying mechanisms involved in energy homeostasis 
with the identification of candidate loci. In recent years, there has been an extensive amount 
of studies to identify disorders in energy balance found in humans.  
 
There are more than 20 rare syndromes associated with obesity [83]. These disorders are 
either caused by discrete genetic defects or chromosomal abnormalities. Most of these 
disorders have the presence of mental retardation (MR) associated with them. In this section I 
will talk about a couple of syndromes that are associated with obesity.  
 
Recently, there have been significant advances in the identification and characterisation of 
the genes implicated in these syndromes, which has led to the revelation of interesting gene 
pathways involved in these syndrome pathways that may lead to obesity; for example, in 
Prader-Willi syndrome (PWS), which is caused by the lack of expression of imprinted genes 
on chromosome 15q11q13 and which are usually expressed in the paternal inherited 
chromosome [84]. There is strong evidence that the C/D box small nucleolar RNA (snoRNA) 
SNORD116 cluster (HBII-85) is the major component of this disease phenotype, which 
includes infantile hypotonia, early-onset morbid obesity and hypogonadism [85]. In Bardet-
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Biedl syndrome (BBS), a human genetic disorder associated with ciliary dysfunction and 
obesity 15 BBS genes (BBS1-BBS15) has been identified and account for 80% of the known 
cases of BBS [86]. In particular, the BBS1 gene has been found to be essential for leptin 
receptor signalling in the hypothalamus; the loss of leptin actions in POMC neurons due to 
defective leptin receptor signalling leads to the development of obesity [86]. In the case of 
Alstrom (ALS) and Carpenter (or acrocephalopolysyndactyly type II) syndrome, two unique 
genes have been found to be the cause of the development of these syndrome, namely ALMS1 
and RAB23 genes, respectively [87, 88]. ALMS1 gene is highly expressed in the brain and it is 
believed that loss of function in this gene may lead to alterations in behaviour and energy 
homeostasis through abnormal effects on appetite and satiety signals [87]. On the other hand, 
the RAB23 gene functions in different ciliary trafficking pathways with no evidence found 
regarding its association with obesity [89]. 
 
Several other chromosomal syndromes with obesity are found, especially chromosomal 
deletions. In these syndromes, obesity is usually developed, but not in all carriers. This may 
suggest that penetrance or variable expression levels may be required for the development of 
obesity. Examples of these syndromes include 1p36 (monosomy 1p36 syndrome), 2q37 
(brachydactyly mental retardation syndrome; BDMR), 6q16 (PWS-like syndrome), 9q34 
(Kleefstra syndrome), 11p13 (WAGR syndrome) and 17p11.2 (Smith- Magenis syndrome; 
SMS) [90]. It is believed that in these syndromes, haploinsufficiency in certain genes is likely 
to be responsible for the specific phenotypes [90]. Sequencing of genes in these regions has 
shown promising results, as seen in HDAC4 (2q37), EHMT1 (9q34) and RAI1 (17p11.2) [91-
95]. In the case of obesity, known candidate genes for obesity have been identified in critical 
map intervals (e.g., SIM1 (6q16), BDNF (11p13)) [96-98]. Genomic regions known to result 
from copy number variations (CNVs) and that are associated with obesity are presented in 
Table 1-1. 
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Table 1-1 Genomic regions encompassing genes involved in the development of obesity 
and developmental delay/intellectual disability. 
Chr Loci Gene Phenotype  OMIM 
chr1 1p36 GABRD Chromosome 1p36 
deletion syndrome 
607872 
chr2 2q37 HDAC4 BDMR syndrome 600430 
chr6 6q16 SIM1 Obesity, severe 603128 
chr9 9q34 EHMT1 Kleefstra syndrome 610253 
chr11 11p13 WT1, PAX6 WAGR syndrome 194072 
chr15 15q11.2 NDN, SNRPN Prader-Willi 
syndrome 
176270 
chr16 16p11.2 SH2B1 Chromosome 16p11.2 
deletion syndrome , 
220 kb 
613444 
chr16 16p11.2 TBX6 Chromosome 16p11.2 
deletion syndrome, 
593 kb 
611913 
chr17 17p11.2 RAI1 Smith-Magenis 
syndrome 
182290 
chr1 1p21.3 DPYD, MIR137 Deletions associated 
with intellectual 
disability and 
(tendency) to 
overweight 
[99] 
chr2 2p25.3 MYT1L Deletions associated 
with intellectual 
disability and 
obesity/overweight 
[100] 
chr6 6q14q15 HTR1E, ME1, 
CYB5R4, SNX14 
Deletions Associated 
with developmental 
delay, obesity, and a 
distinct clinical 
[101] 
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Chr Loci Gene Phenotype  OMIM 
phenotype 
chr6 6q22 VGLL2 Less penetrant locus 
for a PWS-like 
phenotype 
[102] 
chr11 11p14.1 BDNF Deletions associated 
with ADHD, 
developmental delay, 
autism, and obesity 
[103] 
chr19 19q12q13.2 AKT2, CEACAM1, 
CEBPA, LIPE, 
TGFB1 
Duplications 
described in patients 
with developmental 
delay and obesity 
[104] 
   Table reproduced from Koiffmann et al., 2012, using build 36. 
 
1.6.3 Polygenic obesity 
 
Polygenic obesity is the common form of obesity that results from the combined action of 
multiple alleles of more than one gene in combination with environmental risk factors. Each 
single variant produces a small to moderate effect. Different genetic approaches have been 
used to identify obesity susceptible loci. In this section I will present some of them.  
  
1.6.3.1 Linkage analysis 
 
Genome-wide linkage analysis is a method used to identify regions of the genome that 
contain genes that are predisposed to disease. These methods usually involve the typing of 
related individuals (families) using polymorphic markers that are evenly distributed across 
the genome, followed by the calculation of the degree of linkage of the marker to the disease 
trait [11].  
 
Chapter One: Introduction 
39 
 
Genome-wide linkage studies on more common forms of obesity have taken place in several 
different populations and have contributed to the identification of several key susceptible loci 
across the genome; however, the genes within the loci have generally remain elusive. Over 
30 genome-wide linkage scans of body mass index (BMI) and obesity have been published, 
with positive linkage results reported and summarised in “The Human Genome Map” [105]; 
nonetheless, little consistent replication of these loci in other populations has been observed 
[83]. In meta-analysis of 37 genome-wide linkage scans, only a few loci showed significant 
evidence of linkage in the 13q13.2-13q33.1 and 12q23-12q24.3, as well as at the 16q12.2 
regions that encompasses FTO, an obesity associated gene [106]. There are also a couple of 
more loci that showed linkage to BMI and /or obesity and were replicated in multiple studies. 
One of the important discoveries was found in Mexican-Americans, where connections were 
made to plasma leptin levels in extended pedigrees to chromosome 2p21, with a logarithm of 
the odds (LOD) score of 4.9 [107]. This result was also replicated in the French sib pair 
analysis [108], as well as in an African-American study [109]. This region encompasses 
POMC genes, in which mutations cause rare monogenic obesity in humans [68]. Other loci 
showing a link to BMI and obesity, and that have been replicated in multiple studies, include 
the following regions: 1p36 [110, 111], 2q14 [110, 112], 3q27 [113, 114], 6q21-6q23 [115, 
116], 7q31-7q32 [117, 118], 10p11-10p12 [108, 119], 11q14-11q24 [120, 121] and 20q11-
20q13 [122, 123]. 
 
 
1.6.3.2 Candidate gene studies 
 
Candidate gene studies look for variants in genes already implicated in rarer, monogenic 
forms of obesity. Limited success has been achieved in identifying genetic determinants of 
obesity due to the reliance on suspected obesity-causing genes that were identified according 
to a biological hypothesis on the pathogenesis of obesity [124].  
 
Almost 127 candidate genes are reported to be associated with obesity-related phenotypes, 
but only a fraction of these genes have been replicated in populations [83]. The most widely 
replicated obesity and BMI candidate genes are those encoding leptin and leptin receptors, 
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and have been shown to be associated with BMI and obesity in several populations [125-
128]. Another gene that is highly replicated in other populations is the Pro12Ala substitution 
in the peroxisome proliferator-activated receptor gamma (PPARϒ), which has been 
associated with obesity [129] and T2D [130]. In addition to the two above genes, other 
candidate genes associated with obesity and BMI like MC4R [131], brain derived neurotophic 
factor gene (BDNF) [132], PCSK1 [71] and β-adrenergic receptor 3 gene (ADRB3) [133] 
have also been shown to be replicable in other studies. However, candidate gene study results 
have shown conflicting results, which could be due to the differences in study power, sample 
size, patient recruitment, phenotyping and inclusion criteria [134].  
 
These studies support the conclusion that obesity is a complex disease that is influenced by 
many genes that have small effect size; thus, there is a need for a hypothesis free genome-
+wide approach [124].  
 
1.6.4 Genome-wide association studies 
 
Genome-wide association study (GWAS) is a hypothesis-free approach for investigating the 
association between common genetic variations and the disease in question [4]. It has 
provided valuable contributions in the area of genetics of obesity by effectively identifying 
several putative genetic loci associated with the common polygenic form of obesity.  
 
This methodology has been facilitated by recent advances in genetic knowledge of human 
variations and linkage disequilibrium (LD) patterns of single nucleotide polymorphisms 
(SNPs), coupled with improvements in genotyping technology that has made fast, efficient 
and cost-effective whole genome genotyping a possibility [135]. Typically in GWAS, the 
genome is scanned at high resolutions using several hundred thousand to over a million SNPs 
to assess for associations between common variants and disease or related traits. 
Subsequently, replication is sought in additional independent datasets to confirm these 
associations. To overcome the burden of elevated type 1 errors or false positives, significant 
associations are stringently determined only when association levels of SNPs reach genome-
wide levels of significance (p-value < 5x10
-8
) [135, 136].  
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The insulin-induced gene 2 (INSIG2) was the first obesity locus detected using GWAS [137]; 
however, attempts to replicate this in independent datasets have been inconsistent [138-142]. 
FTO was the first locus incontrovertibly associated with obesity through an initial GWAS 
study for T2D [143]. In this study, variants at the intron 1 of the FTO gene lost their 
associations with T2D when study participants‟ BMI was taken into consideration, implying 
that the associations detected were mediated through obesity. The associations of FTO with 
BMI and risk for obesity have been independently identified by other large-scale studies 
[139, 144]. 
 
A major finding from the discovery of FTO (even more for subsequent loci) was that the 
effect sizes of common variants associated with polygenic obesity were modest. This has 
prompted collaborative efforts to increase samples sizes and power in studies through meta-
analyses. These efforts have successfully identified as many as 32 loci for BMI associations 
and 14 others for central obesity measures that are independent of overall obesity. Genetic 
markers associated with obesity identified through GWAS are summarised in (Table 1-2). 
 
A main contribution of GWAS is in hypothesis generation and putative genes identified have 
shed novel insight on disease aetiology, although additional studies would be necessary to 
prove and determine mechanistic roles [145]. Several of the loci detected for BMI or overall 
obesity indicate the prominent role of the hypothalamus. Furthermore, at least three loci 
detected (MC4R, BDNF and POMC) characterised functions in the hypothalamic control of 
energy homeostasis and severe mutations resulting in monogenic forms of obesity [30, 62, 
64]. These findings highlight that overall obesity may also be a disorder of the central 
nervous system rather than a peripheral energy storage problem [146]. Conversely, most loci 
detected for central obesity measures point to a more prominent role in the distribution of fat 
in the body [34, 147].  
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Table 1-2 Details of 32 BMI and 14 waist-hip ratio (WHR) loci detected from recent 
GWAS scans.  
Implicated genes and 
position 
Associated 
Variant 
Per allele 
increase in BMI 
(kg/m2) or WHR 
Risk allele 
frequency in 
Europeans 
(%) 
Putative function related 
to obesity 
Loci associated with 
BMI  
    
FTO (16q22.2) rs1558902 0.39 42 Neuronal function possibly 
associated with appetite 
control. 
Near MC4R (18q22) rs571312 0.23 24 Hypothalamic signalling, rare 
mutations cause monogenic 
obesity 
Near TMEM18 (2p25) rs2867125 0.31 83 Neural development, highly 
expressed at the 
hypothalamus 
Near GNPDA2 (4p13) rs10938397 0.18 43 Highly expressed at the 
hypothalamus 
SH2B18 (16q11.2) rs7359397 0.15 40 SH2B1 involved in neuronal 
control of energy 
homeostasis, leptin release 
Near NEGR1 (1p31) rs2815752 0.13 61 Growth promoter involved 
with neuronal outgrowth 
MTCH2-NDUFS3-
CUGBP1 (11p11.2) 
rs3817334 0.06 41 MTCH2 involved in cellular 
apoptosis, highly expressed at 
the hypothalamus 
Near KCTD15 (19q13.11) rs29941 0.06 67 Highly expressed at the 
hypothalamus 
SEC16B (1q25) rs543874 0.22 19 - 
BDNF (11p14) rs10767664 0.19 78 Neuronal appetite control, 
BDNF deletions involved 
with WAGR syndrome 
characterised by hyperphagia 
and severe obesity. 
Near ETV5 (3q27) rs9816226 0.14 82 Highly expressed at the 
hypothalamus 
SLC39A8 (4q24) rs13107325 0.19 7 - 
Near PRKD1 (14q12) rs11847697 0.17 4 - 
Near GPRC5B-IQCK 
(16q12.3) 
rs12444979 0.17 87 - 
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Implicated genes and 
position 
Associated 
Variant 
Per allele 
increase in BMI 
(kg/m2) or WHR 
Risk allele 
frequency in 
Europeans 
(%) 
Putative function related 
to obesity 
QPCTL-GIPR (19q13.32) rs2287019 0.15 80 GIPR encodes incretin 
receptor 
Near RBJ-POMC-ADCY3 
(2p23.3) 
rs713586 0.14 47 POMC involved in 
hypothalamic signalling, 
Rare mutations cause 
monogenic obesity. 
TFAP2B (6p12) rs987237 0.13 18 - 
MAP2K5-SKOR1 (15q23) rs2241423 0.13 78 - 
NRXN3 (14q31) rs10150332 0.13 21 Possible neuronal reward 
system control 
FAIM2 (12q13) rs7138803 0.12 38 Adipocyte apoptosis, highly 
expressed at the 
hypothalamus 
LRRN6C (9q21.3) rs10968576 0.11 31 - 
Near FLJ35779-HMGCR 
(5q13.3) 
rs2112347 0.1 63 - 
Near FANCL (2p16.1) rs887912 0.1 29 - 
CADM2 (3p21.1) rs13078807 0.1 20 - 
Near TMEM160-ZC3H4 
(19q13.32) 
rs3810291 0.09 67 - 
Near LRP1B (2q22.2) rs2890652 0.09 18 - 
MTIF3-GTF3A (13q12.2) rs4771122 0.09 24 - 
TNNI3K (1p31.1) rs1514175 0.07 43 - 
Near ZNF608 (5q23.2) rs4836133 0.07 48 - 
Near PTBP2 (1p21.3) rs1555543 0.06 59 - 
Near RPL27A-TUB 
(11p15.4) 
rs4929949 0.06 52 TUB involved in 
sensorineural regulation 
NUDT3-HMGA1 
(6p21.31) 
rs206936 0.06 21  
Loci associated with 
WHR, independent of 
BMI 
    
RSPO3 (6q22.33) rs9491696 0.05 52 Vascular development 
Near NFE2L3 (7p15.2) rs1055144 0.04 21 - 
Near VEGFA (6p21.1) rs6905288 0.04 56 Vascular development, key 
mediator of adipogenesis 
Near GRB14 (2q24.3) rs10195252 0.04 60 Associated with insulin and 
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Implicated genes and 
position 
Associated 
Variant 
Per allele 
increase in BMI 
(kg/m2) or WHR 
Risk allele 
frequency in 
Europeans 
(%) 
Putative function related 
to obesity 
triglyceride levels 
TBX15-WARS2 (1p12) rs984222 0.03 37 Transcription factor involved 
in adipocyte and specific 
adipose depot development 
 
NISCH-STAB1 (3p22.1) rs6784615 0.03 94 Interacts with insulin receptor 
substrate 
Near LYPLAL1 (1q41) rs4846567 0.03 28 Encodes protein believed to 
act as a triglyceride lipase 
and is up-regulated in 
subcutaneous adipose tissue 
Near ITPR2-SSPN 
(12p21.1) 
rs718314 0.03 74 - 
Near HOXC13 (12q13.13) rs1443512 0.03 24 Transcription factor involved 
in cell spatial distribution in 
embryonic development 
Near LY86 (6p25.1) rs1294421 0.03 39 Lipopolysaccharide 
recognition molecule 
Near ADAMTS9 (3p14.1) rs6795735 0.03 41 Involved in cell spatial 
distribution in embryonic 
development 
DNM3-PIGC (1q24.3) rs1011731 0.03 57 Involved in glucose 
transporter expression in 
adipocytes 
ZNRF3-KREMEN1 
(22q12.1) 
rs4823006 0.02 57 - 
CPEB4 (5q35.2) rs6861681 0.02 34 Regulates polyadenylation 
regulation 
 
 
1.7 The role of copy number variation in the development of obesity 
 
There has recently been a paradigm shift in complex disease genetics, with the realisation 
that, in contrast to the previous view that common diseases are only the result of common 
variants of relatively mild effects, some common disorders may also be caused by the action 
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of a collection of highly-penetrant variants. Increasing power through large scale meta-
analysis [1, 3, 4] may improve the situation somewhat, but it is now essential to consider 
alternative types of genetic markers (such as copy number variants, known as CNVs) and 
different research strategies, including the investigation of populations with high levels of 
consanguinity and complex extreme phenotypes in order to progress obesity research. In this 
thesis, one of my aims is to investigate CNVs in the genomes of apparently obese individuals 
to search for copy number aberrations that may underlie the obesity and MR phenotypes seen 
in patients with suspected genomic disorders, which might also play a role in common 
obesity.  
 
In this section, I will first present a definition of what CNVs are, describe CNV formation, 
address CNVs and their contribution to disease and present methods for CNV detection. I 
will also show how CNVs play a role in the development of obesity. 
 
1.7.1 Copy number variation in the human genome 
 
CNVs are deoxyribonucleic acid (DNA) segments of 1kb or larger, the copy numbers of 
which vary among different alleles [148]. CNVs can also be termed as deletions, insertions, 
duplications and complex multi-site variants found in all humans [148]. The scientific 
community has recently become aware of these variants, their abundance and effect on all 
chromosomal domains found either in coding or non-coding regions [149]. Several genome 
studies have shown that CNVs are the predominant class of genomic variation in the genome 
that causes greater sequence diversity between two genomes [150]. This consists of 
inversions and chromosomal translocations, as well as losses or gains of DNA sequence 
relative to the human reference sequence (Figure 1-2). A present population studies have 
shown that CNVs with a size of 500kb occur in 5-10% of the population [151]. 1-2% Of this 
population possess one or more CNVs with a size of about 1Mb or larger [151]. It has also 
been found that that there is a significant relationship between the genomic regions affected 
by CNVs and gene content, with the exonic density of the most CNV-rich regions of the 
genome being over 2.7% [152]. A later study also suggested that 60% of 3,552 CNVs are 
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likely to affect protein-coding genes [153]. This suggests that CNVs can be involved in the 
development of genetic disorders [149]. 
 
In 1992, a new technique was developed to detect the amplification of genes that were known 
to occur in cancer cells. This technique is called comparative genomic hybridisation (CGH) 
and is adapted from the technology of fluorescence in situ hybridisation (FISH). It is 
designed for copy number comparison of differentially labelled test and reference DNAs 
using competitive hybridisation onto metaphase spreads from a healthy individual [154]. This 
technique allowed the detection of increasingly small chromosomal aberrations at the 
genome-wide level [155, 156].  
 
Two landmark studies published in 2004 that used high-resolution genome-wide scanning 
nature of array CGH led to the identification of widespread copy number variation in the 
human genome [155, 156]. In these studies, different microarray technologies were used to 
search for CNVs. Iafrate et al. (2004) used bacterial artificial chromosome (BAC) array 
CGH, while Sebat et al. (2004) used ROMA to identify 255 variant loci in 39 healthy 
individuals and 76 CNVs in 20 individuals, respectively [155, 156]. Both studies confirmed 
that the CNVs detected overlapped genes [155, 156]. A database was also developed by 
Iafrate et al. in 2004 to catalogue these genomic variants and is called the Database of 
Genomic Variants (DGV); it is run by The Centre for Applied Genomics (TCAG) 
(http://dgv.tcag.ca/dgv/app/home) [155].  
 
In 2005 Sharp, et al. used a custom-designed microarray that consisted of about 2000 BAC 
probes that targeted 130 potential rearrangement hotspots in the genome [157]. One hundred 
and sixty variants were identified within 47 individuals tested [157]. Following this, in 2006 
Conrad, et al. used apparent errors in Mendelian inheritance from parent-offspring trio data to 
identify 586 deletions [158]. On the other hand, McCarroll, et al. looked for genotyping 
errors such as SNPs not present in the Hardy-Weinberg equilibrium (HWE) and found 541 
deletion variants[159]. Additionally, in 2006, a systemic large-scale genome-wide CNV 
discovery study using SNP genotyping data from 270 HapMap samples was analysed [160]. 
Redon et al. (2006) used both Affymetrix 500k SNP arrays and array CGH with whole-
genome tiling BAC arrays, with ~27,000 probes representing 93.7% of the euchromatic 
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portion of the human genome, to interrogate 270 individuals from the HapMap population 
[160]. They found a total of >1,400 CNV regions (CNVRs), covering 12% (~360Mb) of the 
genome, with a median CNV size of 81kb and 228kb for the SNP and BAC arrays, 
respectively [160]. They also described the varying structure and complexity of CNVs, 
finding both simple CNV deletions/duplications, as well as more complex, sometimes multi-
allelic loci with overlapping boundaries [160]. 
 
Higher-resolution CNV discovery studies were later conducted in 2007-2008 using high-
resolution array platforms that provided a more refined genome-wide map of copy number 
variation. Two studies were conducted one by de Smith et al. using a 244,000 probe 
oligonucleotide aCGH array and the other by McCarroll et al. using an Affymetrix 6.0 SNP 
genome-wide array [161, 162]. Other studies that examined genome-wide sequencing data 
were also conducted to enable CNV analysis at the nucleotide level. Firstly, developments in 
this field was made possible with the development of paired-end (PE) mapping [163, 164], 
and subsequently with second generation sequencing methods, which have now enabled 
further elucidation of the extent of copy number variation in the human genome. Several 
human genomes were sequenced, including those of James Watson [165] and Craig Venter 
[166], and a vast number of CNVs and indels have been identified across these samples. 
These studies provided a substantially smaller estimate of mean CNV size of under 10kb. 
This shifted the initial estimation of CNV proportion in the genome from 12% as reported by 
Redon et al. in 2006 [160] to approximately 5%.  
 
An important study published by Conrad et al., in 2010, remains the highest resolution 
genome-wide human copy number variation detection study [167]. At this time, the 
progression of microarray technology with genomic resolutions of ~50bp had become 
possible. Conrad et al. reported an accurate determination of copy number variation in 41 
European HapMap samples, using 20 NimbleGen arrays containing more than 2 million 
oligonucleotide probes each. Over 8,000 independently validated variants were identified in 
total, at a median size of 3.5kb and overlapping ~3.7% of the genome [167]. 
 
Recently, and as part of the 1000 Genome Project Consortium, 185 whole sequences were 
used for the analysis of structural variants in whole genome sequencing data [168]. The 
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average coverage of the sequencing data was 3.6x [168]. Over 20,000 deletion and 6,000 
structural variants were detected with the majority of them previously unsubscribed [168]. 
From this analysis, it can be seen that high frequency deletions are generally biased away 
from genes. From this study, a reduction of the CNV median size was further reduced to 
729bp, compared to the previous studies [168].  
 
Table 1-3 is a summary of the selection of studies mentioned in this section.    
 
 
 
 
Figure 1-2 Different states of the copy number variant gene. This figure represents 
different copy number states of a gene (green box) on two homologous chromosomes 
showing: a. State=2 two copies „normal‟, b. State=1 one copy loss „heterozygous deletion‟, b. 
State=0 two copy loss „homozygous deletion‟, State=3 one copy gain „heterozygous 
duplication‟ and State=4 three copy gain. 
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Table 1-3 A selection of CNV studies published up to date. 
 
 
Study 
 
 
Year 
 
 
Number of 
samples 
 
 
 
DNA source 
 
 
Methodology 
 
 
Number 
of CNVRs 
(including 
indels) 
 
Mills, et al. 
 
2006 36 LCLs Computational analysis of 
DNA resequencing traces 
  
415,436 
Redon, et al. 2006 270 LCLs SNP array and BAC array 
 
1447 
Korbel, et 
al. 
2007 2 LCLs Paired-end mapping 
 
1175 
Levy, et al. 2007 1 Blood Sanger sequencing followed 
by comparison with human 
reference sequence 
 
6576  
Kidd, et al. 2008 8 LCLs Fosmid paired-end 
sequencing 
 
1471 
Wheeler, et 
al. 
2008 1 Blood Second generation 
sequencing (454), followed 
by comparison with human 
reference sequence 
 
222,718  
Conrad, et 
al. 
2010 40 LCLs Oligo array CGH 
 
8599 
Mills, et al. 2011 185 Blood 
 
Next generation 
sequencing and validation 
using aCGH , PCR and 
SNP microarrays 
6000 
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1.7.2 Mechanism of CNV formation 
 
CNVs may have arisen in the genome in a number of ways, and variation in the structure and 
complexity of CNVs may be a reflection of their mechanisms of formation. Multi-allelic, 
complex CNVs and regions at which both duplications and deletions occur have a greater 
enrichment for segmental duplications than more simple CNVs, suggesting these are more 
likely to occur via non-allelic homologous recombination (NAHR) [160]. The complexity 
and variation in the structure of CNVs may also reflect the presence of CNVs of different 
ages in the genome [160]. For example, CNVs that have conserved boundaries across 
multiple individuals may be ancient mutational events that have occurred only once and may 
be formed by double-stranded DNA break repair mechanisms such as non-homologous end-
joining (NHEJ). This supports the high levels of LD found between common deletions and 
SNPs in the genome [159, 169]. 
 
Reports of de novo CNVs of neurological disorders found contradicting results [170-172]. 
Recurrent copy number variation identified in laboratory mice [173] was found to have lower 
levels of LD between SNPs and CNVs in regions of segmental duplication, which are 
considered to be „hotspots‟ for genomic rearrangements by mechanisms such as NAHR 
between such repeats [174]. This could likely be due to the recurrent nature of these CNVs, 
which generate more allelic diversity [175]. 
 
In a recent study variable, a number of tandem repeats (VNTR) have also been found to be an 
underlying mechanism in the formation of CNVs for approximately 11.2% in validated 
CNVs [167]. It was also found that NAHR mediate the formation of large CNVs, while 
VNTR account for the formation of 3.5 times as many smaller CNVs than NAHR [167]. 
NAHR was found to mediate CNV formation by 13.5% and VNTRs by 11.2% [167].  
  
A further complexity lies in whether a CNV has arisen de novo or whether it has been 
inherited from a parent. Whilst no large-scale analyses of individuals and their parents have 
been carried out to estimate the occurrence of de novo copy number variation across the 
genome, several studies have extrapolated from analyses of particular genomic loci [176, 
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177] with biased frequency results. Estimates of de novo copy number occurrence in the 
human genome were found to range from less than 3.3% [162, 178].  
 
1.7.3 Methods of CNV prediction and validation 
 
In recent years, several techniques have been developed to detect and validate CNVs in 
human genomes. In this section, I will present a brief description of these techniques. More 
details of the techniques used in this thesis can be found in Chapter Two. 
  
Methods of CNV detection can be divided into array based methods, which permit the 
analysis of CNVs on the genome-wide level and non-array based qualitative and quantitative 
methods, which allow for analysis of individual CNVs of interest. Array-based CNV 
prediction can also be divided into using aCGH or SNP genotyping arrays. The first provides 
a relative measure of sample copy number status though direct comparison with the 
referenced DNA sample. The second analysis copies the number of each sample separately.  
 
Different copy number algorithms from SNP genotyping data have been found. Two 
principal platforms for genome-wide SNP genotyping exist using different arrays; one is 
Ilumina Inc. (Dan Diego, USA) and the other is Affymetrix Inc. (Santa Clara, USA). Both 
platforms use high-density oligonucleotide arrays for SNP genotyping, but differ in their 
assay workflow. In this thesis, I used the Affymetrix Inc. (Santa Clara, USA) 6.0 genome-
wide SNP array. For the purpose of CNV calling, allele-specific quantitative signal intensity 
data were used to calculate Log R Ratio (LRR) B allele frequency (BAF) for each SNP, 
which was generated using PennCNV for Affymetrix algorithms (explained in Chapter 
Two). The signal intensity data at each probe was used to independently detect copy number 
by using a spatial relationship, which exists between copy numbers at successive probes and 
which will improve CNV prediction from genome-wide SNP array data. The Hidden Marcov 
Model (HMM) was employed on the algorithm models, which takes advantage of the spatial 
information [178] that is believed to increase sensitivity and specificity of CNV prediction. 
Some of the algorithms that use HMM are quantiSNP, PennCNV and cnvHap [178-180]. In 
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this thesis, I employed PennCNV for genome-wide CNV prediction, carried out using the 
Affymetrix 6.0 SNP array data from Saudi extreme obese and MR cases/controls.  
 
As I mentioned previously, non-array-based copy number measurements exist that and 
specifically designed for analysing target regions of interest. One of the most frequently used 
methods is multiple ligation-dependant probe amplification (MLPA). It is a multiplex 
polymerase chain reaction (PCR)-based method of copy number quantifications that permits 
targeted copy number genotyping of CNVs at one or more loci (explained in Chapter Two). 
It uses multiple probes that are complementary to the DNA sequence within the CNV region 
[181]. Another method for non-array-based copy number measurements is quantitative 
fluorescent PCR (qPCR), also referred to as real-time PCR. It is formulated on a PCR based 
reaction, which is used to amplify and at the same time quantify a targeted DNA molecule 
[182]. It enables both detection and quantification. The quantity can be either an exact 
number of copies or a relative amount when normalised to DNA input or normalised genes 
[182]. The last method for non-array-based copy number measurements is the PCR-based 
qualitative CNV genotyping approach. This method was used in this thesis as a low cost and 
rapid genotyping approach (explained in Chapter Two). It basically uses two sets of primers, 
one within the deletion and the other flanking the deletion breakpoints. This will generate 
PCR products of different sizes that can be distinguished using agarose gel.  
 
1.7.4 The role of copy number variation in the development of obesity 
 
Unlike studies of monogenic and common obesity that are largely focused on SNPs, the exact 
role of CNVs in obesity susceptibility remains poorly understood. CNVs can be divided into 
two categories: those that are common and are estimated to be at a frequency of 5% and 
CNVs that are considered to be rare at a frequency of 1% [36].  
 
Researchers have found an association between a couple of common and rare CNVs with 
obesity (discussed in more detail in the introduction of Chapter Four). Most of the studies 
focused on the role of CNVs in the variation in BMI and obesity susceptibility. Three 
common copy number variants found in three different loci pancreatic polypeptide receptor 
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(PPYR1), neuronal growth regulator 1 (NEGR1) and G protein-coupled receptor, family C, 
group 5, member B (GPRC5B), have all been linked to BMI variation [183, 184]. The most 
established CNV in the obesity field is the large, rare 593kb chromosome 16p11.2 deletion. 
Heterozygous deletion in this locus has been shown to be associated with a highly penetrant 
form of extreme obesity [185]. On the other hand, duplication in this locus has also been seen 
to be associated with reduced body weight [186]. Jarick et al. has also recently reported 
association of a CNV that encompasses olfactory receptor genes, e.g., OR4P4, OR4S2 and 
OR4C6 with early onset obesity [187]. In a recent study, Doco-Fenzy et al. reported a de 
novo rare heterozygous CNV deletion in 2p25, which was associated with early-onset obesity 
[188]. This deletion has only been reported in 13 patients, and is often associated with the 
Prader-Willi-like phenotype [188]. Four patients in this study were found to carry this 
deletion and showed signs of intellectual deficiency and behavioural troubles, as well as 
obesity. A couple of genes within this region were speculated to be involved in the 
development of early onset obesity, namely ACP1, TMEM18 and/or MYT1L [188]. Other 
studies that associate global genomic structural variant (GSV) load with obesity have been 
conducted. Global GSV load reported by Wang et al. showed an enrichment of large 
deletions in obese subjects [189] and others identified rare CNVs present only in obese cases 
[190].  
 
1.8 Strategy to identify monogenetic determinants of obesity 
 
One of the overarching hypotheses in this thesis is that DNA sequencing identifies variants 
that alter susceptibility to obesity. Some rare variants previously discovered produce 
Mendelian obesity phenotypes, while other variants have a more subtle effect. In this thesis, 
one of my main focuses was to investigate monogenic forms of obesity in well-characterised 
consanguineous Saudi families with extreme obesity. My main aim is to identify genes that 
influence obesity susceptibility.  
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1.8.1 Gene discovery 
 
The identification of mechanisms underlying diseases has been the main aim of the study of 
medicine. There are many examples of instances where the understanding of the mechanism 
underlying a certain disease has changed therapy, ranging from the identification of 
helicobacter pylori as a treatable cause of peptic ulcer disease, to the identification of some 
hormonal imbalances underlying obesity that have allowed curative intervention.  
 
In the first section of this introduction chapter, I referred to several studies that set out to 
identify genes and possible pathways for modulating obesity. Since missing heritability 
estimates of obesity could be somewhat different from the current understanding, it is clear 
that there are more variants to be uncovered in the genetics of obesity. Some of the 
approaches for outlining these are given below.  
 
1.8.1.1 Methods for gene discovery-exome sequencing 
 
Since 2005, Next generation sequencing (NGS) has been widely provided [191]. A process 
called „whole exome sequencing‟ is a method developed for coupling targeted capture and 
massively parallel DNA sequencing, which determines nearly all of the coding variation 
present in an individual‟s human genome [192]. The question here is whether exome 
sequencing is a good tool for identifying rare variants underlying complex traits. 
  
Despite the major limitation that exome sequencing does not currently assess the impact of 
non-coding alleles, it is for several reasons nonetheless a very good strategy for the discovery 
of rare alleles in both Mendelian phenotypes and underlying complex traits [192]. Firstly, 
most variants that underline Mendelian disorders are found in the coding region and have 
been found to disrupt the protein-coding sequence [193]. Secondly, large fractions of the 
protein-altering variants that are either missense or nonsense and insertions or deletions, have 
been shown to have functional consequences and/or to be deleterious [194]. 
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Whole exome sequencing (WES) and its contribution to complex traits have been much 
smaller than its contribution to Mendelian traits. In the meantime, WES still functions as an 
important tool in complex traits, e.g. obesity [195], by providing the opportunity to capture 
most or all the rare and very rare variants with minor allele frequency (MAF) of < 0.1% in 
alleles that are found in the protein-coding region.  
 
WES is often used in conjunction with two sampling strategies, namely family-based 
phenotypes and extreme phenotypes [192] (Table 1-4). In families where multiple individuals 
are affected with a common trait, two approaches are used (Figure 1-3). The first is to 
sequence the most distally related individuals that are believed to share fewer genetic variants 
[196]. The second is to involve the sequencing of both parents of offspring trios, in which 
only the offspring are affected, to identify de novo variants [197]. 
 
In an extreme phenotype study design, individuals that are at both ends of the extreme 
phenotype distribution are selected for sequencing [192]. Because the frequencies that 
contribute to the trait are enriched in the extremes of the distribution (Figure 1-3), sequencing 
only the modest sample size can potentially identify novel candidate alleles [198]. This 
strategy was the one used in this thesis.  
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Figure 1-3 Strategies for finding disease-causing rare variants using exome sequencing. 
Four main strategies can be used: a) identify novel variants by sequencing and filtering 
across multiple unrelated affected individuals to find the variant that is shared by the three 
individuals (indicated by the coloured shared region); b) sequencing and filtering among 
affected individuals within one family (shaded circles and squares) to find a novel variant 
within a gene in a shared region in the genome; c) identifying de novo variants by sequencing 
parent-child trios; d) sampling and comparing extreme distribution for a certain quantitative 
phenotype (indicated by arrows). Individuals that carry the same rare variants in the same 
gene (indicated by red arrows) are found to be concentrated in one extreme of the 
distribution.  
This figure was adapted from Bamshad et al., 2011.  
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Table 1-4 Some diseases identified through whole exome. 
Disorder Mode of inheritance Number of 
samples sequenced 
Strategy Gene Reference 
Comparison of unrelated cases      
Kabuki Autosomal dominant 10 10 cases  MLL2 [199] 
Schinzel-Giedion Autosomal dominant 4 4 cases  SETBP1 [200] 
Hadju-Cheney Autosomal dominant 3 3 cases NOTCH2 [201] 
Sensenbrenner Autosomal recessive 2 2 cases  WDR35 [202] 
Comparison of related cases      
hyperphosphatasia-MR Autosomal recessive 3 3 cases  PIGV [203] 
hypolipidemia Autosomal recessive 2 2 cases  ANGPTL3 [204] 
retinitis pigmentosa Autosomal recessive 3 3 cases  DHDDS [205] 
novel skeletal dysplasia Autosomal recessive 4 2 cases + parents POP1 [206] 
spinocerebellar ataxia Autosomal dominant 4 linkage + 4 cases TGM6 [207] 
familial ALS Autosomal dominant 2 linkage + 2 cases VCP [208] 
dilated cardiomyopathy Autosomal dominant 4 linkage + 4 cases BAG3 [209] 
hidradenitis suppurativa Autosomal dominant 3 linkage + 2 cases3 NCSTN [210] 
primary failure tooth eruption Autosomal dominant 4 linkage + 4 cases4 PTH1R [211] 
Homozygosity mapping      
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Disorder Mode of inheritance Number of 
samples sequenced 
Strategy Gene Reference 
Obesity Autosomal recessive 5 5 cases LEPR [195] 
DFNB82 (hearing loss) Autosomal recessive 1 1 case  GPSM2 [212] 
CNS malformations Autosomal recessive 2 2 cases  WDR62 [213] 
Seckel Autosomal recessive 1 1 case  CEP152 [214] 
NPHP-related ciliopathy Autosomal recessive 1 1 case  SDCCAG8 [215] 
autoimmune LPS Autosomal recessive 1 1 case  FADD [216] 
complex I deficiency Autosomal recessive 1 1 case  ACAD9 [217] 
non-syndromic MR Autosomal recessive 2 2 obligate carrier 
parents 
TECR [218] 
Ochoa Autosomal recessive 1 1 case  HPSE2 [219] 
Identification of de novo mutations      
Autism Complex 30 20 parent–child trios multiple [197] 
Table reproduced and modified from Bamshad et al (2010). 
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1.8.1.2 Approach of discrete filtering and stratifying of candidate variants from whole 
exome sequencing data 
 
The discrete filtering approach is used to eliminate candidate genes by assuming that any 
alleles found in the filtering set cannot be causative. This is a powerful approach, as only a 
fraction (~2%) of average single nucleotide variants identified in an individual by WES is 
novel [192]. Most studies that have used WES to detect novel or rare variants have either 
compared their exome sequences to other exome sequences, found either in a small number 
of unrelated individuals or closely related individuals in order to find rare alleles that are 
shared between affected individuals [204, 209, 218]. Basically, novelty is assessed by 
filtering variants against other variants that exist in Single Nucleotide Polymorphism 
Database (dbSNP), as well as in the 1000 Genome Project. This approach may be useful, yet 
tricky at the same time. In a review by Bamshed et al. (2011), the reason why this approach 
can be problematic is discussed. The first is that there is a chance that dbSNP could be 
contaminated with a small number of pathogenic alleles. The second is that filtering of alleles 
in a manner that is independent of their MAF runs the risk of truly eliminating pathogenic 
causing alleles that are segregated in the general population. Analysis of recessive disorders 
that are usually set to have a maximum MAF of 1% is still considered a powerful strategy. It 
is then recommended that in recessive disorders, discrete filtering should be with a maximum 
MAF >1%, which could either be carried out using a large sample size and/or with pedigree-
based approaches [192, 220]. This discrete filtering approach was used in this thesis. In the 
case of dominant disorders a MAF cut-off of 0.1% is recommended [192, 221].  
 
Stratifying candidate alleles based on functionality by giving greater weight to frame shift 
stop codons and the disruption of splice sites than to the presence missense mutations is 
another strategy. Many studies have used this stratifying strategy by using quantitative 
estimates that have a functional impact, by looking at variants that tend to be deleterious and 
checking if they exist in conserved regions as a result of purifying selection [222-225]. Some 
approaches that are used to stratify non-synonymous alleles are SIFT, Polymorphism 
Phenotyping v2 (PolyPhen2) and MutationTester [226-228]. These tools predict changes in 
proteins caused by specific amino acid substitutions and were used in thesis.  
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1.8.1.3 Mode of inheritance on study design 
 
Identifying the mode of inheritance of monogenic disorders strongly influences the 
experimental design and the analytical approach, e.g. the number of cases to sequence. In the 
case of recessive forms of monogenic disease, it has been noticed that studies carried out 
using this model have selected fewer cases to sequence [199] than is the case for dominant 
disorders [214] (Table 1-4). It has also been noticed that there is a greater rate of identifying 
variants that are recessive using WES compared to dominant [192].  
 
The use of pedigree information can substantially narrow down the genomic region for the 
candidate causal allele [192]. For very rare alleles, the probability of identity-by-descent 
given the identity-by-state is high within related individuals [192].  
 
Homozygosity mapping data and linkage analysis for individuals within a pedigree is a 
promising strategy in identifying candidate variants from WES data. Homozygosity mapping 
and linkage analysis are frequently employed to isolate disease genes in families where the 
parents are known to be definably related, typically as cousins, which increase the risk for 
recessive disease. Homozygosity mapping is defined as “the detection of the disease locus by 
virtue of the fact that the adjacent region will preferentially be homozygous by descent in 
such inbred children” [229]. On the other hand, linkage analysis is defined as “an analysis 
that consists of counting recombinants and nonrecombinants, estimating the re-combination 
fraction, and testing whether this fraction is significant” [230] (Figure 1-4). The use of both 
homozygosity mapping and linkage analysis along with WES in recessive disorders has 
shown to be a very promising strategy in narrowing down the region where the variant may 
lie, especially when the haplotypes are shared within affected individuals with the same 
genomic region [172, 195, 207, 211, 214]. This approach was used in this thesis.  
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Figure 1-4 The principle of linkage analysis. The figure shows a) the paternal chromosome 
(blue) and the maternal chromosome (red) in a germ line cell that are labelled in capital 
letters and which represents the paternal alleles, while the lower case represents the maternal 
alleles; b) shows the physical process of recombination that involves the process of crossover 
of the paternal and maternal DNA strands between the paired chromosomes. This results in 
the mix of the paternal and maternal alleles (recombined), which are later passed to the sperm 
or eggs; c) if A is the disease gene and B and C are genetic markers, then recombination is 
likely to occur much more frequently between A and C than between A and B. This will 
allow the disease gene to be mapped relative to the markers B and C. 
 
Figure reproduced from Twyman (2003) (http://genome.wellcome.ac.uk/doc_WTD020778.html) 
 
 
  
a. 
b. 
c. 
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1.8.1.4 Limitations of whole exome sequencing 
 
There are many reasons why whole exome sequencing may fail in the detection of the 
candidate variant. This may be mostly due to technical and analytical limitations. It could 
also be due to design failure owing to bad phenotyping of the affected individual, as it will be 
shown in the case of one my families (later explained in Chapter Three). It could also be 
due to inadequate coverage of the region that contains the causal variant, or can occur 
because the causal variant is covered but not actually called [231]. The variant could also be 
falsely called due to mismapped read outputs from WES.  
 
1.8.1.5 Clinical application (molecular diagnosis)  
 
The discovery of variants that cause either Mendelian disease or complex traits will lead to a 
deeper understanding of the disease mechanism, which will facilitate the development of 
better diagnostics and preventative/therapeutic procedures. When there is a large list of 
candidate genes and when symptoms are shared among multiple disorders, it will be very 
difficult to confirm the disease by clinical evaluation or even laboratory evaluation alone. 
WES was able to find the exact gene that causes genital chloride-losing diarrhoea. It was the 
solute carrier family 26, members 3 (SLC26A3) gene that was found in a girl who was 
previously misdiagnosed with Bartter syndrome [232]. Also, in a recent study by Gill et al., 
two novel LEPR mutations were found in two families that caused a phenotype of extreme 
obesity [195]. This mutation causes leptin deficiency; patients carrying this mutation can be 
treated by giving them leptin hormone supplements [56].  
 
The methods described here will be used on the Saudi consanguineous families segregating 
for extreme obesity in this study. This should enable the identification of mutations in either 
known or novel genes that predispose to obesity. 
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1.9 Overall Aim 
The majority of progress in obesity genetics has resulted from the study of “extremes”, for 
example rare cases of children with syndromic obesity caused by genomic structural 
changes, e.g., Prader-Willi syndrome, or with monogenic forms of disease. The project 
proposed here will utilise both of these approaches to seek new genetic causes of obesity of 
individual “extreme” children and families of Saudi Arabian origin. Two types of patients 
will be investigated: (i) adults/children with obesity in combination with learning disability 
and dysmorphic features; (ii) obese children with apparently monogenic forms of obesity in 
consanguineous families. New genes and loci revealed in these patients will be assessed for 
their potential contribution to more common forms of obesity in population-based collections 
from the Gulf region and across Europe. 
 
1.10 Specific objectives 
 
1) To identify causative loci for novel syndromic forms of obesity by investigating 
Saudi adults/children that have severe obesity, developmental delay and dysmorphic 
features. These patients are often uniquely affected with obesity in their families, which 
could be indicative of de novo obesity gene mutation or rearrangement. 
2) To seek causative loci for new Mendelian forms of obesity in multiplex 
consanguineous families in children that have extreme obesity (z-BMI above 97
th
 centile) by 
homozygosity mapping and linkage analysis in combination with WES.  
3) To assess the contribution of the loci identified in (1) and (2) to “common” forms of 
obesity (and to BMI as a quantitative trait) in Arabic and European populations.  
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2 Materials and Methods 
 
2.1 Study subjects 
 
2.1.1 Mental retardation and extreme obesity in Saudi adult and child cases and 
controls 
 
Samples were collected from five centres belonging to the Coordination Committee of 
Disabled Services in the Saudi Ministry of Health and Developmental Genetics Unit of King 
Faisal Hospital, Saudi Arabia. The study was approved by the Saudi Ministry of Health and 
the King Faisal Specialist Hospital and Research Center. 
 
I personally visited all the rehabilitation centres in Riyadh, Saudi Arabia to collect these 
samples, accompanied by a dysmorphologist and a consultant paediatrician from King Faisal 
Hospital who assessed the patients and helped make a clinical diagnosis of the 
absence/presence of developmental delay on recruitment to the study. The patient clinical 
sheet was developed in the author‟s department, the Department of Genomics of Common 
Disease at Imperial College, London. This included all the phenotypic information required 
for this study (Table 2-1 and Table 2-2). Blood was collected in EDTA blood collection tubes 
with the help of local nurses working in the rehabilitation centres. 
 
Eighty-five adults and children were selected for mental retardation (MR), dysmorphic 
features, and obesity or morbid obesity. For adults, obesity and morbid obesity are defined as 
a BMI ≥ 30 and ≥ 40 kg/m2 respectively, and for children, a BMI above the 90th and 97th 
percentiles respectively. Seventy-two normal controls were also selected. These samples are 
unrelated and are all from Riyadh, Saudi Arabia. Known syndromic cases were excluded. 
Consent forms were signed by either the patient or a parent. 
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Table 2-1: Summary of Saudi MR and extreme obesity cases and control samples 
 
Table 2-2: Frequency of different phenotypic data collected from Saudi MR and 
extreme obesity samples 
 
2.1.2 Saudi consanguineous families with extreme obesity 
 
The study was approved by the ethical committee at Obesity Chair, School of Medicine, King 
Saud University. Affected families were identified with the help of local paediatricians, and 
written informed consent was obtained from the children‟s parents (or legal guardians). A 
team consisting of two paediatricians and a nurse was put together and led by the author. The 
team visited the families either at home or in the clinic. Parents were also interviewed to 
collect information on the prenatal, perinatal and neonatal medical history of all the children. 
Anthropometric measurements and physical examinations were carried out by trained 
physicians and nurses. 
 
A total of ten consanguineous families were identified from four cities in Saudi Arabia: 
Riyadh, Jeddah, Makkah and Jazan. Each family has at least three probands with severe 
early-onset obesity (z-BMI above 97
th
 centile) and one or two normal-weight control subjects 
with both parents being lean (Figure 2-1 and Table 2-3). A detailed pedigree was constructed, 
and the genealogical relationships within the families were crosschecked after interviewing 
the family members. Blood was collected for each individual in these families, and DNA 
extraction was conducted using Gentra Puregene Blood Kits (Qiagen, Crawley, UK). 
Sample Total  Male Female Median age Median zBMI 
Cases 85 55 30 21 32.6730 
Controls 72 42 30 25 26.531 
Sample Developmental delays Behavioural problems Learning difficulties 
Cases 25% (18) 42.2% (30) 26.7% (19) 
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Figure 2-1 Pedigrees of ten Saudi consanguineous families with extreme obesity. These 
pedigrees show an autosomal recessive inheritance pattern. The probands are in shaded black. 
Parents and lean controls from the same family are in clear colour. 
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Table 2-3: Summary of Saudi consanguineous families with extreme obesity - cases and 
control samples 
 
2.1.3 Saudi WES normal controls 
 
Saudi WES normal controls were used, in collaboration with Dr Fowzan Al Kuraya, Head of 
the Developmental Genetics Unit at King Faisal Specialist Hospital and Research Center, 
Riyadh, who provided 250 Saudi WES normal controls. 
 
2.1.4 Replication samples 
 
Three replication cohorts consisting of Saudi, Yemeni, and Sudanese obese samples were 
used, provided by King Saud University, Department of Biology. The samples had a 
phenotype of obesity, with no other disease (Table 2-4). These samples were used to replicate 
the results found by the Saudi MR CNV study. A further set of replication samples from King 
Faisal Specialist Hospital and Research Center was also used, consisting of 100 Saudi 
controls with no known disease. These samples were used to replicate gene mutations found 
in the study of Saudi consanguineous families with extreme obesity. 
 
Table 2-4: Summary of replication samples from King Saud University 
Sample Total number Male Female Median age Median zBMI 
Saudi 125 55 70 26 35 
Yemeni 20 7 13 24 32 
Sudanese 42 10 32 28 34 
 
Sample Total Male Female Median age Median zBMI 
Cases 41 18 22 12 31 (>97
th
 percentile) 
Controls 36 16 19 11 19 (<95
th
 percentile) 
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2.2 DNA extraction 
 
Peripheral blood was drawn from all samples in this study and placed in EDTA anticoagulant 
tubes. DNA was extracted from whole blood using the PUREGENE DNA Isolation Kit 
(Gentra Systems, Minneapolis, MN, USA). The steps required for DNA extraction, as 
recommended by the manufacturer, include cell lysis, protein precipitation, DNA 
precipitation, ethanol wash and DNA hydration. Prior to use in PCR, the DNA was quantified 
using NanoDrop 2000c/2000 UV-Vis Spectrophotometers (NanoDrop, Thermo Fisher 
Scientific Inc.). 
 
2.3 Genotyping arrays 
 
Genotyping was carried out by the author at King Faisal Specialist Hospital and Research 
Center. Three different genotyping arrays were used (Table 2-5). 
 
1. Affymetrix 6.0 (Affymetrix): This features 1.8 million genetic markers, including more 
than 906,600 SNPs and more than 946,000 probes for the detection of copy number 
variation. This is one of the few Affymetrix platforms that allow the use of different 
analysis tools for CNV calling (e.g. PennCNV and CnvHap). 
2. Axiom GWH-96 Array (Affymetrix): A high throughput platform that features 629,443 
SNPs, this is designed to achieve ~90% genomic coverage of rare (1-5% MAF) and 
common variants. 
3. CytoScan HD Array (Affymetrix): This features 750,000 SNPs and more than 2.5 million 
CNV markers (Affymetrix). It has greater than 99% sensitivity and can detect 25-50 kb 
copy number changes across the genome. 
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Table 2-5: Summary of genotyping arrays used in the study 
Study type Sample Cases Controls Array 
CNV study Saudi MR 85 72 Affymetrix 6.0 
Family obesity study  Saudi consanguineous 
families 
41 36 Axiom 
CytoScanHD 
 
 
2.4 Prediction of rare obesity causing CNVs 
 
This section explains how Affymetrix signal intensity files (CEL files) were processed and 
converted to LRR/BAF values for each sample, and how CNV calls were generated using 
different CNV detection algorithms. This section will also explain the process that was 
undertaken to detect candidate obesity causing CNVs results are presented in Chapter four 
(Figure 2-2).  
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Figure 2-2 Identification of rare copy number variants using Affymetrix 6.0 genotyping 
platform. This chart illustrates the workflow of the Saudi adult/child case/control cohort 
mental retardation and extreme obesity study. 
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2.4.1 Data normalisation and quality control 
 
Contrast quality control (QC) measures for Affymetrix 6.0 were used to show how well the 
experiment resolved signals into three genotype clusters. This metric uses a subset of probes, 
and measures the differences in contrast distributions for homozygote and heterozygote 
genotypes. The Contrast QC threshold was 0.4 or greater. The overall quality of the data set 
was assessed by measuring the average Contrast QC for all passing samples, which was 
required to be 1.7 or greater. All 37 samples passed this threshold. 
 
Pre-CNV calling QC was carried out. Raw intensities were extracted from CEL files and 
normalised across samples typed on the same plate using Affymetrix Power Tools, Version 
1.10.2 to minimise batch effects. The log2 ratio, which is a measure of signal intensity and is 
important for subsequent CNV prediction steps, was generated using the plate median. A 
number of statistics, including median and median absolute deviation (MAD), were also 
calculated from the log2 ratio for each sample. 
 
It was necessary to process raw CNV calls generated by PennCNV so that calls from low 
quality samples could be eliminated from the call file. The LRR variance threshold was used 
in QC for a particular dataset. PennCNV sets a default threshold of 0.1 but this was found to 
be too stringent. PennCNV later advised the use of a threshold of 0.24, or even 0.3 or 0.35. 
The LRR variance per-sample was calculated in this study and ranged between 0.09 and 0.15. 
The LRR variance per-sample was plotted and is shown in Figure 2-3. 
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Figure 2-3: LRR variance for per-sample, illustrating that the sample LRR variance 
ranges between 0.09 and 0.15, exceeding the threshold advised by PennCNV 
 
2.4.2 Generation of Log R Ratio and B-allele frequency from Affymetrix data 
 
Affymetrix Power Tools, Version 1.10.2 was used to generate signal intensity data based on 
raw CEL files that store the results of the intensity calculations. Allele-specific signal values 
were extracted from the raw CEL files. Signal intensity values for perfect match (PM) probes 
in all the CEL files were read, followed by the application of quantile normalisation to the 
values and median polish on the data. Signal intensity values were then generated for A and 
B alleles for each SNP. Genotyping calls from CEL files were also generated using the 
Birdseed algorithm for a genome-wide 6.0 array. It was necessary to generate a file 
containing the parameters for the canonical clustering information of each SNP or CN marker 
to calculate the LRR and BAF. Using an algorithm developed by PennCNV, LRR and BAF 
were then calculated for each marker in each individual using the allele-specific signal values 
from the previous step. The LRR and BAF file was then split into individual signal intensity 
files containing the SNP name, sample ID, B-allele frequency and log R ratio, using the split 
option of the kcolumn.pl program in the PennCNV package (Figure 2-4). The files generated 
were then ready for use in PennCNV. 
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2.4.3 CNV prediction algorithms used to detect CNVs from different Affymetrix 
platforms 
 
The different arrays used in this study use different CNV calling algorithms. To detect CNVs, 
PennCNV (http://www.openbioinformatics.org/penncnv/penncnv _tutorial_affy_gw6.html) 
was used on Affymetrix 6.0 Array data and Chromosome Analysis Software (ChAS) was 
used on CytoScan HD Array data. 
 
PennCNV is an integrated hidden Markov model (HMM) algorithm [178], designed to detect 
CNVs with high resolution in both Illumina and Affymetrix platforms. First a signal list file 
for a list of the names of these 157 intensity files was generated (signallistfile.txt); CNVs 
were detected using the B-allele frequency file (affygw6.hg18.pfb), the HMM parameter file 
distributed with the PennCNV software 
(http://www.openbioinformatics.org/penncnv/penncnv_download.html), and the command 
line: detect_cnv.pl -test -hmm lib/affygw6.hmm –pfb lib/affygw6.hg18.pfb -list signallistfile -
log gw6.log -out gw6.rawcnv. Frequencies for loss and gain of each genetic marker were 
calculated using a Perl script that counted the total number (Nt) of copies detected for each 
marker. Two copies were assumed for each marker not included in the PennCNV report 
(gw6.rawcnv), which contained copy numbers (0, 1, 3, 4) for the CNVs. Percentage 
frequencies (100|1-Nt/1824|) are reported based on dividing this count by the number of 
expected chromosomes (1,824) (Figure 2-4). 
 
The genotyping SNP array Axiom used on the consanguineous Saudi families with extreme 
obesity does not allow the detection of CNVs using PennCNV or any other CNV detection 
algorithm. Therefore, CytoScan HD Array was used to generate CNV calls. Chromosome 
Analysis Software (ChAS), developed by Affymetrix, was used to detect CNVs from 
CytoScan HD Array CEL files. ChAS software uses an HMM algorithm similar to that of 
PennCNV to detect CNVs. 
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CEL files from Affymetrix SNP array 
Raw signal intensity files 
Genotype call and confidence files 
Canonical genotype clusters 
LRR and BAF calculation 
CNV calls 
Affymetrix Power Tools software 
 Quantile normalisation 
 Signal extraction 
 Signal summarisation 
 Genotype calling (BRLMM or 
birdseed) 
PennCNV-Affy: generate_affy_geno_cluster.pl 
PennCNV-Affy: normalise _affy_geno_cluster.pl 
PennCNV software 
 File splitting 
 CNV detection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-4: PenCNV-Affy workflow outlining how to process raw CEL files and 
generate canonical genotype clusters, convert signal intensity for each sample to 
LRR/BAF values, and generate CNV calls using PennCNV. 
Source: PennCNV-Affy protocol for CNV detection in Affymetrix SNP arrays (http://www.openbioinformatics.org/penncnv 
/penncnv_tutorial_affy_gw6.html) 
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2.4.4 Filtration and merging of adjacent CNVs 
 
Filtering CNV calls by user-specific criteria was carried out using the PennCNV package. 
Using a perl script, filter_cnv.pl, developed by PennCNV, it was possible to filter out the 
subset of calls required for inclusion in the analysis. The number of SNPs overlapping with 
the CNV was set to a minimum of ten, which would help prevent the inclusion of false-
positive CNVs. 
 
PennCNV also tends to split large CNVs (>500kb) into smaller parts of between 100 and 
150kb CNV calls. The perl script clean_cnv.pl, also developed by PennCNV, was used to 
merge adjacent CNVs automatically. 
 
2.4.5 Removal of spurious CNV calls and identification of overlapping/neighbouring 
genes 
 
This step was performed using GenGen software (Genetic Genomic Analysis of Complex 
data: http://www.open bioinformatics .org). GenGen uses a perl script, scan_region.pl, to 
remove centromeric and telomeric regions that are believed to harbour spurious CNV calls. 
The scan_region.pl script was also used to find genes that overlapped or neighboured the 
CNV calls. 
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2.4.6 Identification of obesity candidate CNVs 
 
Following the criteria set previously, all CNVs that were either deleted or duplicated were 
selected. 
 
2.4.6.1 Stages of CNV analysis 
 
2.4.6.1.1 Stage I: Exclusion of samples with obesity-related or other known syndromes 
 
Karyotyping was not carried out before running the samples on Affymetrix 6.0. While 
visiting the patients, and with the help of a dysmorphologist, attempts were made to exclude 
as far as possible patients with known obesity-related syndromes. Nonetheless, an extra step 
was taken to ensure the exclusion of patients with these syndromes. 
 
2.4.6.1.2 Stage II: Exclusion of all genomic variants found in normal non-diseased samples 
 
To assess what proportion of the variant regions discovered in this study was novel, the data 
were compared with variants reported in the DGV, and all CNVs from BAC studies were 
removed owing to their large size and over-estimation of CNV size. The data were also 
compared with normal Saudi control CNV call data. 
 
 
2.4.6.2 Assessment of CNV candidacy 
 
2.4.6.2.1 Rare CNVs 
 
As this study seeks to identify rare obesity-causing CNVs in the data set, rare CNVs must be 
clearly defined. These are CNVs that are present in less than one per cent of study samples. 
They may be either homozygous deletions or large heterozygous deletions greater than 
500kb. 
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2.4.6.2.2 Generation of a list of rare CNVs 
 
Using the above criteria, a list of potential rare CNVs was generated. UCSC Genome 
Browser, Build hg18, was used to visually examine each candidate CNV and its overlapping 
genes. These were later assessed according to the number of samples sharing the same CNVs, 
whether they encompassed any genes and whether they overlapped with any common CNVs. 
These were then split into four groups (Figure 2-2): 
 CNVs shared between two samples including genes 
 CNVs in one sample including genes 
 CNVs shared between two samples not including genes 
 CNVs in one sample not including genes 
 
2.4.6.2.3 Manual curation of CNVs 
 
LRR and BAF were plotted for each candidate CNV. This process helped identify potential 
CNVs by examining the pattern of LRR and BAF across the CNV region. This would permit 
the exclusion of incorrectly merged CNVs as well as false-positive CNV prediction. 
 
2.4.7 CNV validation using different techniques 
 
2.4.7.1 Multiplex Ligation-Dependent Probe Amplification (MLPA) 
 
MLPA was carried out to validate subjects carrying chromosome 16p11.2 deletion and 
duplication. MLPA was also run on the Saudi, Yemeni and Sudanese obesity replication 
samples. Subjects showing apparent heterozygous deletions and duplications within the 
boundaries of the 16p11.2 region and obesity replication samples were analysed using a 
P343-C1 AUTISM-1 SALSA MLPA kit from MRC Holland (MRC Holland product # 
P343-100R). The P343-C1 AUTISM-1 kit contains 11 probes that fall within the region of 
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chromosome 16p11.2 (18.9-30.2 Mb). Nine of the 11 probes fall within the boundaries of the 
16p11.2 deletion and duplication region (Table 2-6). 
 
Table 2-6: MLPA probes in the P343-C1 AUTISM-1 SALSA MLPA kit from MRC 
Holland falling within the chromosome 16p11.2 region 
Source: MRC Holland product description (MRC Holland) 
 
The kit also contains nine control probes at locations that are known to be non-copy number 
variable. The MLPA protocol run and recommended by MRC Holland required every sample 
that was run on MLPA and showed a deletion or duplication in chromosome 16p11.2 region 
to be repeated four times. 
 
MLPA Hybridisation Reaction 
 
All samples carrying the chromosome 16p11.2 deletion and duplication were set at a 
concentration of 100ng/ul of genomic DNA. Denaturation of DNA was achieved by placing 
5μl of 100ng/μl DNA in the thermocycler for 5 minutes at 98°C. Then 3μl of the MLPA 
reaction mix was added to each DNA sample (Table 2-7). 
 
Length 
(nt) 
SALSA MLPA 
probe 
Gene 
detected 
Partial sequence (24 nt adjacent to ligation site)  Genomic 
location 
(hg 18) 
Distance to 
next probe 
  p-teleomere    
481 11677-L12448 LAT ACCAGTTTGTAT-CCAAGGGGCATC 28.904653 
 
678.2 kb 
 
346 11672-L12443 SPN CCATCAAGATGT-CATCAGTGCCCC 29.582828 
 
145.5 kb 
 
238 11669-L12440 MAZ CCACGGCAGCAT-ACCTGCGCATCC 29.728356 
 
0.8 kb 
 
418 11673-L12444 MAZ GAAGAAATGTTT-TCTTAGGGGAAT 29.729166 
 
23.6 kb 
 
344 00550-L00372 MVP GTCGTGGAGATC-ATTCAGGCCACC 
 
29.752775 
 
65.1 kb 
 
208 11668-L12439 SEZ6L2 GCAGCCAGATTA-CTTAGAGAGGCA 
 
29.817845 
 
95.7 kb 
 
454 11674-l12445 HIRIP3 GGCGAGCCTCAA-AGGCAGTTGAGG 
 
29.913518 
 
0.5 kb 
 
172 11667-L14670 HIRIP3 CCAGGGAAGACA-AACTGGACCTTA 
 
29.913975 
 
14.0 kb 
 
226 13162-L12447 DOC2A CACTTGCTGCCT-GGAGCCTGTAAG 
 
29.928004 
 
108.5 kb 
 
465 11675-L12446 MAPK3 CTGGATCAGCTC-AACCACATTCTG 
 
30.036474 
 
236.3 kb 
 
337 11671-L12442 CD2BP2 GGAAGGCCACTT-TGATGCCGATGG 
 
30.272761 
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Table 2-7: MLPA Hybridisation Reaction Mix 
 
Reagents Volume per reaction x1 Total volume (x187) 
SALSA Probe-mix 1.5μl 280.5μl 
MLPA Buffer 1.5μl 280.5μl 
Total 3μl 561μl 
 
Hybridisation Thermocycler Conditions 
95°C for 1 minute 
60°C for 16 hours 
 
Ligation Reaction 
32μl of Ligation reaction mix was added to each sample reaction (Table 2-8) and placed in 
the thermocycler at 54°C. 
 
Table 2-8: MLPA Ligation Reaction Mix 
Reagents Volume per reaction x1 Total volume (x187) 
Sterile ddH2O 25μl 4675μl 
Ligase-65 Buffer A 3μl 561μl 
Ligase-65 Buffer B 3μl 561μl 
Ligase-65 1μl 187μl 
Total 32μl 5984μl 
 
Ligation Thermocycler Conditions 
54°C for 15 minutes 
98°C for 5 minutes 
4°C hold 
 
PCR Amplification 
 
10μl of MLPA ligation reaction was pipetted into a new tube for all the samples. 10μl of the 
polymerase reaction mix was added to each sample ligation product and placed in the 
thermocycler at 60°C (Table 2-9). 30μl of PCR buffer mix (Table 2-10) was later added to 
each sample ligation product and placed in the thermocycler. 
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Table 2-9: MLPA Polymerase Reaction Mix 
Reagents Volume per reaction x1 Total volume (x187) 
Sterile ddH2O 5.5μl 1028.5μl 
SALSA Enzyme Dilution Buffer 2μl 374μl 
SALSA PCR Primers 2μl 374μl 
SALSA PCR Polymerase 0.5μl 93μl 
Total 10μl 1869.5μl 
 
Table 2-10: MLPA Buffer Reaction Mix 
Reagent  Volume per reaction x1 Total volume (x187) 
Sterile ddH2O 26μl 4862μl 
10X SALSA PCR Buffer 4μl 748μl 
Total  30μl 5610μl 
 
PCR Thermocycler Conditions 
60°C hold Polymerase reaction mix is added  
95°C for 30seconds 
60°C for 30 seconds 
72°C for 1 minute 
72°C for 20 minutes 
4°C hold 
 
The reaction products were then submitted to the sequencing department at King Faisal 
Specialist Hospital and Research Center to run fragmentation analysis on an Applied 
Biosystem 3730xl capillary sequencer. 
 
MLPA Data Analysis 
 
Free Coffalyser.NET Software (http://www.mrc-holland.com/WebForms 
/WebFormMain.aspx) was used to perform the MLPA analysis. The optimised default setting 
specified for the Applied Biosystem 3730xl capillary sequencer was used for the 
fragmentation analysis. The program was set to an experimental type DNA-MLPA, and the 
type of each sample had to be set before running the analysis. There are four sample types. 
References are normal controls against which all the data are normalised. Samples are test 
samples for which copy number status is sought. No-DNA controls are samples added to the 
experiment by the manufacturer. Finally, positive references are samples that carry a known 
and same-type aberration. 
35 cycles 
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After setting up the samples and selecting the experimental type, the „automatic binning‟ 
probe recognition method was selected using the default design lengths. This would relate the 
peak signals to the probe ID. Coffalyser then performed a cross-sample comparison by 
calculating the mean peak height for all control probes for each sample. The peak heights for 
all the test probes for each sample were divided by the mean peak height of all the control 
probes. To allow cross-probe comparison, the program normalised the probe signals of the 
samples to the reference samples using a normalisation factor based on the set reference 
probes. 
 
2.4.7.2 PCR-based validation 
 
Validation of one homozygous deletion within the tribbles homolog 3 (TRIB3) gene was 
carried out by PCR amplification with paired probe sets spanning and within the deleted 
region (Figure 2-5). CNV calls generated from PennCNV allowed boundaries to be mapped 
precisely. Primers were designed using Primer3 software (Version 0.4.0, 
http://frodo.wi.mit.edu/) purchased from Sigma Aldrich (Sigma Aldrich, UK) (Table 2-11). 
Long-range PCR was performed using a Qiagen PCR Kit (see manufacturer‟s protocol for 
details, shown in Table 2-12). 10ng/μl and 23.25μl of the PCR reaction mix described below 
was used in this PCR reaction. All PCR products were examined by 2% agarose gel 
electrophoresis and prepared with 1% tris-borate EDTA (TBE) and 0.1ng/μl ethidium 
bromide at 120V for 30 minutes. 100bp DNA ladder (New England Biolabs) was included in 
the gel to help in the estimation of PCR fragment size. The deletion investigated here was 
selected according to the overlapping gene and whether it had previously been seen to be 
associated with or was in the pathway of known or novel obesity genes. 
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Figure 2-5: PCR amplification with paired probe sets spanning and within the deleted 
region of the TRIB3 gene in the Saudi MR Cohort. Orange arrows indicate external 
primers and red arrows internal primers. This amplification reaction was run on the sample 
carrying the deletion and also on a set of Saudi normal controls. 
 
Table 2-11: Primer sequences of the 6,905bp TRIB3 homozygous CNV deletion 
Primer Sequence  
TRIB3 homozygous 6,905bp internal forward primer CTTGGTTCCTTTGCAATGCT 
 TRIB3 homozygous 6,905bp internal reverse primer TTGAAGGCAGGAAAAACTGG 
 TRIB3 homozygous 6,905bp external forward primer ATGAGCATCAGGTGCCTTCT 
 TRIB3 homozygous 6,905bp external reverse primer TGGCTTCTTCCTCTGGTCAT 
 
 
Table 2-12: PCR reaction mix for genotyping the TRIB3 6,905bp homozygous deletion 
Reagents Volume per 
reaction x1 
Total volume (x40) 
Sterile ddH2O 17.5μl 690μl 
10x PCR buffer (Promega) 2.5μl 100μl 
dNTPs (2.5mM) (Premixed dNTP Epicentre) 1μl 40μl 
TRIB3 homozygous 6,905bp internal or external forward 
primer (5μM) 
1μl 40μl 
TRIB3 homozygous 6,905bp internal or external reverse 
primer (5μM) 
1μl 40μl 
Hotstar Taq polymerase (Qiagen) 0.25μl 10μl 
Total 23.25μl 920μl 
 
 
 
 
 
TRIB3 gene 
Forward 2 Reverse 2 Forward 1 Reverse 1 
6,905bp homozygous deletion 
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PCR Thermocycler Conditions 
95°C for 15 minutes 
95°C for 45seconds 
60°C for 45 seconds 
72°C for 1 minute 
72°C for 10 minute 
10°C hold 
 
2.4.8 Assessment of Global Burden of Large CNVs 
 
Global burden CNVs above 500kb were assessed in the Saudi MR and extreme obesity adult 
and child cases and controls using PLINK (http://pngu.mgh.harvard.edu/~purcell/plink/). The 
global burden rate of CNVs above 500kb was assessed in cases versus controls, using a one-
tailed permutation test of enrichment for deletions and duplications using 100,000 
permutations. 
2.5 Prediction of Monogenic obesity genes: 
 
In this section I will present the methods used in the monogenic obesity study results are 
presented in Chapter Three (Figure 2-6). 
35 cycles 
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Figure 2-6 Identification of Monogenic obesity causing genes using both Affymetrix 
Axiom GW genotyping platform and WES. This chart illustrates the workflow of the Saudi 
consanguineous families with extreme obesity. 
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2.5.1 Linkage Analysis 
 
Linkage analysis was run on the consanguineous Saudi families with extreme obesity. Before 
running the QC measure, SNP selection and linkage analysis, it was necessary to generate a 
pedigree file (PED file) and a mapping file (MAP file) for each family. The PED file contains 
all the family information, including their phenotypes and genotypes. The MAP file maps 
each SNP to its chromosome and position. The format of genotyping files generated by 
Axiom (Affymetrix) had to be converted using custom scripts to generate PED and MAP 
files. The next section explains the steps taken to run the linkage analysis. 
 
2.5.1.1 Quality control of Axiom SNP genotyping platform 
 
Having ensured a 98% SNP calling rate for the Axiom chip run on the ten consanguineous 
obesity families, QC measures were undertaken before running linkage analysis. QC 
measures were run on the ten families using both PLINK 
(http://pngu.mgh.harvard.edu/~purcell/plink/) and Merlin (Version 1.1.2 - 
http://www.sph.umich.edu/csg/abecasis/merlin/tour/linkage.html) (Figure 2-7). Before 
running QC it was important to ascertain that each family was included in a single PED file 
and split chromosome by chromosome. 
 
2.5.1.1.1 PLINK 
 
One of the first QC steps using PLINK was to generate a list of genotype missing rate 
statistics, with a missing proportion of 5% for each individual and SNP. The MAF was later 
calculated with a threshold of 5%. Hardy-Weinberg test statistics were also calculated for 
each SNP with a threshold of 1E-06. 
 
2.5.1.1.2 Merlin 
 
PedStats software (http://www.sph.umich.edu/csg/abecasis/PedStats/) in the Merlin package 
was used to calculate Mendelian error (ME). PedStats provides graphical and text summaries 
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of the information contained in any pair of pedigree and data files. PedStats requires PED and 
DAT files. The DAT file provides a description of the contents of the associated PED file. 
After generating a file with all the ME, Pedwipe 
(http://www.sph.umich.edu/csg/abecasis/merlin/tour/linkage.html) was used to wipe all the 
ME from the PED files. Merlin has an error detection algorithm for detection of Mendelian-
consistent genotyping errors. This algorithm uses a sliding window of haplotypes along a 
chromosome and identifies any genotypes at individual loci which do not fit in with the 
surrounding haplotype. 
 
2.5.1.2 SNP selection for linkage analysis 
 
After QC and before running linkage analysis, SNP selection was carried out. This section 
explains the steps undertaken for SNP selection and later used to run linkage analysis (Figure 
2-7). 
 
2.5.1.2.1 Informativeness of SNPs 
 
Informativeness is the „usefulness‟ of a genetic marker for linkage analysis [233]. It is 
generally measured by its heterozygosity [233]. The higher the value, the more informative is 
a family pedigree. Heterozygosity may also be viewed as a measure of marker 
informativeness [233]. To be more specific, informativeness is the probability of 
heterozygosity expected under HWE [233]. 
 
To measure the informativeness of each marker, Merlin (Version 1.1.2 - 
http://www.sph.umich.edu/csg/abecasis/merlin/tour/linkage.html) was used with three files: a 
PED file, a DAT file, and a MAP file. Merlin generates a file with two columns. The first is 
the SNP ID and the second is the value of informativeness for each SNP. 
 
The next step was to calculate the frequency of the most informative SNPs within each 
family generated from the step above. The most frequent informative SNPs within all 
families were selected and plotted. 
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The R statistical package (R Version 2.13.2) was used to generate a histogram plot of the 
frequency and informativeness of SNPs. 
 
2.5.1.2.2 Proportion of informative SNPs 
 
The proportion of the most informative SNPs to be included for linkage analysis was then 
calculated. Three different proportions of SNPs were selected and run on linkage analysis of 
6,000, 86,000 and 443,834 SNPs. The calculation of the proportion of SNPs to be selected 
from each chromosome was made using the following formula: 
 
Proportion SNPs per chromosome= 
Total number of SNPs *target proportion of SNPs included in linkage analysis 
Total number of SNPs 
 
SNPs not in LD were also pruned out using PLINK 
(http://pngu.mgh.harvard.edu/~purcell/plink/). PLINK calculates the LD between each pair of 
SNPs in a certain window of 30 SNPs. It then removes one of a pair of SNPs if the LD is 
greater than 0.5, shifts the window five SNPs forward and repeats the procedure. 
 
2.5.1.3 Running linkage analysis 
 
Linkage analysis was performed using Merlin (Version 1.1.2) 
(http://www.sph.umich.edu/csg/abecasis/merlin/tour/linkage.html) and the Allegro 
component of EasyLinkage software [234]. In Merlin a non-parametric linkage analysis was 
used with a –rsq option of 0.1 that calculates pairwise r2 between neighbouring markers and 
creates a cluster joining markers for which pairwise r
2
 is greater than 0.1 and all intervening 
markers.  
 
Age and disease were also included as covariates in the Merlin linkage analysis. Linkage 
using Merlin was run twice: once on all families together in one linkage run split 
chromosome by chromosome, and another on individual family linkage runs split 
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chromosome by chromosome. In the case of the EasyLinkage software analysis, non-
parametric linkage analysis was performed on the SNP genotypes in sets of 100 markers with 
a spacing of one marker every 0.2 cM with an –rsq of 0.1 and run on individual families. 
 
Allegro and Merlin are not much different. Allegro uses a fast Fourier transformation to 
increase the computation speed and the and there is no set limit on the number of markers or 
founders. On the other hand, Merlin program employs binary trees. Basically, each level of 
the tree represents one-meiosis and each branch corresponds to transmission of the grand-
maternal or grand-paternal allele. In Merlin there is a limit on the number of nonfounder to be 
16. 
Merlin needs at least two sampled affecteds are needed to calculate an identity by descent 
(IBD) sharing statistic, however Allegro will calculate this statistic for a pair of affected 
individuals even when one member is unsampled. 
 
 
Figure 2-7: SNP selection and linkage analysis illustrating the workflow of the SNP 
selection process and linkage analysis on the ten consanguineous Saudi obesity families 
 
 
SNPs Generated from Axiom Affymetrix SNP array for all the 
individuals in the 10 family obesity samples 
QC on the genotyping data: 
missingness, MAF, HWE and ME 
Calculate 
informativeness of 
SNPS 
Select 
proportion of 
SNPs for 
linkage 
Non-parametric linkage analysis 
Final 
SNPs for 
linkage 
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2.5.1.4 Runs of homozygosity 
 
Homozygosity mapping was carried out using PLINK 
(http://pngu.mgh.harvard.edu/~purcell/plink/). For runs of homozygosity (ROH), a window 
of 100 SNPs was selected that would slide across the genome. The length of ROH was set at 
1000 kb. The density kb/SNP was set at 50 SNPs and the largest gap between ROH was 
1000kb. These are the default settings for detecting ROH using PLINK, to determine whether 
or not a window appears to be homozygous. It also calculates the proportion of homozygous 
windows overlapping with that position. The R statistical package (R Version 2.13.2) was 
used to plot ROH in each family. 
 
AutoSNPa was also used as a tool to detect ROH [235]. This software represents genetic data 
graphically, enabling the regions of homozygosity to be detected by eye (Figure 2-8), thereby 
visually narrowing the interval containing the causative gene [235]. 
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Figure 2-8: Graphical representation of chromosome 6 SNP data for case (left) and 
control (right) individuals. Black bands represent „common homozygous‟ genotypes, while 
yellow bands represent „heterozygous‟ and „rare homozygous‟ genotypes. A region of shared 
homozygosity centred on 100Mb is readily apparent using this colour scheme. 
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2.5.2 Whole Exome Sequencing 
 
This section briefly explains the process of WES generated by SOLiD 4 genetic analysers 
(Life Technologies), which was carried out not by the author but by the sequencing core 
facility at King Faisal Specialist Hospital and Research Center, Genetics Department. It was, 
however, necessary to ensure that the DNA was of high quality, was documented by gel 
assay and supported A260/A280 measurements. The DNA was at a concentration of about 
20-30 μg (in low TE buffer). 
 
2.5.2.1 Exome DNA fragment library and depth of coverage 
 
The first step of WES is to generate library files. In this step each DNA sample was randomly 
sheared with sonication, and then sequencing adaptors (P1 and P2 adaptors by Life 
Technologies) were aligned onto the end. In this assay PE sequencing was used with forward 
sequencing read up to 50bp from the P1 adaptor in the 5‟-3‟ direction plus a reverse sequence 
read up to 35bp reads in the 3‟-5‟ direction. 35bp is the maximum reverse read. The PE 
sequencing is believed to improve data mapping and the accuracy of the analysis of repetitive 
regions and structural variants (Figure 2-9) [236]. 
 
An exome library is enriched for specific targeted regions that include exons and a flanking 
region. An extra step was taken in sequence capturing to separate the targeted sequencing 
from the rest of the genome. In this step the Agilent Technologies SureSelect Human All 
Exon 25 reactions kit was used. 
 
Next generation sequencing consists of many random short reads that scarcely cover the 
whole genome. Therefore, it was necessary to generate multiple sequences larger than the 
actual size of the genome, e.g. 10-fold, 20-fold, 30-fold and so on. These are known as the 
average depth of coverage. This step is important in ensuring that a sufficient proportion of 
the genome is sequenced and also helps to distinguish true sequence variants from 
sequencing error. 
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Figure 2-9: Library preparation. Genomic DNA is randomly sheared into short 
fragments of less than 500bp. The library fragments are then attached to adaptors (shown in 
blue and green). 
Source: Figure reproduced from the Ten Step Guide produced by the University of Calgary, Alberta, Canada 
(http://research4kids.ucalgary.ca/genomics/10steps-3) 
 
2.5.2.2 Emulsion PCR and bead enrichment 
 
It is important at this stage to choose an emulsion PCR (emPCR) reaction that will provide 
sufficient sequencing beads for the depth of the sequencing required. In this run, the 
sequencing core facility at King Faisal Specialist Hospital and Research Center, Genetics 
Department used an E80 emPCR scale with a yield of around 130 million enriched beads. 
Libraries were also quantified using Taq-Man reverse transcription polymerase chain reaction 
(RT-PCR) assay. An aqueous phase was then prepared containing a DNA library, the 
reagents required for PCR amplification and solid-phase magnetic sequencing beads 
containing the P1 capture sequence. To set up an emPCR reaction, water in oil emulsion was 
created with a milky white texture containing billions of aqueous phase droplets surrounded 
by oil. In this phase, sufficient library and sequencing beads are needed to maximise the 
population of aqueous micelles and increase coverage. The PCR took place in a special 
thermal cycler known as an EZ-Bead Amplifier (Figure 2-10). After PCR, denaturation of the 
template bead enrichment stage separated beads with extended templates from undesired 
beads. The templates on the selected beads were then deposited onto a sequencing slide. 
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Figure 2-10: Process of emPCR to whole exome sequencing illustrating the process from 
emPCR to sequencing. A. emPCR reaction is placed in a tube. B. A single reaction droplet 
containing DNA capture bead, single DNA template and PCR reagents. C. The same droplet 
prior to amplification in which the DNA capture bead is covered with a number of copies of 
template DNA. D. Emulsions are broken and the different bead populations can be seen. E. 
Enrichment process of the beads. F. Sequencing of beads using SOLiD 4. 
Source: Figure reproduced from the Ten Step Guide produced by the University of Calgary, Alberta, Canada 
(http://research4kids.ucalgary.ca/genomics/10steps-3) 
 
2.5.2.3 Sequencing ligation 
 
Universal primers n, n-1, n-2, n-3 and n-4 were hybridised to the adaptor P1 sequence on the 
template beads. Four di-base probes competed for ligation with the sequencing primer in the 
presence of ligase. The di-base probe was interrogated every first and second base in each 
ligation reaction. The probe was then cleaved and another ligation cycle was started (Figure 
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2-11). The extension product was removed and the template was reset with a primer 
complementary to the universal primer position for the second round of the ligation cycle, 
with five rounds of primer resets for each sequence tag. Every base was interrogated in two 
different universal primers involving two ligation cycles. Multiple ligation cycles were 
performed. In this run 15 ligation cycles were carried out to obtain 75bp read. 
 
 
Figure 2-11: Sequencing by ligation showing the ligation step in which the universal 
primer binds to the adaptor on the template with the help of ligase. Four different di-base 
probes (shown in green, orange, blue and red) compete for ligation to the sequence primer by 
interrogating every first and second base. Process cleavage is then performed, and multiple 
ligation cycles are repeated. 
Source: Figure reproduced from the Ten Step Guide produced by the University of Calgary, Alberta, Canada 
(http://research4kids.ucalgary.ca/genomics/10steps-3) 
 
2.5.3 Generation of variant calls from whole exome sequencing data using genome 
quest 
 
GenomeQuest is a sequencing data management company, based in the US 
(http://www.genomequest.com). This company has a contract with King Faisal Specialist 
Hospital and Research Center, Genetics Department, to carry out bioinformatics work and 
generate variant calls from SOLiD 4 csfasta and .qual files. GenomeQuest applied the QC 
measures, mapped sequencing reads to the reference genome, and carried out the variant 
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calling. The generation of variant calls from SOLiD 4 output files was not carried out by the 
author. 
2.5.3.1 Filtration of variants generated from whole exome sequencing and identification 
of candidate gene mutations 
 
All variants generated from GenomeQuest are saved in the company‟s servers. The author 
was given a user ID and password to access the data. The data were in table format consisting 
of seven columns: description of variant, chromosome/position, gene name, coverage locus, 
% coverage allele, predicted impact and if positioned in known variant (Table 2-13). Four 
phases were undertaken to identify candidate gene mutations. 
 
2.5.3.1.1 Phase I: Extraction of variants from GenomeQuest 
 
GenomeQuest provides a list of all variants generated from WES data for each individual e.g. 
.vcf file. Ten individuals, one from each family, were analysed. Each individual had an 
individual variant file. Phase I filtration was run on each individual using GenomeQuest 
filtration options. This phase consisted of four steps. The first step was to select variants 
positioned in exons (coding region). The second step was to exclude all variants with a silent 
prediction impact (silent mutations). The third step was to set a percentage of coverage allele 
to greater than 95, which helped in the selection of potentially homozygous alleles. The 
fourth step was to set a threshold of x8 sequencing depth. 
 
2.5.3.1.2 Phase II: Prioritisation of homozygous mutations 
 
A list of homozygous gene mutations was generated. Homozygous mutations were prioritised 
mainly according to the occurrence of the same mutation in more than one family, and also 
according to: 
1. Genes overlapping with ROH and with regions that have a LOD score of 1 and above. 
2. Genes in the pathway of known obesity or diabetes genes. 
3. Genes expressed in the brain. 
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4. Genes expressed in adipose tissue. 
5. Association with obesity. 
6. Association with diabetes. 
All the information required to perform this filtration process was collected from research 
papers and various databases. For the gene pathways, both STRING (http://string-db.org/) 
and GeneDistiller 2 (http://www.genedistiller.org/) were used. Gene expression information 
was collected from GeneCards (http://www.genecards.org/) and GeneDistiller 2 
(http://www.genedistiller.org/). Information regarding genes associated with obesity and 
diabetes was collected from a range of publications. 
 
2.5.3.1.3 Phase III: Comparison of candidate homozygous mutations with normal Saudi 
controls 
 
Candidate homozygous gene mutations found in any of the families were compared with 
variants generated from Saudi controls using the SOLiD 4 platform (Life Technologies). 
 
2.5.3.1.4 Phase IV: Comparison of mutations using SIFT and PolyPhen-2 software 
 
SIFT (Version 4.0.3b, http://sift.jcvi.org/) and PolyPhen-2 (Version 2.1.0, 
http://genetics.bwh.harvard.edu/pph2/) were used to predict whether an amino acid 
substitution affected the protein function. Both SIFT and PolyPhen-2 predict the degree of 
conservation of amino acid residues in sequence alignments derived from closely related 
sequences. This prediction enables the classification of mutations as damaging or non-
damaging. The software can be applied to non-synonymous polymorphisms and missense 
mutations. In this analysis, all candidate mutations in known and candidate novel obesity 
genes were submitted to both SIFT and PolyPhen-2. 
 
A final list of candidate gene mutations was generated and was ready to be sequenced using 
Sanger sequencing. Table 2-13 presents six columns consisting of the ID of the variant, a 
description of the type of mutation and amino acid change, chromosome and position, gene 
Chapter Two: Material and Methods 
98 
 
name and database name, indicating the sample ID and what kind of sequencing was carried 
out. 
Table 2-13: Capture of WES variants generated from GenomeQuest 
Description Chromosome 
And Position 
Gene 
Name 
Coverage 
Locus 
% 
Coverage 
Allele 
Predicted  
Impact 
Positioned In Known 
Variant 
Mismatch 
allele on 
chromosome 
11 position 
17414556 
from G to A 
NC_000011.9-
17414556-
17414556 
ABCC8 6 100 NM_000352.3 
Silent TTC (F) 
to TTT (F) at 
protein position 
1576 ; 
TRUE rs73419228 
ref:G observed:A/G 
class:single 
validation:by-
cluster,by-
1000genomes 
function:coding-synon 
locustype:exact 
Mismatch 
allele on 
chromosome 
11 position 
17483110 
from G to A 
NC_000011.9-
17483110-
17483110 
ABCC8 22 45.4545 empty FALSE 
Reference 
allele on 
chromosome 
11 position 
17483110 
from G to G 
NC_000011.9-
17483110-
17483110 
ABCC8 22 54.5455 empty FALSE 
Mismatch 
allele on 
chromosome 
11 position 
17418477 
from C to A 
NC_000011.9-
17418477-
17418477 
ABCC8 14 100 NM_000352.3 
TRUE Amino 
acid change 
GCC (A) to 
TCC (S) at 
protein position 
1369 ; 
TRUE rs757110 ref:C 
observed:G/T 
class:single 
validation:by-
cluster,by-
frequency,by-2hit-
2allele,by-hapmap,by-
1000genomes 
function:missense 
locustype:exact 
 
2.5.4 PCR-based validation of candidate genes identified from whole exome 
sequencing 
 
Primers were designed using Primer 3 software (reference). These were also checked for 
specificity using Blast (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The length of the primers was 
between 10 and 25 nucleotides. The desirable G-C content was between 40 and 60% with an 
annealing temperature (Tm) between 55 and 75°C. Primers were designed for all genes to 
include 100pb upstream from the beginning of the exon and 100 kb downstream from the end 
of the exon. Primer information and the families in which they were used are described in 
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Table 2-14. Primer sequencing is given in Table 2-15 to Table 2-18. 10ng/μl and 23.25μl of 
PCR reaction mix were used in this PCR reaction. All PCR products were examined by 2% 
agarose gel electrophoresis and prepared with 1% tris-borate EDTA (TBE) and 0.1ng/μl 
ethidium bromide at 120V for 30 minutes. 100bp DNA ladder (New England Biolabs) was 
included in the gel to assist in the estimation of PCR fragment size. The mutations 
investigated here were selected according to the variants found from WES following the 
filtration process explained above. 
 
Table 2-14: Candidate genes and families in which they were sequenced 
Gene name Family  
MC4R Family 8 
LIPN3 Family 8 
FES Family 8 
CHRNA7 Family4, Family6 and Family 10 
 
Table 2-15: Primer sequences of CHRNA7 gene 
Primer Sequence  
CHRNA7 exon 1 forward primer ctcgtcacgtggagaggc 
CHRNA7 exon 1 reverse primer gtgcagcccagacaagca 
CHRNA7 exon 2 forward primer aggagggagtcgggggta 
CHRNA7 exon 2 reverse primer acgctgtctaaaaagcccct 
CHRNA7 exon 3 forward primer ctcagggaggtgttttggaa 
CHRNA7 exon 3 reverse primer ctgcagatctgggcttttct 
CHRNA7 exon 4 forward primer ggaagtgcttggtgcattct 
CHRNA7 exon 4  reverse primer tcagaagcaagcatctcagg 
CHRNA7 exon 5 forward primer agccaaggaagtgaagtgct 
CHRNA7 exon 5 reverse primer aacatatccagcatctctgtgaaa 
CHRNA7 exon 6 forward primer tgcatattggcacatggagt 
CHRNA7 exon 6 reverse primer gcaggggaagtttctgcat 
CHRNA7 exon 7 forward primer gctccatcaaagacagaccc 
CHRNA7 exon 7 reverse primer cacccaaactcgcttcagtt 
CHRNA7 exon 8 forward primer actgtgttagctgcagtgcg 
CHRNA7 exon 8 reverse primer ttttaaagcttgcccaggaa 
CHRNA7 exon 9 forward primer tgcttgtgtgtggtatacacattg 
CHRNA7 exon 9 reverse primer tctcagcagaaggtctccag 
CHRNA7 exon 10 forward primer ggagccctcgttagacagaa 
CHRNA7 exon 10 reverse primer atcctgggcacactctaacc 
CHRNA7 exon 11 forward primer ggtgtgcctgtcctgtgac 
CHRNA7 exon 11 reverse primer aaataaaccctaggaggagcc 
CHRNA7 exon 12_1 forward primer tactgctgttgggatcagcc 
CHRNA7 exon 12_1 reverse primer GAAGGCCATGAGGCACAG 
CHRNA7 exon 12_2 forward primer CCAAGATCCTGGAGGAGGTC 
CHRNA7 exon 12_2 reverse primer TTCCAGGCAGTGGGCTAAT 
CHRNA7 exon 12_3 forward primer AGATATCCTTGGCACATCCG 
CHRNA7 exon 12_3 reverse primer TAAACAGAAACCTGCGTCCC 
CHRNA7 exon 12_4 forward primer TTTTACCAGCCTGCCTGACT 
CHRNA7 exon 12_4 reverse primer TGGCCAGGTATCCAGAGAAG 
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Primer Sequence  
CHRNA7 exon 12_5 forward primer AGGCTGGGAACTCTTCTGGT 
CHRNA7 exon 12_5 reverse primer TGAGACCATCCTGGCTAACA 
CHRNA7 exon 12_6 forward primer CACCATGCCTGGCTAATTTT 
CHRNA7 exon 12_6 reverse primer GAGGAATGATCCTGCTCCAA 
CHRNA7 exon 12_7 forward primer GCGGTGTGTGTGTGTGTGTA 
CHRNA7 exon 12_7 reverse primer GGTCCCCTCTGAGAGAGAAAA 
CHRNA7 exon 12_8 forward primer GTGCACATAGTTAGAAAAGTATGAGTG 
CHRNA7 exon 12_8 reverse primer CCTTAAACCCAGCAATTCCA 
CHRNA7 exon 12_9 forward primer TTGGCATACTTGTACATACATCTTGA 
CHRNA7 exon 12_9 reverse primer TGCCAATAAATAAGGAAATCAATAAA 
CHRNA7 exon 12_10 forward primer TGCACTTTGGGACATTTTTG 
CHRNA7 exon 12_10 reverse primer GAATAATGCTTTAGAAATGAAAGGC 
CHRNA7 exon 12_11 forward primer CAGTTGTTCAAAATGCAGCC 
CHRNA7 exon 12_11 reverse primer CACATTGGAAAGGAGAAGTCAA 
CHRNA7 exon 12_12 forward primer TCCCATTGTATAAGAAAGTAGTTGG 
CHRNA7 exon 12_12 reverse primer tgagaaggctttgacaaaaatc 
 
Table 2-16: Primer sequences of FES gene 
Primer Sequence  
FES exon 1 forward primer Ctcctcccttccgtttcc 
FES exon 1 reverse primer Cacctgggtgggtctctg 
FES exon 2 forward primer Gcagtccatcctgaccctac 
FES exon 2 reverse primer Ctgccagatctccagccact 
FES exon 3 forward primer aatgcttgggagccattgt 
FES exon 3 reverse primer cacttccccagtgaatccag 
FES exon 4 forward primer ccagaagtctccaggtgctc 
FES exon 4 reverse primer ccttgtcacggtccttgtct 
FES exon 5 forward primer agggaatccgaagccagt 
FES exon 5 reverse primer attttctgggtcctgcctct 
FES exon 6 forward primer atttgcctagagtggcatgg 
FES exon 6 reverse primer ctcatcgaacgtgacacagg 
FES exon 7 forward primer tcctgcgacagtatgggtaa 
FES exon 7 reverse primer acagtctccacgacctagcc 
FES exon 8 forward primer agggctaggtcgtggagact 
FES exon 8 reverse primer tgggagggtggatgagaata 
FES exon 9 forward primer ccctaactgctgctggctac 
FES exon 9 reverse primer ctctcgctcctgctcctg 
FES exon 10 forward primer ggatgaccgccactccac 
FES exon 10 reverse primer gacatctgcagcctggaatc 
FES exon 11 forward primer cctgtggatggctctgcat 
FES exon 11 reverse primer ggtctctgtggccccttc 
FES exon 12 forward primer tggcatcttttctggaggtc 
FES exon 12 reverse primer gagggtcactcactctgcatc 
FES exon 13 forward primer cccacccctggtcacata 
FES exon 13 reverse primer acaagtggggaatcagatgg 
FES exon 14 forward primer gagggtcaaactcccagaga 
FES exon 14 reverse primer gcctcgaggactaaacacca 
FES exon 15 forward primer acccccttatagtgccgaag 
FES exon 15 reverse primer GATGTTGGGGTGGCTGTACT 
FES exon 16 forward primer aagcagcccatctacatcgt 
FES exon 16 reverse primer ctaccacagaggccaactcc 
FES exon 17 forward primer cagcttttgtccttggcttt 
FES exon 17 reverse primer gtcgctttcggaggagtagc 
FES exon 18 forward primer gcacctgaggcccttaacta 
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Primer Sequence  
FES exon 18 reverse primer ttattctgcctggtgggaag 
FES exon 19 forward primer ggagaacagtgcatccttcag 
FES exon 19 reverse primer gcatactgcctgtcctcctc 
 
Table 2-17: Primer sequences of LPIN3 gene 
Primer Sequence  
LPIN3 exon 1 forward primer accctgtcttagaggacccg 
LPIN3 exon 1 reverse primer ggaaggaatgtaggatggca 
LPIN3 exon 2 forward primer agcttcttgtggaggagctg 
LPIN3 exon 2 reverse primer ccactctgcagtagccacct 
LPIN3 exon 3 forward primer actggaggaccagccagg 
LPIN3 exon 3 reverse primer cagaagaggcacaggaaagg 
LPIN3 exon 4 forward primer agatgactgtgtggtgagcg 
LPIN3 exon 4 reverse primer cagcatgagcagaggaaaca 
LPIN3 exon 5 forward primer cctgatgtccaggctctcat 
LPIN3 exon 5 reverse primer gcaaatggaaacctcagacc 
LPIN3 exon 6 forward primer atgggtaggcaggctcaag 
LPIN3 exon 6 reverse primer cgagtttcagtccctccaac 
LPIN3 exon 7 forward primer cttaccctggcccacatct 
LPIN3 exon 7 reverse primer tacttgaagtcccagcaccc 
LPIN3 exon 8 forward primer gtccacactgctgagcacat 
LPIN3 exon 8 reverse primer tcctcacaggcccttgatag 
LPIN3 exon 9 forward primer gccctcctcgtattcttgtc 
LPIN3 exon 9 reverse primer caccctcacagtcttccctg 
LPIN3 exon 10 forward primer gtcacatgggatgtgccag 
LPIN3 exon 10 reverse primer tcacccttcacttccttgct 
LPIN3 exon 11 forward primer gggtcccaagaacaacgtaa 
LPIN3 exon 11 reverse primer catctttcccaggctccc 
LPIN3 exon 12 forward primer gacaggtccagcctcctctt 
LPIN3 exon 12 reverse primer agaattagctcagcccctcc 
LPIN3 exon 13 forward primer agtgcctggctgtcatcaat 
LPIN3 exon 13 reverse primer gagtccacaacccctctcc 
LPIN3 exon 14 forward primer gtggagctgccttggagtaa 
LPIN3 exon 14 reverse primer cccaagatgtcctgtcctgt 
LPIN3 exon 15_1 forward primer gcaggctaaagccagagaaa 
LPIN3 exon 15_1 reverse primer GAAACAGCTGCTGGATGTCA 
LPIN3 exon 15_2 forward primer CCCAGAGAGGTGATCGAGAA 
LPIN3 exon 15_2 reverse primer cagactccccggtaagaggt 
LPIN3 exon 16_1 forward primer gtggcagctcaggctcagt 
LPIN3 exon 16_1 reverse primer CTGGGCAACAGAACAAGACC 
LPIN3 exon 16_2 forward primer GGGGCAATTAGCTTGTCATC 
LPIN3 exon 16_2 reverse primer GGCTGTACCACACTCCCACT 
LPIN3 exon 16_3 forward primer AGGACAGGGAGAAGAGGGAG 
LPIN3 exon 16_3 reverse primer AGTAGGGCAGGCTCTGGATT 
LPIN3 exon 16_4 forward primer CAACCTCTCCTCCCACTGTC 
LPIN3 exon 16_4 reverse primer GTGCCCACACTGTCCTCTTC 
LPIN3 exon 16_5 forward primer CCTCATTCAGGCCACTTTGT 
LPIN3 exon 16_5 reverse primer Ccagatgtttctggctcctc 
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Table 2-18: Primer sequences of MC4R gene 
Primer Sequence  
MC4R exon 1_1 forward primer GGTGTCATCAGCTTGTTGGA 
MC4R exon 1_1 reverse primer TGCAAGCAAGGAGCTACAGA 
 
Touchdown PCR Thermocycler Conditions 
95°C for 15 minutes 
95°C for 45 seconds 
67°C for 45 seconds -1/cycle 
72°C for 1 minute 
Go to 2 for 9 cycles 
95°C for 45 seconds 
57°C for 45seconds 
72°C for 1 minute  
Go to 6 for 29 cycles 
72°C for 10 minutes 
10°C hold 
 
Touchdown PCR was used on all PCR reactions. This PCR avoids non-specific sequence 
amplification. The melting point of the primers determines the upper limit of the annealing 
temperature. Temperatures just below this point will cause very specific base pairing between 
the primer and template. At lower temperatures primers bind with less specificity. Non-
specific primer binding obscures the PCR results as the non-specific sequences in which 
primers anneal in early steps of amplification will remove any specific sequences because of 
the exponential nature of PCR amplification [237]. 
 
The initial step of the touchdown PCR protocol uses a high annealing temperature, and for 
every subsequent two cycles the annealing temperature is decreased by 1°C. This allows the 
primers to anneal at the highest temperature and thus avoids non-specific binding. The first 
sequence amplified and the primers bound are in the region that is most likely to be of 
interest. These regions are further amplified during subsequent rounds at lower temperatures. 
The primers were all made up in one tube to 5μM with a total volume of 500μl. The reaction 
conditions are shown in Table 2-19. 
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Table 2-19: PCR reaction mix for sequencing the MC4R, LIPN3, FES and CHRNA7 
genes 
Reagents Volume per reaction x1 Total volume (x40) 
Sterile ddH2O 17.5μl 690μl 
10x PCR buffer (Promega) 2.5μl 100μl 
dNTPs (2.5mM) (Premixed dNTP Epicentre) 1μl 40μl 
Gene forward primer (5μM) 1μl 40μl 
Gene reverse primer (5μM) 1μl 40μl 
Hotstar Taq polymerase (Qiagen) 0.25μl 10μl 
Total 23.25μl 920μl 
 
2.5.5 Sequencing 
 
The first step of the sequencing method is to clean up the PCR product. Clean-up is done 
using 10μl of the PCR product mixed with 5μl of EXOSAP (USB). This is then placed in a 
thermocycler at 37°C for 15 minutes and 80°C for 15 minutes. Next, the product is taken to 
the Sequencing Core Facility at King Faisal Specialist Hospital and Research Center to run 
the sequencing reaction and clean-up stage. The sequencing was performed using an ABI 
3700 sequencing machine. Sequences were performed in both forward and reverse directions 
for all the exons for melanocortin 4 receptor (MC4R), cholinergic receptor, nicotinic, alpha 7 
(CHRNA7), feline sarcoma oncogene (FES) and lipin 3 (LPIN3). Sequencing data were 
analysed using Mutation Surveyor software 
(http://www.softgenetics.com/mutationSurveyor.html). This software can rapidly locate 
differences between a sequence and its reference. Mutation Surveyor can detect Indels, 
homozygous mutations, heterozygous mutations, duel insertions and heterozygous insertions 
and deletions (Figure 2-12). 
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Figure 2-12: Sequencing software package Mutation Surveyor. This captured 
chromatogram picture generated by Mutation Surveyor shows the reference sequence (top) 
and the sequence (bottom). The lower table shows nucleotide changes in the sequence, their 
location and whether they cause any protein changes. 
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3 Monogenic Forms of Obesity in Consanguineous Saudi 
Families with Extreme Obesity 
 
3.1 Introduction 
 
Investigation of consanguineous families has proved an effective approach for the elucidation 
of monogenic recessive forms of obesity [37, 47-50]. A consanguineous marriage is generally 
defined as a marriage between cousins or other related individuals [238]. More generally they 
are „unions of individuals with at least one common ancestor such as occurring within 
population isolates, small towns, and tribes; intra-community or endogamous marriages‟ 
[239]. Consanguinity increases the frequency of recessive disorders by increasing the risk of 
bringing together two copies of a mutated gene that is present in a single copy in the 
individual‟s parents [240, 241]. Study of consanguineous families is a powerful approach to 
the identification of high-penetrance recessive functional alleles that may be even rarer in 
out-bred populations, and in which the homozygous state of these disease-causing alleles is 
virtually non-existent. Indeed, consanguinity results in increased numbers and size of 
„regions of homozygosity‟ (ROH) that can be used to pinpoint disease loci. Studies of Saudi, 
Pakistani and Omani families have enabled rapid and efficient identification of the causative 
mutations of retinitis pigmentosa, Knobloch syndrome and Bardet-Biedl syndrome 
respectively [240, 242, 243]. 
 
The population of Saudi Arabia remains tribal, with high levels of consanguinity. The most 
common and frequent form of consanguinity is marriage between paternal first cousins 52% 
[244]. Double first cousin and second cousin marriages also exist but are less common 39.3% 
[244]. This presents the opportunity to investigate such families in order to define novel 
genes for obesity, a condition that is very prevalent in Saudi Arabia. 
 
Previous examination of consanguinous cases with obesity has provided the first direct 
evidence that genetic factors play a considerable role in bodyweight regulation, and the 
discovery of LEP and LEPR mutations [37, 47-50] has led to a deeper understanding of 
appetite control [1, 4, 37, 47, 48, 50, 51]. The hypothalamus, where leptin acts, plays a 
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central role in the regulation of appetite and body weight [30]. From these and other 
discoveries, it is now clear that obesity is a neuroendocrine disorder in which environmental 
factors and genetic predisposition interact in the development of the disease [30, 60]. Indeed, 
mutations in most key genes of the leptinergic-melanocortinergic pathway cause monogenic 
obesity [30, 62-64]. Examples are found in PC1, POMC and MC4R genes [22-30]. These 
mutations are usually inherited in an autosomal dominant (MC4R) or recessive (POMC, PC1) 
fashion, and altogether account for about 5-6% of severely obese children [30, 64, 68]. 
 
This chapter describes the strategy of employing the „extreme obesity phenotype‟ [2] to 
identify monogenic (Mendelian) obesity cases in the ten Saudi consanguineous families. To 
do this a whole-exome sequencing approach was used to screen for known and possibly 
novel monogenic obesity genes in these families. Some previous studies have proved that this 
high-throughput approach may be successful in identifying numerous new rare de novo or 
inherited causal mutations [195, 245-248]. No systematic study of this kind on genetic forms 
of obesity has been carried out previously in Saudi and/or Middle Eastern populations. 
 
3.2 Whole genome SNP array quality control 
 
Before running linkage analysis and ROH, whole genome SNP arrays must go through QC. 
As mentioned in Chapter Two, Axiom chip (629,443 SNPs) was run on all members of the 
ten consanguineous Saudi families with extreme obesity. Ninety-eight per cent of all the 
Axiom chips passed the cut-off threshold of a 97% calling rate. 
 
Quality control was undertaken using various software (see Chapter Two, Section 2.5.1.1). 
The missing proportion was 5% by individual and zero by SNP. The frequency test of MAF 
< 0.05 was failed by 110,401 SNPs. Thirty-seven markers failed the HWE test of p ≤ 1E-06 
in cases and five markers failed in controls. ME was calculated for each chromosome and 
removed from the PED file. Table 3-1 shows the total number of genotypes removed with 
more than 10% ME per chromosome. 
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Table 3-1: Number of missing genotypes removed from each chromosome with more 
than 10% Mendel error rate 
Chromosome Number of Mendelian Errors Removed 
Chromosome 1 29276 
Chromosome 2 28166 
Chromosome 3 24666 
Chromosome 4 24434 
Chromosome 5 22409 
Chromosome 6 24434 
Chromosome 7 18634 
Chromosome 8 20168 
Chromosome 9 16388 
Chromosome 10 15921 
Chromosome 11 15289 
Chromosome 12 15865 
Chromosome 13 13658 
Chromosome 14 11403 
Chromosome 15 10563 
Chromosome 16 9894 
Chromosome 17 6722 
Chromosome 18 10480 
Chromosome 19 4557 
Chromosome 20 7840 
Chromosome 21 5076 
Chromosome 22 3385 
 
3.3 Discovery of Genomic Regions of Interest 
 
Two principal processes were used for the discovery of genomic regions of interest. Linkage 
analysis and ROH of ten pedigrees was followed by WES of eight individuals, which will be 
presented in the next section, with analysis restricted to linkage and ROH intervals, or within-
family analysis of WES variant sharing. 
 
Linkage analysis was followed by ROH analysis to narrow the region of interest. An 
exploration of strategies using different linkage and ROH software is presented in this 
section. 
 
3.3.1 Informativeness of SNPs 
 
Before running the linkage analysis, the informativeness of each marker was calculated using 
Merlin (see Chapter Two). The output file consists of three columns: marker, chromosome 
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and informativeness value of marker. The frequency of the most informative SNPs was later 
calculated and plotted using R statistical package (R Version 2.13.2) (Figure 3-1). The most 
informative SNPs were selected according to a frequency within all families of between 0.25 
and 0.3 (Figure 3-1). 
 
Having selected the most informative markers, and before running the linkage analysis, one 
further step was undertaken, as explained in Chapter Two, to prune out SNPs which were 
not in LD by removing one of a pair of SNPs if the LD was greater than 0.05. 
 
Figure 3-1: Informativeness value for all markers within all families and their 
frequency. Markers with informativeness value between 0.25 and 0.3 have the highest 
frequency. 
  
 
Informativeness value 
0.0 0.1 0.2 0.3 0.4 
0 
10000 
20000 
30000 
40000 
Chapter Three: Monogenic Forms of Obesity 
110 
 
3.3.2 Linkage analysis 
 
Following selection of the most informative low-LD SNPs, with calculation of proportions 
6,000, 86,000 and 444,000 as explained in Chapter Two, linkage analysis was run on each 
of these different proportions of SNPs to see which proportion would give a better LOD 
score. 
 
Linkage analysis was run using two different software packages: Merlin (Version 1.1.2, 
http://www.sph.umich.edu/csg/abecasis/merlin/tour/linkage.html) and EasyLinkage software 
[234, 249]. Chapter Two provides a more detailed explanation of the parameters used for 
linkage analysis. This section presents the results of running both Merlin and EasyLinkage. 
 
3.3.2.1 Merlin 
 
Merlin was run twice. The first linkage analysis included all ten families run together in a 
single linkage analysis. The second run was done family by family. The analysis was a non-
parametric linkage analysis with a –rsq of 0.1 (see Chapter Two, Section 2.10.3). 
 
All regions with LOD > 1 were taken over for further analysis. The position of the first 
bordering marker with an LOD > 0 was recoded as the boundary of the linkage interval. 
 
3.3.2.1.1 Running linkage on all ten families 
 
The three proportions of SNPs used for linkage analysis mentioned above were run on all ten 
families in a single linkage analysis to establish whether these families share the same 
linkage interval. The LOD scores for each proportion of SNPs used in this analysis are 
presented below. 
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3.3.2.1.1.1 Linkage analysis results using 6,666 SNPs 
 
This analysis generated ten linkage peaks ranging between 0.7 and 1.6 (Table 3-2 and Figure 
3-2, 3-3). The highest LOD score was in chromosome 20 with an LOD score of 1.6. 
Chromosome 20 passed the threshold of LOD > 1 and was considered as an area of linkage. 
 
Table 3-2: Linkage intervals using 6,666 SNPs. Limits of each peak are defined by 
position of first adjacent marker with LOD > 0. 
Chromosome Start position End position Start marker End Marker Max LOD 
2 11515000 23761200 rs71439058 rs7576864 0.7 
5 150160000 155240000 rs73280108 rs702848 0.7 
8 80915000 94070000 rs16919579 rs880264 0.8 
9 10024 2685000 rs200405949 rs113533325 0.7 
9 19872000 21555000 rs73436250 rs116361520 0.7 
15 24298000 29136000 rs74003421 rs143108722 0.7 
17 74030000 78584000 rs145301667 rs12945061 0.7 
18 6475000 61093000 rs79464609 rs7238199 0.7 
19 3986000 61353000 rs10418537 rs73505809 0.7 
20 55739000 63025519 rs111509196 rs188206903 1.6 
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Figure 3-2: LOD scores from linkage analysis of 6,666 SNPs for chromosome 2, 5, 8 and 
9. The figure shows nine chromosomes with LOD scores between 0.7 and 1.6. 
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Figure 3-3: LOD scores from linkage analysis of 6,666 SNPs for chromosome 18, 19 and 
20. The figure shows nine chromosomes with LOD scores between 0.7 and 1.6. 
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3.3.2.1.1.2 Linkage analysis results using 86,000 SNPs 
 
This analysis generated 11 linkage peaks ranging between 0.7 and 1.4 (Table 3-3 and Figure 
3-4). The highest LOD score was in chromosome 20 with an LOD score of 1.4. Chromosome 
20 passed the threshold of LOD > 1 and was considered as an area of linkage.  
 
Table 3-3: Linkage intervals using 86,000 SNPs. Limits of each peak are defined by 
position of first adjacent marker with LOD > 0. 
Chromosome Start position End position Start marker End Marker Max LOD 
5 150160000 155240000 rs73280108 rs980914 0.8 
8 80915000 94070000 rs16919579 rs880264 0.8 
9 10024 2736000 rs200405949 rs1454634 0.7 
9 19689000 22275000 rs2383114 rs78845166 0.7 
15 90458000 98449000 rs60916012 rs77643863 0.8 
17 60515000 62214000 rs146646642 rs6504205 0.7 
17 73319000 76612000 rs117279037 rs62073849 0.7 
18 1837000 1972000 rs1371274 rs73377739 0.7 
18 5867000 11118000 rs117417820 rs7232631 0.7 
18 50585000 65707000 rs8094770 rs72933583 0.7 
20 55739000 60705519 rs73165353 rs72933583 1.4 
 
 
Figure 3-4: LOD scores from linkage analysis of 86,000 SNPs. The figure shows nine 
chromosomes with LOD scores ranging between 0.7 and 1.4. 
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3.3.2.1.1.3 Linkage analysis results using 444,000 SNPs 
 
This analysis generated 30 linkage peaks ranging between 0.7 and 2.0 (Table 3-4 and Figure 
3-5). The highest LOD score was in chromosome 20 with an LOD score of 2.0. Chromosome 
20 passed the threshold of LOD > 1 and was considered as an area of linkage. It is important 
to note that, although the number of peaks is greater when running 444,000 SNPs, all the 
linkage peaks are within the same regions as in the 6,666 SNP and 86,000 SNP linkage 
analyses. 
 
Table 3-4: Linkage intervals using 444,000 SNPs. Limits of each peak are defined by 
position of first adjacent marker with LOD >0. 
Chromosome Start position 
bp 
End position 
bp 
Start marker End Marker Max LOD 
2 215150000 237612000 rs77669679 rs80259855 0.8 
5 150160000 155240000 rs73280108 rs702848 0.8 
8 80915000 94070000 rs16919579 rs880264 0.8 
9 204850 1601711 rs16921172 rs10962222 0.7 
9 1714233 1884092 rs1038050 rs2039318 0.7 
9 1917561 1938161 rs13439958 rs10964085 0.7 
9 1975039 2359639 rs6475358 rs10114018 0.7 
9 19579427 20097229 rs3780215 rs10811317 0.7 
11 221659 3540513 rs6421986 rs10767177 0.7 
11 88644704 88680133 rs5023644 rs5017677 0.7 
11 91994044 95745272 rs16917259 rs662766 0.7 
11 97804083 115616371 rs4494277 rs2285253 0.7 
15 24021115 25108837 rs1094837 rs5001649 0.8 
15 25802742 26057621 rs7181164 rs1345098 0.8 
15 26621229 26906344 rs10873629 rs7171512 0.8 
15 38118873 39114445 rs8036796 rs2624261 0.8 
15 53772230 54336060 rs1516418 rs28681565 0.8 
15 54661020 58072391 rs572288 rs12902487 0.8 
15 90458000 98449000 rs60916012 rs77643863 0.8 
17 2678932 2778987 rs9894753 rs9904506 0.7 
17 16479054 48020189 rs9911849 rs9902552 0.7 
17 52301586 54610248 rs7219990 rs7208587 0.7 
17 58361461 64783538 rs8064588 rs9916520 0.7 
17 76091180 76913009 rs16970811 rs7222767 0.7 
18 4335000 53242000 rs79743982 rs41396445 0.7 
18 60113000 63314000 rs948757 rs8092208 0.7 
19 3986000 61353000 rs10418537 rs73505809 0.8 
20 7024440 12893663 rs7274534 rs35774676 2.0 
20 16855220 16140886 rs6080459 rs6034404 2.0 
20 55739000 63025519 rs111509196 rs188206903 2.0 
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Figure 3-5: LOD scores from linkage analysis of 444,000 SNPs showing nine 
chromosomes with LOD scores ranging between 0.7 and 1.4. 
 
3.3.2.1.2 Running linkage on individual families 
 
Linkage analysis was also run per family using Merlin. This analysis was carried out to 
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8, 9, 11, 15, 17, 18, 19 and 20) were re-analysed for each family. The SNP with the highest 
LOD score for each chromosome was selected and is shown in Tables 3-5 to 3-15. After 
running the linkage analysis per family on the selected chromosomes, the sum of the SNP 
with the highest LOD score was then calculated within all families (Table 3-16). 
 
Table 3-5: rs12062017 SNP with highest LOD score per family in chromosome 1 
Chromosome Family SNP LOD score 
1 9 rs12062017 0.639308 
1 5 rs12062017 0.456869 
1 8 rs12062017 0.342675 
1 1 rs12062017 0.162727 
1 2 rs12062017 0.162727 
1 4 rs12062017 0.162727 
1 3 rs12062017 -0.003548 
1 7 rs12062017 -0.01418 
1 6 rs12062017 -0.052852 
1 10 rs12062017 -0.052852 
 
Table 3-6: rs17517928 SNP with highest LOD score per family in chromosome 2 
Chromosome Family SNP LOD score 
2 6 rs17517928 0.463969 
2 4 rs17517928 0.463757 
2 10 rs17517928 0.384576 
2 9 rs17517928 0.307464 
2 7 rs17517928 0.271646 
2 2 rs17517928 0.162727 
2 1 rs17517928 0.162727 
2 5 rs17517928 -0.005034 
2 3 rs17517928 -0.00691 
2 8 rrs17517928 -0.052852 
 
Table 3-7: rs496826 SNP with highest LOD score per family in chromosome 3 
Chromosome Family SNP LOD score 
3 10 rs496826 0.463756 
3 7 rs496826 0.271646 
3 6 rs496826 0.1679 
3 2 rs496826 0.162759 
3 4 rs496826 0.162728 
3 8 rs496826 0.162727 
3 5 rs496826 -0.015073 
3 1 rs496826 -0.052852 
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Table 3-8: rs10051931 SNP with highest LOD score per family in chromosome 5 
Chromosome Family SNP LOD score 
5 8 rs10051931 0.463757 
5 5 rs10051931 0.458614 
5 1 rs10051931 0.420065 
5 7 rs10051931 0.195926 
5 2 rs10051931 0.17639 
5 4 rs10051931 0.16273 
5 10 rs10051931 -0.002055 
5 3 rs10051931 -0.00236 
5 6 rs10051931 -0.052825 
 
Table 3-9: rs11994661 SNP with highest LOD score per family in chromosome 8 
Chromosome Family SNP LOD score 
8 3 rs11994661 1.43422 
8 1 rs11994661 0.685606 
8 10 rs11994661 0.463757 
8 7 rs11994661 0.27165 
8 8 rs11994661 0.162727 
8 5 rs11994661 -0.040272 
8 6 rs11994661 -0.052843 
8 2 rs11994661 -0.052852 
8 4 rs11994661 -0.052852 
8 9 rs11994661 NA 
 
Table 3-10: rs12351388 SNP with highest LOD score per family in chromosome 9 
Chromosome Family SNP LOD score 
9 4 rs12351388 0.685606 
9 8 rs12351388 0.463757 
9 7 rs12351388 0.271646 
9 1 rs12351388 0.162727 
9 2 rs12351388 0.162727 
9 6 rs12351388 0.162727 
9 10 rs12351388 0.162727 
9 9 rs12351388 -0.000712 
9 3 rs12351388 -0.006821 
9 5 rs12351388 -0.04411 
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Table 3-11: rs12365463 SNP with highest LOD score per family in chromosome 11 
Chromosome Family SNP LOD score 
11 1 rs12365463 0.937326 
11 7 rs12365463 0.507175 
11 8 rs12365463 0.463757 
11 10 rs12365463 0.166175 
11 4 rs12365463 0.162727 
11 6 rs12365463 0.162727 
11 5 rs12365463 0.042936 
11 3 rs12365463 -0.016 
11 9 rs12365463 -0.016003 
11 2 rs12365463 -0.052852 
 
Table 3-12: rs11074004 SNP with highest LOD score per family in chromosome 15 
Chromosome Family SNP LOD score 
15 4 rs11074004 0.685606 
15 1 rs11074004 0.463757 
15 5 rs11074004 0.234725 
15 7 rs11074004 0.195926 
15 2 rs11074004 0.162727 
15 8 rs11074004 0.162727 
15 10 rs11074004 0.162701 
15 3 rs11074004 0.017349 
15 9 rs11074004 -0.006909 
15 6 rs11074004 -0.052852 
 
Table 3-13: rs2367502 SNP with highest LOD score per family in chromosome 17 
Chromosome Family SNP LOD score 
17 1 rs2367502 0.940878 
17 10 rs2367502 0.384576 
17 2 rs2367502 0.162728 
17 6 rs2367502 0.162727 
17 8 rs2367502 0.162727 
17 5 rs2367502 0.0922 
17 9 rs2367502 -0.00508 
17 3 rs2367502 -0.006133 
17 7 rs2367502 -0.024487 
17 4 rs2367502 -0.028029 
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Table 3-14: rs12150959 SNP with highest LOD score per family in chromosome 19 
Chromosome Family SNP LOD score 
19 6 rs12150959 0.463757 
19 10 rs12150959 0.463757 
19 7 rs12150959 0.271646 
19 9 rs12150959 0.256765 
19 1 rs12150959 0.162727 
19 2 rs12150959 0.162727 
19 4 rs12150959 0.162727 
19 5 rs12150959 0.126226 
19 3 rs12150959 -0.003596 
19 8 rs12150959 -0.052852 
 
Table 3-15: rs6062678 SNP with highest LOD score per family in chromosome 20 
Chromosome Family SNP LOD score 
20 10 rs6062678 0.68555 
20 8 rs6062678 0.46344 
20 1 rs6062678 0.385124 
20 3 rs6062678 0.382469 
20 5 rs6062678 0.221701 
20 2 rs6062678 0.164648 
20 4 rs6062678 0.162939 
20 6 rs6062678 0.162728 
20 9 rs6062678 0.125403 
20 7 rs6062678 -0.024323 
 
Table 3-16: Sum of SNPs with highest LOD > 0 score for each chromosome calculated 
from the per family linkage analysis 
Chromosome SNP Sum LOD score of highest SNP per 
family 
20 rs6062678 2.5 
11 rs12365463 1.83 
9 rs12351388 1.8 
8 rs11994661 1.68 
2 rs17517928 1.65 
15 rs11074004 1.6 
17 rs2367502 1.6 
19 rs12150959 1.6 
5 rs10051931 1.45 
3 rs496826 0.95 
1 rs12062017 0.9 
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3.3.2.2 EasyLinkage 
 
A second linkage software package was used in order to determine whether the LOD score 
would improve using other tools less affected by the power of the study. In EasyLinkage, 
Allegro [234, 250], a non-parametric linkage analysis, was also carried out with –rsq 0.1, 1 
marker every 0.2 cM with 100 markers per set, on the same set of 444,000 SNPs used in 
Merlin (Chapter Two, section 2.5.1.3). The analysis was run on individual families and the 
LOD score calculated (Table 3-17 and Figure 3-6, 3-7, 3-8, 3-9 & 3-10). 
 
All regions with LOD > 1 were taken over for further analysis. The position of the first 
bordering marker with a LOD > 0 was recoded as the boundary of the linkage interval.
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Table 3-17: Linkage intervals generated from EasyLinkage, Allegro using 444,000 
SNPs. Limits of each peak are defined by position of first adjacent marker with LOD > 
0. 
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0.2 with 100 Family 1 1 2.6 rs17116488 rs17584208 97390523 109634710 
0.2 with 100 Family 1 11 2.6 rs11042575 rs1076204 9951975 17463450 
0.2 with 100 Family 1 14 2.6 rs8012666 rs12433927 91602373 92825315 
0.2 with 100 Family 1 15 2.6 rs12900191 rs36081257 90398296 90637674 
0.2 with 100 Family 1 15 2.4 rs183625152 rs112541880 30503704 35607465 
0.2 with 100 Family 1 17 2.6 rs12601250 rs17660368 11620010 13294631 
0.2 with 100 Family 1 17 2.6 rs6502283 rs10445255 13447416 13837415 
0.2 with 100 Family 1 17 2.6 rs333938 rs903103 64835376 68554079 
0.2 with 100 Family 2 10 2.5 rs4918907 rs2817649 97013331 98889145 
0.2 with 100 Family 2 10 2.5 rs3750717 rs2418828 101814944 108644346 
0.2 with 100 Family 2 10 2.5 rs2050706 rs17095060 117109465 118406197 
0.2 with 100 Family 2 6 2.6 rs6455787 rs510579 162331368 165633951 
0.2 with 100 Family 3 NA NA NA NA NA NA 
0.2 with 100 Family 4 2 2.4 rs4106226 rs12472692 213006638 215586084 
0.2 with 100 Family 4 2 2.5 rs828918 rs10490756 216677093 218395997 
0.2 with 100 Family 4 2 2.5 rs4674350 rs16861659 219489746 221276162 
0.2 with 100 Family 4 7 2.5 rs3904881 rs17240798 76027543 81442007 
0.2 with 100 Family 4 11 2.5 rs682742 rs4944288 77520907 80699012 
0.2 with 100 Family 4 22 2.5 rs4823313 rs9616101 44412591 45486853 
0.2 with 100 Family 4 22 2.5 rs35957702 rs2341010 47653862 49486246 
0.2 with 100 Family 5 3 2.25 rs2028597 rs9828514 107041527 109204704 
0.2 with 100 Family 5 3 2.25 rs4630940 rs7649789 119735537 124750928 
0.2 with 100 Family 5 5 2.6 rs292415 rs17072571 162982395 164444082 
0.2 with 100 Family 5 18 2.6 rs1940425 rs10853287 2080517 2931377 
0.2 with 100 Family 5 19 2.6 rs10422776 rs968483 49706733 51353846 
0.2 with 100 Family 6 1 2.5 rs6698441 rs2802846 200919562 203249336 
0.2 with 100 Family 6 2 2.6 rs7601145 rs4674024 213551392 216339611 
0.2 with 100 Family 6 2 2.6 rs4324305 rs4674332 217038157 219312570 
0.2 with 100 Family 6 2 2.6 rs6710315 rs2680860 219846235 222166199 
0.2 with 100 Family 6 4 2.6 rs11931426 rs4475192 57348675 68079667 
0.2 with 100 Family 6 19 2.5 rs2854640 rs11564549 49793175 53288774 
0.2 with 100 Family 7 11 2.8 rs10766744 rs1876821 20893556 24546930 
0.2 with 100 Family 7 11 2.8 rs7123683 rs16921142 28446502 30673376 
0.2 with 100 Family 7 13 2.8 rs7332117 rs2985983 44322278 44996193 
0.2 with 100 Family 7 15 2.6 rs9635395 rs11857288 95104881 95787367 
0.2 with 100 Family 8 3 2.6 rs532106 rs12490338 126297380 126682734 
0.2 with 100 Family 8 4 2.6 rs34526816 rs4696953 19340541 19932011 
0.2 with 100 Family 8 6 2.2 rs34911798 rs9403987 139092765 149182336 
0.2 with 100 Family 8 11 2.6 rs1384649 rs4757817 18896898 19488775 
0.2 with 100 Family 8 11 2.6 rs16905788 rs11025864 18896898 19488775 
0.2 with 100 Family 8 18 2.6 rs4940714 rs12605528 56141511 62068817 
0.2 with 100 Family 8 20 2.6 rs34692315 rs6010742 20150372 20964999 
0.2 with 100 Family 9 NA NA NA NA NA NA 
0.2 with 100 Family 10 3 2.25 rs2028597 rs9828514 107041527 109204704 
0.2 with 100 Family 10 3 2.25 rs4630940 rs7649789 119735537 124750928 
0.2 with 100 Family 10 5 2.6 rs292415 rs17072571 162982395 164444082 
0.2 with 100 Family 10 18 2.6 rs1940425 rs10853287 2080517 2931377 
0.2 with 100 Family 10 19 2.6 rs10422776 rs968483 49706733 51353846 
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Figure 3-6: LOD scores from linkage analysis of 444,000 SNPs for families 1 and 2 consisting of one pedigree for each family. The plots 
show the LOD score and the amount of marker coverage for each chromosome. The upper box shows the model used and the highest 
LOD score marker. 
Project: ANALYSIS BY BANAN
Family name: TOTALS
Used map: Axiom GW Hu  (sex−averaged)
Marker positions: 14821 ok / 0 ? / 0 outside
Inheritance: Recessive
Common allele: 99.99 %
Disease allele: 0.01 %
LC1 PCOPY rate: 0.00 %
LC1 PENET wt/mt: 0.00 %
LC1 PENET mt/mt: 100.00 %
Allele frequencies: Codominant
Marker CHR cM LOD ALPHA HLOD
1. rs7743791 6 174.07 2.5317 0.0000 2.5317
2. rs7743791 − rs9365407 6 174.18 2.5317 0.0000 2.5317
3. rs7760647 − rs9356003 6 173.97 2.5316 0.0000 2.5316
4. rs4709603 6 174.28 2.5316 0.0000 2.5316
5. rs35264836 6 173.87 2.5315 0.0000 2.5315
pLOD (MPT) Allegro v1.2c (MultiPointPar) − Computation in sets of 100 markers, spacing 0.2000 cM
Analysis time: 15.10.2011 − 14:41:53
Time elapsed:  54 s
Path: C:\Documents and Settings\arrays\Desktop\AlAskar_linkage\Analysis by Banan
Pedigree structure file: pAlAskar pedigree file.pro − SNP data file: Al Askar family SNP (Banan).snp
Copyright ©, Tom H. Lindner & Katrin Hoffmann
easyLINKAGE Plus v5.08, January 12, 2007
Marker coverage and chromosomes
1
276
2
262
3
222
4
206
5
207
6
190
7
188
8
167
9
161
10
180
11
156
12
173
13
130
14
128
15
134
16
132
17
138
18
122
19
114
20
119
21
79
22
76 cM
3.00 3.00
2.75 2.75
2.50 2.50
2.25 2.25
2.00 2.00
1.75 1.75
1.50 1.50
1.25 1.25
1.00 1.00
0.75 0.75
0.50 0.50
0.25 0.25
0.00 0.00
Project: AL MUTAIRI 2_LINKAGE
Family name: TOTALS
Used map: Axiom GW Hu  (sex−averaged)
Marker positions: 14820 ok / 0 ? / 0 outside
Inheritance: Recessive
Common allele: 99.99 %
Disease allele: 0.01 %
LC1 PCOPY rate: 0.00 %
LC1 PENET wt/mt: 0.00 %
LC1 PENET mt/mt: 100.00 %
Allele frequencies: Codominant
Marker CHR cM LOD ALPHA HLOD
1. rs10488040 7 88.94 2.5327 0.0000 2.5327
2. rs6970158 − rs7796089 7 89.05 2.5327 0.0000 2.5327
3. rs7789223 7 89.15 2.5327 0.0000 2.5327
4. rs35644813 − rs11765218 7 89.26 2.5327 0.0000 2.5327
5. rs11980095 7 89.36 2.5327 0.0000 2.5327
pLOD (MPT) Allegro v1.2c (MultiPointPar) − Computation in sets of 100 markers, spacing 0.2000 cM
Analysis time: 16.10.2011 − 11:51:48
Time elapsed:  54 s
Path: D:\Data\Linkage Projects\NK\Haya\Al Mutairi 2_linkage
Pedigree structure file: pAlmutairi 2pedigree file.pro − SNP data file: Ready_SNP_Al Mutairi 2 family.snp
Copyright ©, Tom H. Lindner & Katrin Hoffmann
easyLINKAGE Plus v5.08, January 12, 2007
Marker coverage and chromosomes
1
276
2
262
3
222
4
206
5
207
6
190
7
188
8
167
9
161
10
180
11
156
12
173
13
130
14
128
15
134
16
132
17
138
18
122
19
114
20
119
21
79
22
76 cM
3.00 3.00
2.75 2.75
2.50 2.50
2.25 2.25
2.00 2.00
1.75 1.75
1.50 1.50
1.25 1.25
1.00 1.00
0.75 0.75
0.50 0.50
0.25 0.25
0.00 0.00
Chapter Three: Monogenic Forms of Obesity 
124 
 
 
Figure 3-7: LOD scores from linkage analysis of 444,000 SNPs for families 3 and 4 consisting of one pedigree for each family. The plots 
show the LOD score and the amount of marker coverage for each chromosome. The upper box shows the model used and the highest 
LOD score marker. 
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Allele frequencies: Codominant
Marker CHR cM LOD ALPHA HLOD
1. rs10490756 2 216.42 2.5326 0.0000 2.5326
2. rs2552534 − rs2059409 2 216.53 2.5326 0.0000 2.5326
3. rs10199795 2 216.64 2.5326 0.0000 2.5326
4. rs4672850 2 216.18 2.5325 0.0000 2.5325
5. rs17653287 − rs1035671 2 216.30 2.5325 0.0000 2.5325
pLOD (MPT) Allegro v1.2c (MultiPointPar) − Computation in sets of 100 markers, spacing 0.2000 cM
Analysis time: 08.10.2011 − 15:07:08
Time elapsed:  56 s
Path: D:\Data\Linkage Projects\NK\Haya\Linkage file Alqahtani 3 family
Pedigree structure file: p Al Qahtani 3 family pedigree file.pro − SNP data file: Ready_SNP file Axiom Al Qahtani 3 family.snp
Copyright ©, Tom H. Lindner & Katrin Hoffmann
easyLINKAGE Plus v5.08, January 12, 2007
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Project: JADOH_LINKAGE
Family name: TOTALS
Used map: Axiom GW Hu  (sex−averaged)
Marker positions: 14770 ok / 0 ? / 0 outside
Inheritance: Recessive
Common allele: 99.99 %
Disease allele: 0.01 %
LC1 PCOPY rate: 0.00 %
LC1 PENET wt/mt: 0.00 %
LC1 PENET mt/mt: 100.00 %
Allele frequencies: Codominant
Marker CHR cM LOD ALPHA HLOD
1. rs17068467 6 143.47 2.6565 0.0000 2.6565
2. rs13202524 − rs34671108 6 143.57 2.6565 0.0000 2.6565
3. rs10457687 6 143.67 2.6565 0.0000 2.6565
4. rs11155036 − rs4896445 6 143.35 2.6562 0.0000 2.6562
5. rs17406620 − rs9403077 6 143.77 2.6562 0.0000 2.6562
pLOD (MPT) Allegro v1.2c (MultiPointPar) − Computation in sets of 100 markers, spacing 0.2000 cM
Analysis time: 19.10.2011 − 12:59:41
Time elapsed:  5 min 17 s
Path: Z:\Haya\Jadoh_linkage
Pedigree structure file: pJadoh pedigree file.pro − SNP data file: Ready_SNP_Axiom Jadoh family.snp
Copyright ©, Tom H. Lindner & Katrin Hoffmann
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Figure 3-8: LOD scores from linkage analysis of 444,000 SNPs for families 5 and 6 consisting of one pedigree for each family. The plots 
show the LOD score and the amount of marker coverage for each chromosome. The upper box shows the model used and the highest 
LOD score marker. 
  
Project: AL ASHTAL_LINKAGE
Family name: TOTALS
Used map: Axiom GW Hu  (sex−averaged)
Marker positions: 14847 ok / 0 ? / 0 outside
Inheritance: Recessive
Common allele: 99.99 %
Disease allele: 0.01 %
LC1 PCOPY rate: 0.00 %
LC1 PENET wt/mt: 0.00 %
LC1 PENET mt/mt: 100.00 %
Allele frequencies: Codominant
Marker CHR cM LOD ALPHA HLOD
1. rs6583061 1 125.45 2.6577 0.0000 2.6577
2. rs11184356 − rs12406035 1 125.55 2.6577 0.0000 2.6577
3. rs2923297 1 125.66 2.6577 0.0000 2.6577
4. rs11184493 1 126.10 2.6577 0.0000 2.6577
5. rs2769972 1 128.66 2.6577 0.0000 2.6577
pLOD (MPT) Allegro v1.2c (MultiPointPar) − Computation in sets of 100 markers, spacing 0.2000 cM
Analysis time: 19.10.2011 − 16:30:54
Time elapsed:  2 min 17 s
Path: C:\Documents and Settings\arrays\Desktop\Al Ashtal_linkage
Pedigree structure file: pAl Ashtal pedigree file.pro − SNP data file: Ready_SNP_Axiom Al Ashtal family.snp
Copyright ©, Tom H. Lindner & Katrin Hoffmann
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Project: ALQAHTANI 2_LINKAGE
Family name: TOTALS
Used map: Axiom GW Hu  (sex−averaged)
Marker positions: 14826 ok / 0 ? / 0 outside
Inheritance: Recessive
Common allele: 99.99 %
Disease allele: 0.01 %
LC1 PCOPY rate: 0.00 %
LC1 PENET wt/mt: 0.00 %
LC1 PENET mt/mt: 100.00 %
Allele frequencies: Codominant
Marker CHR cM LOD ALPHA HLOD
1. rs3924417 11 49.11 2.6547 0.0000 2.6547
2. rs831594 11 48.91 2.6546 0.0000 2.6546
3. rs34849093 − rs6484672 11 49.01 2.6546 0.0000 2.6546
4. rs17769732 − rs2093465 11 49.34 2.6546 0.0000 2.6546
5. rs4755771 11 48.70 2.6545 0.0000 2.6545
pLOD (MPT) Allegro v1.2c (MultiPointPar) − Computation in sets of 100 markers, spacing 0.2000 cM
Analysis time: 11.10.2011 − 16:22:41
Time elapsed:  2 min 20 s
Path: D:\AlQahtani 2_linkage
Pedigree structure file: pAlQahtani 2pedigree file.pro − SNP data file: Al Qahtani 2_SNP_file.snp
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Figure 3-9: LOD scores from linkage analysis of 444,000 SNPs for families 7 and 8 consisting of one pedigree for each family. The plots 
show the LOD score and the amount of marker coverage for each chromosome. The upper box shows the model used and the highest 
LOD score marker. 
Project: AL MUTAIRI 1 LINKAGE
Family name: TOTALS
Used map: Axiom GW Hu  (sex−averaged)
Marker positions: 14834 ok / 0 ? / 0 outside
Inheritance: Recessive
Common allele: 99.99 %
Disease allele: 0.01 %
LC1 PCOPY rate: 0.00 %
LC1 PENET wt/mt: 0.00 %
LC1 PENET mt/mt: 100.00 %
Allele frequencies: Codominant
Marker CHR cM LOD ALPHA HLOD
1. rs4145513 4 205.71 −0.1632 1.0000 0.0000
2. rs11933143 4 205.20 −0.2679 1.0000 0.0000
3. rs6844114 − rs4145513 4 205.57 −0.4601 1.0000 0.0000
4. rs11933143 − rs11132733 4 205.31 −0.5657 1.0000 0.0000
5. rs7141928 14 122.37 −1.4942 1.0000 0.0000
pLOD (MPT) Allegro v1.2c (MultiPointPar) − Computation in sets of 100 markers, spacing 0.2000 cM
Analysis time: 13.10.2011 − 12:54:26
Time elapsed:  1 min 50 s
Path: Z:\Haya\Al Mutairi 1 Linkage
Pedigree structure file: pAlmutair1pedigree file.pro − SNP data file: Ready_SNP_Al Mutairi family.snp
Copyright ©, Tom H. Lindner & Katrin Hoffmann
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Project: AL QAHTANI 1_ LINKAGE
Family name: TOTALS
Used map: Axiom GW Hu  (sex−averaged)
Marker positions: 14831 ok / 0 ? / 0 outside
Inheritance: Recessive
Common allele: 99.99 %
Disease allele: 0.01 %
LC1 PCOPY rate: 0.00 %
LC1 PENET wt/mt: 0.00 %
LC1 PENET mt/mt: 100.00 %
Allele frequencies: Codominant
Marker CHR cM LOD ALPHA HLOD
1. rs1041887 22 54.85 2.5053 0.0000 2.5053
2. rs9614436 − rs1041887 22 54.65 2.4608 0.0000 2.4608
3. rs9614436 22 54.45 2.4114 0.0000 2.4114
4. rs9615057 − rs2239770 22 55.03 2.3643 0.0000 2.3643
5. rs2239770 22 55.21 2.1445 0.0000 2.1445
pLOD (MPT) Allegro v1.2c (MultiPointPar) − Computation in sets of 100 markers, spacing 0.2000 cM
Analysis time: 09.10.2011 − 12:54:43
Time elapsed:  2 min 22 s
Path: D:\Data\Linkage Projects\NK\Haya\Al Qahtani 1_ linkage
Pedigree structure file: pAlQahtani 1pedigree file.pro − SNP data file: Al Qahtani 1 SNP file by two.snp
Copyright ©, Tom H. Lindner & Katrin Hoffmann
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Figure 3-10: LOD scores from linkage analysis of 444,000 SNPs for families 9 and 10 consisting of one pedigree for each family. The 
plots show the LOD score and the amount of marker coverage for each chromosome. The upper box shows the model used and the 
highest LOD score marker.  
Project: AL SUBIANI_LINKAGE
Family name: TOTALS
Used map: Axiom GW Hu  (sex−averaged)
Marker positions: 14831 ok / 0 ? / 0 outside
Inheritance: Recessive
Common allele: 99.99 %
Disease allele: 0.01 %
LC1 PCOPY rate: 0.00 %
LC1 PENET wt/mt: 0.00 %
LC1 PENET mt/mt: 100.00 %
Allele frequencies: Codominant
Marker CHR cM LOD ALPHA HLOD
1. rs11027610 11 39.76 2.8303 0.0000 2.8303
2. rs1528557 − rs10767126 11 39.65 2.8301 0.0000 2.8301
3. rs1879230 − rs16911971 11 39.87 2.8301 0.0000 2.8301
4. rs11600566 11 39.54 2.8298 0.0000 2.8298
5. rs17306796 11 39.98 2.8298 0.0000 2.8298
pLOD (MPT) Allegro v1.2c (MultiPointPar) − Computation in sets of 100 markers, spacing 0.2000 cM
Analysis time: 20.10.2011 − 12:42:23
Time elapsed:  2 min 18 s
Path: C:\Documents and Settings\arrays\Desktop\Al Subiani_Linkage
Pedigree structure file: pAl Sbiani pedigree file.pro − SNP data file: Ready_SNP_ Al Subiani family.snp
Copyright ©, Tom H. Lindner & Katrin Hoffmann
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Project: MAROOKAH
Family name: TOTALS
Used map: Axiom GW Hu  (sex−averaged)
Marker positions: 14653 ok / 0 ? / 0 outside
Inheritance: Recessive
Common allele: 99.99 %
Disease allele: 0.01 %
LC1 PCOPY rate: 0.00 %
LC1 PENET wt/mt: 0.00 %
LC1 PENET mt/mt: 100.00 %
Allele frequencies: Codominant
Marker CHR cM LOD ALPHA HLOD
1. rs17850096 14 125.95 −1.7283 1.0000 0.0000
2. rs17850096 − rs34532658 14 126.71 −1.7658 1.0000 0.0000
3. rs2091918 − rs17850096 14 125.35 −1.9719 1.0000 0.0000
4. rs34532658 14 127.47 −2.2752 1.0000 0.0000
5. rs7154133 − rs916547 14 127.58 −2.5604 1.0000 0.0000
pLOD (MPT) Allegro v1.2c (MultiPointPar) − Computation in sets of 100 markers, spacing 0.2000 cM
Analysis time: 17.10.2011 − 18:06:36
Time elapsed:  16 s
Path: C:\Documents and Settings\arrays\Desktop\Marookah
Pedigree structure file: pMarookahpedigree file.pro − SNP data file: Ready_SNP_Devided_Axiom Marooka family.snp
Copyright ©, Tom H. Lindner & Katrin Hoffmann
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3.3.3 Runs of Homozygosity 
 
After running the linkage analysis, ROH analysis was carried out to help narrow the region in 
which linkage was found. Ideally, the ROH should overlap with regions of linkage in samples 
that have extreme obesity compared with controls. Two software packages, PLINK and 
AutoSNPa, were used to identify ROH in these families. More details on the parameters used 
can be found in Chapter Two, section 2.5.1.4. 
 
3.3.3.1 PLINK 
 
The output data from PLINK show that more than one individual with extreme obesity within 
one family share the same ROH region compared with the controls. These ROH regions are 
found in chromosomes 5, 15 and 19 and are presented in Table 3-18 and Figure 3-11, 3-12, 3-
13, 3-14 & 3-15. At this stage of the analysis, the results of the linkage analysis have not been 
integrated with ROH. These results would be integrated later and candidate genes selected 
(see Chapter Two, Section 2.5.1.4). 
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Table 3-18: Runs of Homozygosity generated from PLINK found in cases with extreme 
obesity 
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3 8 11R-01357 Case rs1980283 rs12635520 61763660 67004478 ADAMTS9,PDE12, 
PRKCD,SLC22A14 
5 1 11R-01345 Case rs7704616 rs7379525 10854289 11908867 NA 
5 1 11R-01345 Case rs16888939 rs13156017 21130619 22286177 NA 
5 2 11R-01392 Case rs9293063 rs1020015 23286607 24377631 TRIO 
5 3 11R-01351 Case rs2921600 rs13189148 14913723 15984537 ANKH 
5 3 11R-01353 Case rs2921600 rs13189148 14913723 15984537 ANKH 
5 3 11R-01351 Case rs6893246 rs4866126 17490742 18869390 NA 
5 3 11R-01353 Case rs6893246 rs4866126 17490742 18869390 NA 
5 8 11R-01357 Case rs36051618 rs12514487 29763415 31130826 NA 
5 9 11R-01474 Case rs13186621 rs6884163 12073143 13292442 NA 
15 1 11R-01345 Case rs2596177 rs789895 31575670 34147193 NA 
15 1 11R-01346 Case rs2596177 rs789865 31575670 34160712 NA 
15 2 11R-01387 Case rs7169664 rs1075991 65292120 66466235 LOC653061, RORA 
15 3 11R-01351 Case rs1863463 rs2169637 24463613 25517776 GABRA5,GABRB3,GA
BRG3 
15 3 11R-01353 Case rs1863463 rs2169637 24463613 25517776 GABRA5, 
GABRB3,GABRG3 
15 3 11R-01354 Case rs17303404 rs11071694 59127461 60931289 RORA, C2CD4A, 
C2CD4B, VPS13C 
15 3 11R-01349 Case rs17303404 rs11071694 59127461 60931289 RORA, C2CD4A, 
C2CD4B, VPS13C 
15 3 11R-01351 Case rs17303404 rs11071694 59127461 60931289 RORA, C2CD4A, 
C2CD4B, VPS13C 
15 3 11R-01349 Case rs11853853 rs11631120 64809524 75751161 BBS2, ADPGK 
15 3 11R-01351 Case rs11853853 rs11631120 64809524 75751161 BBS2, ADPGK 
15 10 11R-01397 Case rs34192054 rs16939752 40495112 43231425 SPG11, BM2, TJP1, 
CHRNA7 , 
LOC653061, FZD4, 
CYP27A1, HFE 
19 4 11R-01492 Case rs243356 rs10469455 4366452 24375933 GDF15, MYO9B 
19 4 11R-01491 Case rs11670064 rs10469455 14308600 24375933 GDF15, MYO9B 
19 10 11R-01398 Case rs8105122 rs10469455 15950378 24375933 GDF15, MYO9B 
19 10 11R-01397 Case rs8105122 rs10469455 15950378 24375933 GDF15, MYO9B 
20 7 11R-01357 Case rs243873 rs6079459 13019231 14407573 SPTLC3, ISM1, 
TASP1, ESF1, 
SEL1L2, MACROD2, 
FLRT3 
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Figure 3-11: Plots of ROH shared between individuals with extreme obesity showing 
chromosomes 3 with ROH in individuals with extreme obesity within the same families 
or between families. Individuals with extreme obesity are shown in red and controls in 
black. The green box shows the ROH that is found only in individuals with extreme 
obesity and not in controls. 
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Figure 3-12: Plots of ROH shared between individuals with extreme obesity showing 
chromosomes 5 with ROH in individuals with extreme obesity within the same families 
or between families. Individuals with extreme obesity are shown in red and controls in 
black. The green box shows the ROH that is found only in individuals with extreme 
obesity and not in controls.  
Chapter Three: Monogenic Forms of Obesity 
132 
 
 
 
Figure 3-13: Plots of ROH shared between individuals with extreme obesity showing 
chromosomes 15 with ROH in individuals with extreme obesity within the same families 
or between families. Individuals with extreme obesity are shown in red and controls in 
black. The green box shows the ROH that is found only in individuals with extreme 
obesity and not in controls. 
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Figure 3-14: Plots of ROH shared between individuals with extreme obesity showing 
chromosomes 19 with ROH in individuals with extreme obesity within the same families 
or between families. Individuals with extreme obesity are shown in red and controls in 
black. The green box shows the ROH that is found only in individuals with extreme 
obesity and not in controls. 
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Figure 3-15: Plots of ROH shared between individuals with extreme obesity 
showing chromosome 20 with ROH in individuals with extreme obesity within 
the same families or between families. Individuals with extreme obesity are shown in 
red and controls in black. The green box shows the ROH that is found only in 
individuals with extreme obesity and not in controls. 
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3.3.3.2 AutoSNPa 
 
AutoSNPa is another software package that was used to calculate ROH and compare the 
results with the ROH generated using PLINK. AutoSNPa looks for ROH that is shared in 
individuals with extreme obesity versus non-obese controls within each family and is 
represented graphically. AutoSNPa was run on each family individually (Chapter Two, 
Section 2.5.1.4). Table 3-19 and Figure 3-16 show ROH within seven families in which ROH 
were found in cases only versus controls within the same family. 
 
Table 3-19: ROH generated from AutoSNPa found in cases with extreme obesity 
Family ID Chromosome ROH Boundaries 
Family 1 1 102000000-11000000 
Family 1 11 10000000-16000000 
Family 1 15 31575670-34147193 
Family 1 17 62000000-67000000 
Family 2 10 96000000-98000000 
Family 2 10 104000000-108000000 
Family 4 2 209000000-21000000 
Family 4 7 80000000-82000000 
Family 6 4 63000000-65000000 
Family 7 3 85000000-87000000 
Family 7 15 81000000-83000000 
Family 8 4 169000000-171000000 
Family 8 18 53034671-60230180 
Family 10 3 123000000-125000000 
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Figure 3-16: ROH graphical plots generated using AutoSNPa. Each row of plots 
represents a family. The grey line in the middle of the plot separates the cases and controls, 
with cases on the right and controls on the left. The red box highlights ROH regions shared 
between cases (for individual plots see Appendix B).  
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3.4 Whole Exome Sequencing Variant Discovery 
 
Having identified genomic regions that might be of interest within the ten different families, 
the next goal was to identify variants in genes that have a large effect on the development of 
obesity. 
 
In this study, WES was run on eight individuals, one from each family. Samples were 
selected on the basis of the highest BMI sample in each family. This section will explain how 
variants were selected from WES and prioritised and will present the results of the filtering 
process undertaken to reach the candidate gene (see Chapter Two, section 2.5.3). 
 
3.4.1 WES output and target coverage 
 
A total of 1,282,103,919 reads was obtained from the sequences of all ten individuals. The 
mean sequencing depth for 75Mbp target was between ~14x +/- 10x (Table 3-20 and Figure 
3-17). WES metrics are dependent on the technologies chosen for capture and sequencing. 
Four previous studies using WES report the identification of novel Mendelian disease genes 
using the kit used in this study, SureSelect enrichment and SOLiD 4 sequencing (Life 
Technologies) [200, 202, 217, 251]. 
 
Table 3-20: Sequencing metrics 
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NGS 30 Family 2 173764218 81,706,691 35,197,046 10,350,836 46,509,645 36 
NGS 31 Family 10 129568914 59,824,849 28,308,977 9,919,216 31,515,872 33.6 
NGS 32 Family 1 153710958 74,065,060 23,251,247 5,580,838 50,813,813 35 
NGS 33 Family 8 105503667 49,710,658 20,116,020 6,082,351 29,594,638 35.5 
NGS 34 Family 5 210106327 77,371,466 35,516,208 13,508,137 41,855,258 31.33 
NGS 35 Family 7 157964593 73,242,969 33,330,573 11,478,655 39,912,396 53 
NGS 36 Family 6 185514579 85,579,626 43,823,250 14,355,327 41,756,376 40 
NGS 37 Family 4 165970663 77,472,580 35,031,696 11,025,503 42,440,884 33 
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Figure 3-17: Sequence metric results showing percentages of three sequencing metrics 
aligned uniquely, aligned non-uniquely and not aligned. 
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3.4.2 Variant Calling from GenomeQuest 
 
As mentioned in Chapter Two, variant calling was carried out by GenomeQuest, a data 
management company (http://www.genomequest.com). GenomeQuest applied the QC 
measures, mapped sequencing reads to the reference genome and carried out the variant 
calling (Chapter Two, section 2.5.3). 
 
A total of 56,106 distinct quality-filtered variants were identified by GenomeQuest across 
eight samples, with 3,000-10,000 variants in each sample (Table 3-21). The variants 
presented in this section have not yet been filtered or prioritised. This section also presents 
the average coverage of the variant alleles called per sample (Table 3-21 and Figure 3-18 & 
3-19). 
 
Table 3-21: GenomeQuest variant calling metrics in each sample 
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NGS 30 Family 2 6649 4834 4702 610 465 66 266 14 +/- 10 x 
NGS 31 Family 10 7077 5270 5135 625 472 67 279 14 +/- 9 x 
NGS 32 Family 1 3066 2362 2303 327 249 63 134 12 +/- 8 x 
NGS 33 Family 8 3396 2464 2382 223 168 38 86 11 +/- 6 x 
NGS 34 Family 5 10039 6919 6669 879 645 72 393 14 +/- 10 x 
NGS 35 Family 7 8046 5756 5585 706 536 75 315 14 +/- 9 x 
NGS 36 Family 6 10472 7545 7306 1439 1045 197 587 15 +/- 10 x 
NGS 37 Family 4 7361 5442 5309 837 668 75 375 14 +/- 9 x 
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Figure 3-18: Distribution of coverage of variant alleles for the NGS 30, 31, 32, & 33 
WES samples 
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Figure 3-19: Distribution of coverage of variant alleles for the NGS 34, 35, 36 & 37 
WES samples 
 
3.4.3 Filtering and prioritisation of candidate obesity-causing variants 
 
Having gained a view of the data quality, a filtering approach was applied to prioritise 
candidate obesity genes in these pedigrees. 
 
3.4.3.1 Filtering by variant class 
The first step was to select variants positioned in exons (coding region). The second step was 
to exclude all variants with a silent prediction impact (silent mutations) and all known 
variants found in dbSNP134. The third step was to set the percentage of allele coverage to 
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Chapter Three: Monogenic Forms of Obesity 
142 
 
greater than 95 in order to select potentially homozygous alleles, and the fourth step was to 
set a threshold of x8 sequencing depth. 
 
Table 3-22 shows the filtered homozygous, coding, and potentially novel obesity-causing 
variants. 
 
3.4.3.2 Prioritisation of homozygous candidate obesity variants 
 
After generating a list of homozygous mutations, the variants were prioritised according to 
their occurrence in more than one WES sample and whether they overlapped with ROH and 
with previously-detected LOD regions (sections 3.3.2 and 3.3.3). Homozygous variants were 
also prioritised according to their occurrence in the pathway of known obesity genes, and 
whether they are expressed in the brain, expressed in adipose tissue, associated with obesity 
or with diabetes (Chapter Two, section 2.5.3).  
 
Table 3-23 shows the prioritised homozygous genes and prioritisation information. 
 
3.4.3.3 Discrete filtering against other exome sequencing 
 
The results were compared with variants identified in 15 other controls that had undergone 
WES in King Faisal Specialist Hospital Laboratory, Genetics Department Research Center 
using the same SOLiD platform (Table 3-22). 
 
3.4.3.4 Comparison with SIFT and Poly-Phen-2 software 
 
Finally, after the filtering and prioritising process, all candidate variants were assessed for 
pathogenicity using both SIFT and PolyPhen-2 (Table 3-22). 
 
In the next section, the types of variants found and their effect will be discussed in more 
detail. 
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Table 3-22: Filtering by variant class and the identification of candidate gene variants 
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Table 3-23: Prioritisation of homozygous candidate obesity variants 
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3.4.4 Candidate Variants 
 
Six variants were identified in total as a result of the filtration and prioritisation steps. The 
previous section presented the results of methods used to detect novel obesity-causing 
variants found in either known or potential obesity-causing genes. This section will show the 
types of variants found in each gene and assess whether such variants cause pathogenicity. 
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3.4.4.1 Variants lying within/integrating with linkage analysis and ROH 
 
Two variants lie within the linkage plot and ROH. One variant is in a known obesity gene 
and another occurs in a potential obesity-causing gene. 
3.4.4.1.1 Known monogenic obesity gene 
 
The variant found was in MC4R, a monogenic obesity-causing gene. The MC4R variant is in 
chromosome 18 at 58039330 bp. It is a non-synonymous, homozygous mutation with a 
damaging effect (Table 3-24). This mutation was not found in the 250 Saudi WES data. 
 
One of the most important prioritisation strategies used in this study was to identify variants 
overlapping with linkage regions and ROH, and this MC4R met this criterion. Linkage 
analysis was run on Family 8 of the individual (NGS33) with the WES MC4R variant. Family 
8 showed a significant linkage on chromosome 18, including the MC4R gene, which is the 
most common monogenic obesity gene. The linkage locus ran from SNP rs4940714 position 
56141511 bp to rs12605528 position 62068817 bp with an LOD score of 2.2 at cytoband 
18q21-q22 (Figure 3-20). 
 
Overlapping findings are important in confirming the linkage region. ROH data generated 
from PLINK and AutoSNPa confirmed a region of homozygosity overlapping with the 
linkage region in Family 8 on chromosome 18 from 53034671 bp to 60230180 bp, between 
SNP rs8092341 and rs35225159 (Figure 3-21). It is important to note that this ROH was 
shared by the two affected individuals. 
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Figure 3-20: EasyLinkage software output, revealing a linkage peak on chromosome 18 
with a maximum LOD score of 2.2. 
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Figure 3-21: Homozygosity mapping for Family 8 using autoSNP and PLINK. The red 
box indicates the ROH on chromosome 18 between 53034671 and 60230180 where the 
MC4R gene resides. The ROH is shared by two siblings with the novel homozygous MC4R 
mutation. 
 
3.4.4.1.2 Potential obesity-causing gene 
 
Another variant within a cholinergic receptor, CHRNA7 gene was found in three NGS 
samples: NGS32 (Family 1), NGS36 (Family 6) and NGS37 (Family 4). This occurs in 
chromosome 15 at 32460280 bp and is a deletion of a C nucleotide that causes a frameshift. 
This frameshift mutation causes alteration in the protein, which in turn causes a change in the 
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reading frame, resulting in a completely different translation from the original sequence 
(Table 3-24). This mutation was not found in the 250 Saudi WES data. 
 
CHRNA7 was also found to be present in the linkage region for Family 1 (NGS32). The 
linkage locus ran from SNP rs183625152 position 30503704 bp to rs112541880 position 
35607465 bp with an LOD score of 2.4 at cytoband 15q13.2 (Figure 3-22). ROH was also 
found in the same region of linkage for sample NGS32 (Family 1), a region of homozygosity 
that overlaps with the linkage region in Family 1 on chromosome 15 from 31575670 bp to 
34147193 bp, between SNP rs2596177 and rs789895 (Figure 3-23). NGS36 and NGS37 had 
no linkage peak or ROH in the same region. This deletion was not found in the WES data of 
250 Saudi controls. 
  
Chapter Three: Monogenic Forms of Obesity 
148 
 
 
 
 
Figure 3-22: EasyLinkage software output, revealing a linkage peak on chromosome 15 
with a maximum LOD score of 2.4. 
  
Project: AL ASHTAL_LINKAGE
Family name: TOTALS
Used map: Axiom GW Hu  (sex−averaged)
Marker positions: 14847 ok / 0 ? / 0 outside
Inheritance: Recessive
Common allele: 99.99 %
Disease allele: 0.01 %
LC1 PCOPY rate: 0.00 %
LC1 PENET wt/mt: 0.00 %
LC1 PENET mt/mt: 100.00 %
Allele frequencies: Codominant
Marker CHR cM LOD ALPHA HLOD
1. rs6583061 1 125.45 2.6577 0.0000 2.6577
2. rs11184356 − rs12406035 1 125.55 2.6577 0.0000 2.6577
3. rs2923297 1 125.66 2.6577 0.0000 2.6577
4. rs11184493 1 126.10 2.6577 0.0000 2.6577
5. rs2769972 1 128.66 2.6577 0.0000 2.6577
pLOD (MPT) Allegro v1.2c (MultiPointPar) − Computation in sets of 100 markers, spacing 0.2000 cM
Analysis time: 19.10.2011 − 16:30:54
Time elapsed:  2 min 17 s
Path: C:\Documents and Settings\arrays\Desktop\Al Ashtal_linkage
Pedigree structure file: pAl Ashtal pedigree file.pro − SNP data file: Ready_SNP_Axiom Al Ashtal family.snp
Copyright ©, Tom H. Lindner & Katrin Hoffmann
easyLINKAGE Plus v5.08, January 12, 2007
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Figure 3-23: Homozygosity mapping for Family 1 using autoSNP and PLINK. The red 
box indicates the ROH on chromosome 15 from 31575670 bp to 34147193 bp where the 
CHRNA7 gene resides. The ROH is shared by two siblings with the novel homozygous 
CHRNA7 mutation. 
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3.4.4.2 Variants not lying within/integrating with linkage analysis and ROH 
 
Variants that do not overlie the linkage plot and ROH are presented here. Two variants are in 
known obesity genes and the other four variants are in potential obesity-causing genes (Table 
3-24). 
 
3.4.4.2.1 Potential obesity-modifying genes 
 
Two of the potential obesity-modifying genes, LPIN3 and Feline Sarcoma Oncogene (FES), 
found in NGS33 (Family 8) are non-synonymous homozygous mutations with damaging 
effect. Neither mutation was found in the 250 Saudi WES data (Table 3-24). 
 
Table 3-24: Candidate obesity variants generated from WES 
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3.5 Validation of variants found in candidate obesity genes 
 
Having identified the candidate variants from the WES data, the next step was to validate 
these variants using Sanger sequencing. For each of the candidate genes a set of forward and 
reverse primers were designed to cover all the exons in these genes. Chapter Two, section 
2.5.4 describes the primer designs and PCR conditions used to sequence these genes. This 
section presents the results of Sanger sequencing for each of the genes sequenced. 
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3.5.1 Known monogenic obesity genes 
 
One known monogenic obesity gene was sequenced, the MC4R gene (Table 3-25). 
 
3.5.1.1 MC4R gene 
 
Two individuals in Family 8 had a homozygous MC4R mutation. This mutation is a novel 
homozygous mutation p.S85G (c.255 T>C) associated with extreme obesity (Figure 3-24) 
with a pathogenicity score of 1. This is the first time that a mutation has been reported in a 
family from Saudi Arabia. Both affected samples with the MC4R homozygous mutation, a 
14-year-old boy and a 17-year-old girl, have severe early-onset obesity and hyperphagia. 
They were normal weight at birth but started to gain weight rapidly after a year. The 
heterozygous father is overweight with a BMI of >28, and the heterozygous mother is 
extremely obese with a BMI of >40. One sibling has a heterozygous mutation and is 
overweight. 
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Figure 3-24: Overview of the novel MC4R mutation identified in family 8, showing (a) 
the MC4R PCR product gel run of all Family 8 samples for the MC4R gene, (b) the 
pedigree of the family with the novel MC4R mutation and carriers of this mutation, and 
(c) a chromatograph of the novel homozygous missense mutation in MC4R. 
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3.5.2 Potential obesity-causing genes 
 
Three potential obesity-causing genes were sequenced: CHRNA7, LPNI3 and FES (Table 3-
25). 
 
3.5.2.1 CHRNA7 gene 
 
Three individuals in Family 6 have a 127691_127692het_delTG deletion in exon 8 of the 
CHRNA7 gene (Figure 3-25). This causes a frameshift mutation in exon 8 of obese 
individuals. This mutation is reported for the first time in obese families both in Saudi and 
worldwide. All the affected individuals with this frameshift mutation – a 17-year-old girl, and 
boys aged 11 and 20 – have severe early-onset obesity. These three affected individuals also 
have eczema and hair abnormalities. They were normal weight at birth but started to gain 
weight rapidly from two years of age. The parents are lean with a BMI of 25. A sibling who 
does not carry this mutation is also of normal weight. 
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Figure 3-25: Overview of the novel CHRNA7 frameshift mutation identified in Family 6, 
showing (a) the CHRNA7 PCR product gel run of all Family 6 samples for exon 8 of the 
CHRNA7 gene, (b) the pedigree of the family with the novel CHRNA7 frameshift 
mutation, and (c) a chromatograph of the novel frameshift mutation in the CHRNA7 
gene. 
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3.5.2.2 LPIN3 gene 
 
Three individuals in Family 8 have a heterozygous LPIN3 mutation. This mutation is a novel 
heterozygous mutation p.W110W/C (c.333 G>GC) and probably has a damaging effect by 
altering the protein function that was assessed by both SIFT and PolyPhen-2 software. It is 
the first report in Saudi Arabia and worldwide. The mutation appears to be autosomal 
dominant (Figure 3-26 and Table 3-25). The father, with a BMI of 28, and two children in the 
same family, a 14-year-old boy (BMI >95 centile) and a 7-year-old boy (BMI < 85 centile), 
carry this mutation, while the mother and two other siblings do not. This is the same family 
as that with the MC4R mutation. 
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Figure 3-26: Overview of the novel LPIN3 heterozygous mutation identified in Family 8, 
showing (a) the PCR product gel run of all Family 8 samples for exon 4 of the LPIN3 
gene, (b) the pedigree of the family with the novel LPIN3 heterozygous mutation, and 
(c) a chromatograph of the novel heterozygous mutation in the LPIN3 gene. 
a. 
b. 
c. 
220bp 
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3.5.2.3 FES gene 
 
Two individuals in Family 8 have a homozygous non-synonymous FES mutation in exon 1 
(Figure 3-27 and Table 3-25). This is a silent mutation p.S5S (c.15 C>T) found only in two 
extreme individuals, a 14-year-old boy and a 17-year-old girl with severe early-onset obesity 
and hyperphagia. This is the same family as that with the MC4R mutation. 
 
Table 3-25: Gene variants after validation with Sanger sequencing 
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Figure 3-27:Overview of the FES homozygous synonymous mutation in Family 8, 
showing (a) the PCR product gel run of all Family 8 samples of the exon 1 of FES gene, 
(b) the pedigree of the family with the FES homozygous synonymous mutation, and (c) 
a chromatograph of the homozygous synonymous mutation in the FES gene. 
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3.6 Discussion 
 
Monogenic obesity refers to a number of rare forms of severe obesity that result in mutations 
greatly affecting an individual gene or chromosome. Despite their rarity, the study of 
monogenic obesity has shed light on understanding the pathogenesis of obesity and several 
pathways and mechanisms involved in the development of this condition [1, 4, 252, 253]. 
 
Globally, monogenic forms of obesity have so far been demonstrated in five per cent of the 
most severely obese patients [1]. It has previously been revealed that individuals with a long 
history of consanguinity have an average of 11 per cent homozygosity with >3cM in length in 
their genome, resulting in an increased incidence of autosomal recessive disease [254]. 
 
This chapter has described the in-depth analysis of ten consanguineous Saudi families with 
extreme obesity using mature technologies for variant discovery (linkage analysis, ROH and 
WES). Using these different analytical techniques, three candidate variants have been 
identified. 
 
3.6.1 Linkage and ROH regions 
 
Linkage analysis is usually used to analyse markers in related individuals to determine 
phased haplotypes and to test for co-segregation of disease and marker loci. The key issue in 
linkage analysis is to select the correct genetic model. This is extremely difficult, especially 
in the case of complex diseases, owing to the number of genetic and environmental factors 
that affect the etiology of the disease. A nonparametric linkage model (NPL) was used to 
evaluate allele sharing among affected individuals, which produces results with no particular 
model assumption (penetrance) [31]. The reason for using this model is that many monogenic 
obesity genes, such as MC4R, vary in their penetrance levels and are age-, generation- and 
environmentally-dependent [22, 56]. 
 
Two different linkage software packages – EasyLinkage (Allegro) [234] and Merlin [249] – 
were used to run the nonparametric multipoint linkage analysis [234, 249, 250]. These two 
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packages produce maximum-likelihood of multilocus linkage maps for thousands of DNA 
markers in three-generation pedigrees and can be constructed in minutes [255]. They have 
previously been shown to be successful tools to identify linkage regions that encompass 
genes associated with different diseases [234, 256-258]. These two software packages have 
been used to help determine the exact linkage region shared by the two packages. As 
mentioned in Chapter Two, section 2.5.1.2, a subset of the Axiom GWH-96 whole genome 
SNP array (Affymetrix) was used, selecting the most informative SNPs and preventing the 
over-estimation of linkage regions. Little difference was found between the results of 
analysing three different sets of SNPs (6,666, 48,000 and 444,000) on all families using 
Merlin. The highest LOD score generated from the three different subsets of SNPs was 2.0 in 
chromosome 20: 5573900-63025519bp between rs111509196 and rs188206903 SNPs 
(Figures 3-2, 3-3, 3-4 and 3-5). Other regions were found in chromosomes 2, 5, 8, 9, 11, 15, 
17 and 19, with LOD scores ranging between 0.7 and 1.6 (Tables 3-2, 3-3 and 3-4). Lower 
LOD scores in these chromosomes may be due to family-specific co-segregation of the 
linkage region. Little difference was found when running the per-family linkage analysis 
(Table 3-16). On the other hand, when running EasyLinkage (Allegro) [234], higher LOD 
scores of ~2.5 LOD were generated. Only five linkage regions generated from Merlin [249] 
were replicated in EasyLinkage (Allegro) [234] in chromosomes 2, 5, 11, 15, and 19 and 
these were selected for further analysis. 
 
Looking at the specific linkage regions that were replicated in both linkage software packages 
and comparing these to other studies, especially genome-wide linkage scans of BMI and 
obesity, it is interesting that two linkage regions from these studies seem to be replicated in 
this data set. The first is chromosome 11q14, which showed substantial evidence for linkage 
to BMI in both Framingham Heart Study cohorts comprising mainly of Caucasians and Pima 
Indians with LOD scores of 2.9 and 3.6 respectively [115, 120]. The second is in 
chromosome 20q13. Three studies conducted on European- and African-American families 
and families from the University of Pennsylvania all showed loci linkage to BMI, with LOD 
scores of 2.57 and 3.17 respectively [122, 259]. This is strong evidence that on chromosomes 
11q14 and 20q13 there is a locus influencing susceptibility to obesity, which requires further 
investigation. 
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Also from this linkage analysis, it appears that Families 3 and 9 have negative linkage scores 
and no linkage peaks. This may be because these families were mistakenly considered to be 
consanguineous, or the cases may have been mistakenly phenotyped. 
 
ROH was run to narrow down the linkage region. Two ROH regions overlapped with linkage 
regions and were present in Families 1 and 8. The region in Family 1 was in chromosome 15 
between 30503704 and 35607465 bp (Tables 3-17 and 3-18) and in Family 8 it was in 
chromosome 18 between 53034671 and 60230180 bp (Tables 3-17 and 3-19). 
 
3.6.2 WES variant detection 
 
After running the linkage analysis, two families (Families 3 and 9) had no linkage peaks and 
were excluded as candidates for sequencing. The individual with the highest BMI in each of 
the other eight families was selected for WES. 
 
From the analysis of eight individuals a total of 1,282,103,919 reads was obtained. fifty to 
sixty per cent of the reads appear not to align to the reference (Table 3-20 and Figure 3-17). 
Furthermore, examination of the output variant calling metrics revealed that the mean 
coverage of the variant alleles was 14 +/- 10x with 20 per cent of the coverage of variant 
allele at a depth of 6-7x (Table 3-21 and Figure 3-18 and 19). 
 
This study suggests that the principal limitation in variant detection is the adequate capture of 
target regions. Using other alignment tools, Agilent Technologies SureSelect Human All 
Exon 50 Mb usually maps 96.6 per cent of the reads to human DNA [260]. In this study, only 
50 per cent were mapped to the reference sequence. Variants detected in this study still fell 
within the normal range of ~5000 variants [260]. Most of the coverage of variant allele fell at 
a coverage depth of 6-7x compared with the initial target of 30x. 
 
In this study, the goal was high coverage, but it appears that insufficient coverage was 
achieved at the intended run capacity. This may be due largely to uneven target enrichment. 
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Initial results are encouraging and are discussed in the next sections. With improved target 
coverage, more promising results will be generated. 
 
3.6.3 Linkage analysis and sequencing of the probands 
 
As mentioned previously, linkage analysis and ROH were used to narrow down the region 
suspected to overlie the candidate variants. From the linkage analysis, two candidate regions 
previously seen to show linkage to BMI – chromosomes 11q14 and 20q13 – were also found 
in linkage analysis in this study [120, 122, 259]. The priority was to look for variants within 
these regions. After filtering and prioritising WES variant calls, variants that lay within these 
regions were sought, but none was found. 
 
The next step was to look for variants lying within other linkage and ROH regions found in 
chromosomes 2, 5, 8, 9, 11, 15, 17, 18, and 19. Two variants lying within both the linkage 
and ROH candidate regions were found. The first was in the CHRNA7 gene (Family 6) in the 
chromosome 15 linkage and ROH regions. The second was in the MC4R gene (Family 8). No 
linkage peak in Family 8 appeared in that region when analysed using both Merlin and 
EasyLinkage (Allegro) (Figure 3-28). On returning to the data and re-examining the 
pedigrees, it appeared that a third affected individual had been mistakenly phenotyped as 
extremely obese. Linkage was re-run after correcting the phenotypes in this family and as a 
result a linkage peak of 2.2 appeared in chromosome 18 (Figure 3-29). 
 
From this subsequent analysis, it appears that some of the families have been mistakenly 
phenotyped as extremely obese rather than non-obese. This may explain why some candidate 
obesity variants were incorrectly ruled out on the basis of failing to identify the correct 
linkage and ROH regions. 
 
The EasyLinkage software output 1 (Figure 3-28) reveals no linkage peak on chromosome 18 
in Family 8 before correcting for affected status. Three individuals were considered as 
extremely obese while only two were actually extremely obese. This figure shows no linkage 
peak on chromosome 18 when mistakenly phenotyping a non-affected individual as affected. 
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The EasyLinkage software output 2 (Figure 3-29) also reveals a linkage peak on chromosome 
18 in Family 8 after correcting the affected status. 
 
 
 
 
 
         
Figure 3-28: EasyLinkage software output 1 for Family 8    
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Figure 3-29: EasyLinkage software output 2 for Family 8 
 
3.6.4 Obesity-causing variants 
 
Of the three WES candidate obesity variants, two belonged to the same family, Family 8. All 
the variants were later sequenced by Sanger sequencing to confirm their existence. 
 
3.6.4.1 Family 8 
 
In Family 8 a novel MC4R mutation was found: p.S85G (C.2gg T>C) (Figure 3-30). This 
mutation is the first case to be reported in Saudi Arabia and the Arab population. MC4R is a 
known monogenic obesity gene. It is a G protein-coupled receptor expressed mainly in the 
brain [261] and is a key player in the central regulation of the leptin-melanocortin axis that 
controls human energy homeostatis [261]. Loss-of-function mutations in the MC4R gene 
have previously been shown to be the most frequent cause of familial forms of obesity, as 
seen in studies of Pakistani families with extreme obesity [56, 262]. Homozygous mutations 
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in the MC4R gene have a very high penetrance in young generations, causing early-onset 
severe obesity [56, 262]. 
 
In this family, the two affected siblings suffered from early-onset obesity and hyperphagia, a 
typical phenotype of probands carrying this mutation. Interestingly, the heterozygous carriers 
(both parents and one son) have different obesity phenotypes (Figure 3-30). The father and 
sibling who are heterozygous for the mutation are overweight, with a BMI of 28 and < the 95 
percentile respectively. On the other hand, the mother, who is also heterozygous for the 
mutation, is extremely obese with a BMI of 40. Most studies indicate a co-dominant mode of 
inheritance, with heterozygous subjects having less severe phenotypes than homozygous 
probands [263, 264]; however, this study produces different results. 
 
Another variant identified in Family 8 was in the LPIN3 gene. From the WES sequencing 
data, a homozygous mutation (p.Gly110Arg) with a damaging effect was found in this gene. 
When validated using Sanger sequencing, it appeared to be a heterozygous mutation found in 
both father and son, who are carriers of the MC4R mutation (Figure 3-30). All individuals in 
Family 8 with the LPIN3 heterozygous mutation have insulin resistance. This mutation 
appears to be an autosomal dominant mutation. 
 
Finding the LPIN3 mutation in a family with an MC4R mutation is an interesting result. The 
LPIN3 gene belongs to a family of three lipin proteins: LPIN1, LPIN2 and LPIN3. These 
proteins act as phosphatidate phosphate enzymes required for glycerolipid biosynthesis [265]. 
They are also considered to be transcriptional coactivators that induce expression of lipid 
metabolism genes (PPARα and PPARϒ) [265]. These genes are expressed in key metabolic 
tissues, including adipose tissue, skeletal muscles, and liver [265]. The physiological function 
of the LPIN family has not been fully elucidated. 
 
Little is known about the LPIN3 gene, but LPIN1-knockout mice have been shown to be 
extremely lean with lipodystrophy, characterised by loss of body fat, fatty liver, 
hypertriglyceridemia, and insulin resistance. Homozygous mutations in the LPIN1 and LPIN2 
genes have been reported in humans [266]. All patients with an LPIN1 gene mutation have 
developed muscle pain, weakness, and myoglobinuria [267]. On the other hand, homozygous 
Chapter Three: Monogenic Forms of Obesity 
166 
 
mutations in the LPIN2 gene have caused the development of Majeed Syndrome, 
characterised by recurrent osteomyelitis, cutaneous inflammation, and anaemia [268]. 
Polymorphisms in the LPIN1 gene have been associated with several components of 
metabolic syndrome. LPIN1 polymorphisms have been associated with high BMI [269-271], 
high insulin levels [270, 272, 273] and high resting metabolic rate [273]. 
 
As mentioned previously, MC4R mutation carriers in Family 8 have variable BMI. The two 
overweight MC4R mutation carriers, father and son, who are overweight (Figure 3-30) have 
the LPIN3 heterozygous mutation. On the other hand, the third MC4R carrier (the mother), 
who is extremely obese with a BMI of 40 kg/m
2
, does not have the LPIN3 heterozygous 
mutation (Figure 3-30). This suggests that the LPIN3 gene may affect the development of 
obesity by increasing adipogenesis in carriers of this mutation. This result may explain the 
differences in BMI between heterozygous carriers of the MC4R mutation. Further 
investigation of the function of this gene is required. This could be done by assessing how the 
substitution affects lipin protein function (PAP activity, coactivator activity, and potentially 
also subcellular localization).  It would be best to introduce this variant into expression 
constructs and then assess the mutant protein activity.   If this amino acid substitution has an 
affect on some aspect of protein function, we could then do further studies involving 
complementation in primary lipin-3 KO adipocytes 
 
Two other variants were found in Family 8. The FES gene is a gene that encodes tyrosine-
protein kinase and acts downstream of cell surface receptors, playing a role in the regulation 
of the actin cytoskeleton, microtubule assembly, cell attachment, and cell spreading [274]. It 
occurs in the axon guidance pathway and appears to have a gene-gene interaction with insulin 
receptor 1 (IRS1) gene (KEGG pathways database and STRING Interaction Network). The 
WES variant calling data revealed no non-synonymous mutation in this gene, and when 
validated using Sanger sequencing no mutation was detected. 
 
These results show that Family 8 may have more than one gene affecting the development of 
obesity in different ways. Figure 3-30 shows the variants detected in this family. The 
individual with most variants has the highest BMI. The heterozygous carriers of the MC4R 
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mutation have variable BMI, which may be explained by the effect of other genes that may 
either cause adipogenesis or assist in the development of obesity. 
 
Figure 3-30: MC4R and LPIN3 mutations in Family 8 showing the BMI of each 
individual 
 
3.6.4.2 Family 6 
 
The WES analysis revealed that sample NGS36 in Family 6 had a C deletion at p.126 in the 
CHRNA7 gene. After validating the results using Sanger sequencing, it was observed that the 
three affected samples with extreme obesity had a TG heterozygous deletion in exon 8 
(Figure 3-25). CHRNA7 is a member of the family of ligand-gated ion channels that mediates 
fast signalling transmission at synapses, and is highly expressed in the brain [275]. It is found 
mainly in the hippocampus [275]. Gene-gene interaction generated by STRING (http://string-
db.org/) shows that CHRNA7 has a gene-gene interaction with Janus kinase-2 (JAK2), which 
interacts with SH2B adaptor protein 1 (SH2B1) (Figure 3-31). Presynpatic alpha7 nAChRs 
are found on glutamate terminals that facilitate transmitter release in various brain regions 
[275]. Alpha7 nAChRs have been associated with Alzheimer's disease, schizophrenia, 
attentional process, cognitive process, and working memory [276-278]. Nicotine acting at 
alpha7 nAChRs plays a key role in modulating inflammation [279]. The nonselective nAChR 
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agonist nicotine has been shown to have a broad involvement in both the central nervous 
system and peripheral nAChR in regulating body mass and other metabolic pathways [279]. 
It is well known that the administration of nicotine to rodents and humans produces adaptive 
changes to food behaviour and energy metabolism [280]. Nicotine has also been seen to 
reduce the incidence of Type 1 diabetes in mice and to improve insulin sensitivity in rat 
adipocytes [281, 282]. α7 nAChR is found particularly in the lateral hypothalamus that 
regulates food appetite and plays a key role in regulating appetite, food consumption, and 
body mass [283]. 
 
There is sufficient evidence to suggest that the CHRNA7 gene may play an important role in 
the development of obesity but the etiological relevance of this mutation in this family is not 
established yet. Further investigation and functional studies are required. 
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Figure 3-31: Evidence-based representation of CHRNA7 protein interaction. CHRNA7 
has been shown to interact directly with JAK2, and SH2B1, and has been linked to 
neuroactive ligand-receptor interaction pathways. Line colour represents type of 
evidence. 
Source: Image generated using Search Tool for Retrieval of Interacting Genes (STRING) at 
http://string-db.org 
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3.7 Summary 
 
Monogenic obesity exists in the Saudi population. It appears that known and novel mutations 
are infrequent but cannot be excluded owing to the low coverage of some of these genes. The 
identification of mutations and deletions in MC4R, CHRNA7 and LPIN3 genes opens up the 
possibility of explaining the pathogenesis of obesity in this consanguineous population by 
seeking other novel obesity genes specific to this population. This will help explain the high 
prevalence of obesity in Saudi Arabia. 
 
The use of WES in this study has allowed an extensive search for novel gene mutations in 
individuals with genetic defects in either known or potentially novel obesity and diabetes 
genes. The study reveals that WES may increase the possibility of a genetic diagnosis of 
obesity. However, the coverage of certain obesity genes is low, which may increase the 
possibility of mistakenly excluding mutations in known obesity genes. In the meantime, the 
coverage of known obesity genes must be improved before WES can replace Sanger. New 
capture kits that are recently available with coverage up to 80% will be used in future studies.  
 
3.8 Limitations 
 
There are a number of limitations in this study: 
 Affected samples in pedigrees may have been misdiagnosed with extreme obesity that is 
why no linkage peaks were present when running the analysis. Reassessing affected 
individuals against controls is essential in these kinds of studies. 
 Coverage of causative variants may be inadequate owing to uneven target capture, poor 
capture, or poor sequencing. 
 The candidate variant may be covered but missed, filtered, or incorrectly genotyped by 
variant calling software. 
Chapter Three: Monogenic Forms of Obesity 
171 
 
 The disease-causing variant may be present in dpSNP134. Variants from many 
individuals of indeterminate obesity phenotypes have contributed to dbSNP, and the 
phenotypes in this study may have been unrecognised in the control cohort. 
3.9 Future work 
 
There are several potential areas for future work. 
 
3.9.1 Re-run of whole exome sequencing 
 
WES will be run on the other eight families that did not show any candidate variants, 
selecting one affected sample with the highest BMI and one lean control from each family to 
run on the same or a different WES platform. This will provide a better comparison of 
variants within the same family by comparing the cases and controls. Also, the samples will 
be run using the new SureSelect capture kits with high coverage depth (about 80%) and will 
be run on HiSeq 2500 Illumina will be used to improve the coverage.  
 
3.9.2 Identification of underlying mechanisms 
 
Having found some potentially novel obesity genes, it is essential to identify the underlying 
mechanism. Initial assessment of the possible effects of novel causative variants/mutations 
will be carried out using proprietary and publicly-available bioinformatics tools. Laboratory-
based functional work could be carried out to investigate the mechanism by which the 
variants identified influence the risk of obesity. Available techniques include: 
 Ribonucleic acid (RNA) silencing: RNA silencing has been used to investigate the 
pathophysiological mechanisms of diabetes in pancreatic β-cells and can be used to 
investigate how obesity genes lead to increased adiposity. 
 Expression of messenger ribonucleic acid (mRNA) can be measured using microarrays 
and with real-time PCR using the ABI TaqMan 7900HT. 
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 Promoter assay, such as the luciferase reporter assay, can be used to measure levels of 
transcription of obesity genes within adipocytes. 
 Levels of CpG island methylation in the promoter can be measured using the ABI 
MethylSeqR kit, in which bisulphite treatment is used to convert unmethylated cytosines 
into uracil, while methylated cytosines remain unaffected. Sequencing of both treated and 
untreated DNA is then carried out to reveal methylation sites. 
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4 The Contribution of Rare Copy Number Variants to Obesity 
Susceptibility 
 
4.1 Introduction 
 
CNVs are DNA segments of 1kb or larger whose copy number varies among different alleles 
[160]. CNVs may also be described as deletions, insertions, duplications, and complex multi-
site variants found in all humans [160]. The scientific community has recently become aware 
of these variants, their abundance and their effect on all chromosomal domains found in both 
coding and non-coding regions [149]. Several genome studies have shown that CNVs are the 
predominant class of genomic variation [150]. A recent population study has shown that 
500kb CNVs occur in 5-10 per cent of the population. One to two per cent of this population 
possesses one or more CNVs of 1Mb or larger [151]. It has also been found that an 
enrichment of CNVs high in exonic density occurs in the most gene-rich regions of the 
genome [152]. A later study also suggests that 60 per cent of 3,552 CNVs are likely to affect 
protein-coding genes [153]. This suggests that CNVs may be involved in the development of 
genetic disorders [149]. 
 
The extent to which different CNVs affect phenotype is dependent on the genes with which 
they overlap and whether or not they have any effect on gene function [284]. Whole genes 
may vary in copy number and may consequently lead to a variation in gene expression, where 
gains and losses in copy number will increase and decrease gene expression levels [284]. 
Stranger et al. have estimated that CNVs account for 17.7 per cent of heritable variation in 
gene expression and may therefore be phenotypically harmful [285]. Some common gene 
CNVs have been found to increase susceptibility to certain complex diseases. Some studies 
have found disease to be associated with variants [284-286]. A substantial number of these 
associations has been found to be involved in the immune system. For example, low copy 
numbers of the FCGR3B gene are associated with systemic lupus and other systemic 
autoimmune disorders [286]. Variants have also been seen to overlap with cancer-related 
genes such as oncogenes and tumour suppressor genes, e.g. TUSC2, TUSC4, NAT6, LPP, 
MLTT3 and MEN1 [158, 161, 287]. Genes involved in brain development have also been 
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found to be enriched in CNVs and may increase susceptibility to neurological and psychiatric 
disorders, such as bipolar disorder and schizophrenia. Some candidate genes in both these 
disorders, e.g. PDEβ, CHRNA7, DISC1 and GSK3β, have been found to overlap with known 
variants [149]. Furthermore, recent investigations into the genetics of autism have found both 
CNVs and minor mutations in genes, e.g. SHANK3, NLGN4 and NRXN1, to be reported in a 
small number of individuals with autism [288]. 
 
It is also important to note that, although the largest GWAS have revealed SNPs to be 
associated with complex diseases, they appear to explain only a fraction of the genetic 
component [149]. An alternative hypothesis is that rare variants play an important role in the 
development of complex diseases [149]. Population data on CNVs have shown low 
frequencies of rare variants worldwide [153]. Some recent studies have found an elevated 
incidence of rare deletions in schizophrenia, autism, and MR [151]. 
 
Several different approaches have been used to study CNVs. Early CNV studies tended to use 
array comparative genomic hybridisation (aCGH) [284], but there has been a recent shift 
toward CNV profiling using high-density SNP arrays. For example, Affymetrix 6.0. genome-
wide oligonucleotide arrays are now designed to detect both SNPs and CNVs. Affymetrix 6.0 
includes 906,600 SNP probes and 940,000 CNV probes [289], which facilitates dense 
coverage and high throughput studies exploring the role of CNVs in complex diseases such 
as obesity and T2D [179]. 
 
Different algorithms have been used to identify CNV calls from SNP and aCGH arrays using 
the intensity of the hybridisation of sample DNA to the array probes. Coin et al. have divided 
these algorithms into two general classes, „wide‟ and „deep‟ [179]. The „wide‟ method uses a 
one-dimensional spatial model of copy-number variation, often using a hidden Markov model 
(HMM) [179]. It also processes each sample independently with fixed allele signal intensity 
clusters [179]. For example, PennCNV was used for the Illumina platform [178], and was 
later modified to be compatible also with Affymetrix platforms [289]. The „deep‟ method 
uses the distribution of allele intensities across all samples but focuses on a few probes at a 
time [179]. Some packages have separate „wide‟ and „deep‟ method components [289]. For 
example, Birdsuite was developed to detect CNVs in SNP genotyping arrays specifically for 
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Affymetrix platforms [289]. One of the most recent algorithms is a nomenclature algorithm 
developed by Coin et al. [179]. This algorithm uses „CNV genotype‟ for the numerical copy 
number in a sample at a given probe position; „SNP geno-type‟ for the allelic composition 
within a fixed CNV genotype at a biallelic probe; and „CNV-SNP genotype‟ for combined 
CNV and SNP genotype [179]. 
 
A promising strategy to identify missing heritability in obesity and other complex disorders is 
to look at cohorts with extreme phenotypes that are likely to be enriched with rare variants 
[185]. This will facilitate their discovery by identifying loci that may reveal more rare 
variants [185]. It has been found that the most productive approach is to examine extreme 
cases of obesity in small well-phenotyped cohorts and to replicate the findings in GWAS 
population studies [185]. 
 
The investigation of rare GSVs in children with „extreme‟ syndromic forms of obesity (for 
example, where obesity is seen with learning disability and other dysmorphic features) has 
recently also been very fruitful [189, 290, 291]. The Department of Genomics of Common 
Disease at Imperial College, London, has also recently reported a highly penetrant form of 
obesity in subjects with a BMI of > 40 kg/m² with rare deletions of at least 500kb at 16p11.2, 
first identified in children with a learning disability, which is present at appreciable 
frequencies in collections of obese adults and children in European populations [185]. Wang 
et al. later investigated whether large and rare CNVs differentiate moderate to extreme 
European obese subjects from never-overweight controls [189]. It has been found that obese 
subjects who carry large CNV deletions have moderately high BMI [189] and that these large 
CNV deletions disrupt candidate obesity genes e.g. NAP1L5 and UCP1 [189]. In a childhood 
obesity study that examined children of European-American ancestry with a BMI in the 
upper 5th percentile [190], 17 rare CNV loci were found in three European-American obese 
children [190]. It was found that eight of these were replicated in an African-American obese 
child cohort [190]. The CNV deletion was found to disrupt the following genes: EDIL3, 
S1PR3, FOXP2, TBCA, ABCB5, ZPLD1, KIF2B, ARL15, EPHA6-UNQ6114 [190]. 
 
The role played by GSVs in obesity merits further investigation. The strategy of analysing 
adults and children with extreme phenotypes, including obesity and learning disabilities, and 
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following up significant findings in wider sample sets has been highly successful. This 
strategy is adopted in this study, using children identified by the Coordination Committee of 
Disabled Services in the Saudi Ministry of Health and Developmental Genetics Unit in King 
Faisal Hospital, Saudi Arabia. Screening Saudi Arabian adults and children with complex 
phenotypes, including obesity, learning disability, and dysmorphic features, for such GSVs 
will reveal new loci for obesity. 
 
This aspect of the project (investigation of syndromic obesity cases) will yield new obesity 
genes and loci, the implications of which will then be assessed in more common forms of 
obesity through analysis of large-scale population cohorts. In this way, it is hoped that new, 
highly penetrant, causes of obesity will be identified, which might also be observed to be a 
component of population collections of „common‟ obesity, as in the case of the 16p11.2 
deletion described above. This type of mutation already explains more than one in twenty 
cases of severe obesity and it is anticipated that this proportion will grow. In summary, a 
small number of „extreme‟ subjects will be selected to add to the growing collection of 
genetic causes of obesity, which, although individually rare, have very strong effects and are 
highly predictive at an individual level. 
 
4.2 Data normalisation and quality control 
 
The average contrast QC for all passing samples should be 1.7 or greater. All 157 samples 
passed this threshold. Calls from low-quality samples should be eliminated from the call file. 
As mentioned in Chapter Two, Section 2.4.1, an LRR variance threshold was used in QC 
for a particular data set. The LRR variance per-sample in this study ranged between 0.09 and 
0.15. Figure 4-1 plots the per-sample LRR variance. 
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Figure 4-1: LRR variance per- sample 
 
4.3 Frequency of copy number variation in cases versus controls 
 
After filtering out all the CNVs found in the telomeres and centromeres of all the 
chromosomes and merging all the CNV calls which form a part of a larger CNV, a total of 
4,004 CNVs were detected in both cases and controls. The frequency of CNVs varied 
between cases and controls, especially in heterozygous deletions, as shown in (Figure 4-2). 
As well as varying in frequency, CNVs also varied in size between cases and controls 
(Figures 4-3 and 4-4). Cases had a higher frequency of <100kb heterozygous deletions than 
the controls (Figures 4-3 and 4-4, Table 4-2). The median sizes of different types of CNV 
deletions and duplications are shown in Table 4-1. 
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Figure 4-2: Frequency of observed CNVs in 85 cases and 72 controls. Each bar represents the number of different types of CNVs observed in 
cases compared with controls. 
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Figure 4-3: Comparison of distribution of sizes of CNVs found in cases. The CNVs found in the cases in this study are plotted for each size 
range on the x-axis. Each bar represents the frequency of different sizes for the four different types of CNVs detected in this study. 
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Figure 4-4: Comparison of distribution of sizes of CNVs found in controls. The CNVs found in the cases in this study are plotted for each 
size range on the x-axis. Each bar represents the frequency of the different sizes for the four different types of CNVs detected in this study.  
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Table 4-1: Median size of different types of CNVs detected in this study 
Sample Heterozygous 
deletion 
(Median) 
Homozygous 
deletion 
(Median) 
Duplication 3 
copies (Median) 
Duplication 4 copies 
(Median) 
Cases 20.52kb 6.25kb 142.45kb 26.44kb 
Controls 24.58kb 6.7kb 115.52kb 9.07kb 
 
Table 4-2: Frequency of CNV deletions and duplications in cases and controls 
Copy Number Variants  Cases 
(N=85) 
Controls 
(N=72) 
 
<100kb    
 
Deletions 
 
Duplications 
43.6% 
 
76.3% 
32.2% 
 
79% 
 
100kb-500kb 
Deletions 
 
Duplications 
10.18% 
 
17.8% 
7.1% 
 
17.6% 
 
>500kb 
Deletions 
 
Duplications 
3.34% 
 
5.5% 
3.2% 
 
0.18% 
 
4.4 CNV prediction 
 
In order to assess the contribution of rare copy-number variants to obesity susceptibility, 
genome-wide CNV prediction was carried out in Saudi MR and extreme obesity adult and 
child case and control samples. CNV prediction was carried out using PennCNV [178], and 
copy numbers were modelled using LRR and BAF signal intensity measures from Affymetrix 
6.0 genome-wide array data for these samples (see Chapter Two, Section 2.4). Affymetrix 
data were available for the 85 cases and 72 controls. All CNVs that were either deleted or 
duplicated, were selected and put through different stages of analysis. 
 
4.4.1 Stage I: Exclusion of samples with obesity-related or other known syndromes 
 
4.4.1.1 Trisomy 21 
 
Five samples had Trisomy 21. Two of these had full Trisomy 21 with a large duplication 
ranging from chr21:9,758,742-46,921,385 overlapping with the critical region of Trisomy 21, 
which is anywhere between chr21qll.205 and chr21q22.300 [292] (Table 4.3). The other 
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three had partial Trisomy 21 with smaller duplication ranging from chr21:9,758,742-
10,197,783. It is important to note here that the critical region of Trisomy 21 is in the long 
arm of chromosome 21 and that the partial Trisomy 21 cases found in these samples were 
found to be in the short arm. In a paper by Korbel et al., a couple of samples were found to 
have the same duplication and further investigation was recommended to establish how this 
duplication may contribute to the development of Trisomy 21 [293]. Trisomy 21 patients 
generally present with cognitive impairment, dysmorphic features and a number of non-
specific manifestations, which all the samples that carry full Trisomy 21 duplication carry but 
of which the severity and frequency are highly variable between different individuals [294]. 
 
4.4.1.2 1p36 microdeletion syndrome 
 
One sample had 1p36 deletion syndrome at chr1:696,962-5,399,280 with a size of ~4.7 Mb 
(Table 4-3). This deletion overlaps with the critical region of 1p36 deletion syndrome, which 
has been seen to be variable in both clinical presentation and deletion size [295]. It is a 
heterozygous terminal deletion of the most distal chromosomal band on the short arm of 
chromosome 1 and ranges in size from ~1.5 to 410.5 Mb [295]. It has also been shown that 
1p36 deletion syndrome is a non-contiguous gene deletion syndrome, as there is no evidence 
that this deletion has an underlying gene causing this syndrome [295]. Genes that have been 
found to overlap with a mapped critical region for obesity in samples that carry 1p36 deletion 
syndrome, such as Protein kinase C zeta (PRKCZ), phospholipase C eta (PLCH) and hairy 
and enhancer of split 5 (HES5), have also been found to overlap with the current sample 
[296]. This sample has typical phenotypes of patients with the 1p36 deletion syndrome, 
including straight eyebrows, deep-set eyes, mid-face hypoplasia, [297]broad and flat nasal 
root/bridge, long philtrum, pointed chin, large, late-closing anterior fontanel, 
microbrachycephaly, epicanthal folds and posteriorly rotated, low-set, abnormal ears [298]. 
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4.4.1.3 Late-onset Alzheimer’s disease 
 
Late-onset Alzheimer‟s disease was also found in another sample with a CNV deletion in 
chr4: 40,838,233-40,908,819, which included amyloid beta (A4) precursor protein-binding, 
family B, member 2 (APBB2), a gene that has previously been seen to be associated with 
late-onset Alzheimer‟s disease (Table 4.3) [299]. 
 
4.4.1.4 Charcot-Marie-Tooth disease 
 
A 57,951 kb deletion at chr5:148,407,813-148,465,763 was also found in one of the samples. 
This includes the SH3 domain and tetratricopeptide repeats 2 (SH3TC2) gene in which 
mutations result in autosomal recessive Charcot-Marie-Tooth disease type 4C, characterised 
by loss of muscle tissue and touch sensation (Table 4-3) [297]. 
 
4.4.1.5 Velocardiofacial DiGeorge syndrome 
 
This syndrome was found in one sample. A missense mutation in proline dehydrogenase 
(oxidase) (PRODH) gene has been shown to cause Velocardiofacial DiGeorge syndrome 
[300]. A complete deletion of the PRODH gene at Chr22: 17,173,947 -17,386,984 was seen 
in this sample (Table 4.3). Typical symptoms of patients carrying Velocardiofacial DiGeorge 
syndrome include birth defects, such as congenital heart disease, defects in the palate most 
commonly related to neuromuscular problems with closure (velo-pharyngeal insufficiency), 
learning disabilities, mild differences in facial features, and recurrent infections, which are 
similar to those seen in these samples [300]. 
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Table 4-3: List of syndromes found in this cohort 
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10DG1416 Trisomy 21 dup 21 37,162,643 9,758,742 46,921,385 - 
10DG1099 Trisomy 21 dup 21 23,361,408 23,559,977 46,921,385 - 
09DG00530 Trisomy 21 dup 21 281,236 9,758,742 10,039,978 - 
10DG1414 Trisomy 21 dup 21 439,041 9,758,742 10,197,783 - 
10DG1433 Trisomy 21 dup 21 439,041 9,758,742 10,197,783 - 
10DG1105 1p36 microdeletion 
syndrome 
del 1 4,702,318 696,962 5,399,280 - 
10DG1426 Alzheimer disease 
late onset 
del 4 70,586 40,838,233 40,908,819 APBB2 
10DG1102 Charcot-Marie-
Tooth Disease 
del 5 57,950 148,407,813 148,465,763 SH3TC2 
10DG1103 velocardiofacial 
DiGeorge syndrome 
del 22 213,037 17,173,947 17,386,984 PRODH 
 
The table shows the samples that were found to have the different syndromes in this cohort, 
giving the name of the syndrome, location, and size of the deletion or duplication. 
 
4.4.2 Stage II: Exclusion of all genomic variants found in normal non-diseased 
samples 
 
As previously mentioned, in this study a total of 4,004 CNVs were found in cases and 
controls. In this analysis, only CNV deletions were considered. To assess what proportion of 
the variant regions discovered in this study was novel, the data were compared with variants 
found in controls from the same population. A total of 865 CNVs were found to overlap with 
variants found in the controls and were thus excluded from further analysis. Furthermore, 573 
CNVs were found only in controls and were also excluded from further analysis. Under the 
hypothesis that low-frequency, high-penetrance variants underlie severely obese phenotypes 
observed in these samples, CNVs that are rare (<1%) in this data set were later examined. A 
total of 584 rare CNVs were found in cases and were separated between those that include 
genes and those that do not. 
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4.5 Assessment of CNV candidacy 
 
Having generated a list of 365 rare CNVs, UCSC Genome Browser, Build hg18 was used as 
a reference sequence to examine each candidate CNV and its overlapping genes. These were 
later assessed according to the number of samples sharing the same CNVs, whether they 
encompassed any genes and whether they overlapped with any common CNVs. They were 
grouped into four categories (Figure 4-5). 
 
4.5.1 CNVs shared between two samples including genes 
 
Eight CNV regions were observed. The CNVs were found to be candidates if they did not 
have any overlapping common control variants (Table 4-4). The eight CNVs are 
heterozygous deleted (Table 4-4). The sizes of these deletions range from 12kb to 4.7Mb, and 
all contain one or more genes. Some regions of the genome show a high degree of complexity 
seen in one heterozygous CNV deletions chr5: 69110733 to 70290662, which include dense 
clusters of overlapping variants. 
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4.5.2 CNVs in one sample including genes 
 
Forty-three CNV regions were observed. CNVs were found to be candidates if they did not 
have any overlapping common control variants (Table 4-5 and Table 4-6). Forty-one of the 
43 CNVs are heterozygous deleted (Table 4-4) and 13 are homozygous deleted (Table 4-5). 
The heterozygous CNV deletions range in size from 4kb to 1.44Mb and the homozygous 
deletions range between 6 kb and 157.5 kb. All contain one or more genes. Some regions of 
the genome show a high degree of complexity seen in one heterozygous CNV deletions chr9: 
36587 to 1481796, which include dense clusters of overlapping variants. 
 
4.5.3 CNVs shared between two samples not including genes 
 
A hundred and one CNV regions were identified that overlapped by > 50% between two 
samples and did not include any genes in the CNV region (see Appendix A). These are all 
heterozygous and homozygous deletions. Sixty-five of the 101 CNVs are heterozygous 
deleted and 36 are homozygous deleted. The heterozygous CNV deletions range in size from 
1kb to 250Mb and the homozygous deletions range between 1kb and 302kb. In some 
samples, genes were found within 100kb upstream or downstream of that region. 
 
4.5.4 CNVs in one sample not including genes 
 
Two hundred and thirteen CNV regions were observed (see Appendix A). These are all 
heterozygous and homozygous deletions. Sixty-five of the 101 CNVs are heterozygous 
deleted and 36 are homozygous deleted. The heterozygous CNV deletions range in size from 
1kb to 250Mb and the homozygous deletions range between 1kb and 302kb. In some 
samples, genes were found within 100kb upstream or downstream of that region. 
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Figure 4-5: Assessment of CNV candidacy illustrating the process of identifying the 
most important CNVs from the 365 rare CNVs generated by this analysis 
Chapter Four: Contribution of Rare Copy Number Variants to Obesity Susceptibility 
189 
 
Table 4-4: List of candidate heterozygous CNV deletions including genes and shared by two samples 
Variant ID Number of 
samples 
Chromosome del/dup Number 
of SNPs 
Start End Size Genes 
CNVHTCA4 2 1 del 15 15,167,612 15,180,443 12,832 KAZN 
CNVHTCA31 5 2 del 21 50,302,629 50,318,004 15,376 NRXN1 
CNVHTCA24 3 1 del 37 246798656 246863836 65181 OR2T10, OR2T11, OR2T34 
CNVHTCA68 5 3 del 58 196868323 196987753 119431 MIR570, MUC20, MUC4, SDHAP2 
CNVHTCA44 2 2 del 128 193089962 193360433 270472 PCGEM1 
CNVHTCA74 18 4 del 58 70158099 70270740 112642 TMPRSS11E, UGT2B21 
CNVHTCA97 6 5 del 16 70290651 70427009 136359 GTF2H2B, GTF2H2C, GTF2H2D, GUSBP9, 
LOC100170939, SMA3, SMA4, NAIP 
CNVHTCA256 2 16 del 213 29474810 30134444 659635 HIRIP3, SEZ6L2, DOC2A, MAZ, CD2BP2, MVP, SPN, 
MAZ, HIRIP3, MAPK3, LAT 
 
 
Table 4-5: List of prioritised candidate heterozygous CNV deletions including genes and shared by one sample 
Variant ID Number of 
samples 
Chromosome del/dup Number of 
SNPs 
Start End Size Genes 
CNVHTCA45 1 2 del 41 203000000 203000000 16,427 BMPR2 
CNVHTCA40 1 2 del 25 138000000 138000000 20,680 THSD7B 
CNVHTCA15 1 1 del 24 170249712 170291151 41,440 DNM3 
CNVHTCA42 1 2 del 55 170078758 170181039 102,282 FASTKD1, KBTBD10, PPIG 
CNVHTCA7 1 2 del 67 58355567 58461192 105,626 DAB1 
CNVHTCA295 1 20 del 132 14771144 14889584 118,441 MACROD2, MACROD2-AS1 
CNVHTCA2 1 1 del 27 1488015 1662463 174,449 C1orf233, CDK11A, CDK11B, MIB2, MMP23A, 
MMP23B, SLC35E2, SLC35E2B, SSU72 
CNVHTCA106 1 5 del 110 133543411 133802067 258,657 CDKL3, CDKN2AIPNL, MIR3661, PPP2CA, UBE2B 
CNVHTCA192 1 10 del 186 67889770 68119974 230,205 CTNNA3 
CNVHTCA253 1 16 del 54 1152524 1444150 291,627 BAIAP3, C16orf42, C16orf91, CACNA1H, CCDC154, 
CLCN7, GNPTG, TPSAB1, TPSB2, TPSD1, TPSG1, 
UBE2I, UNKL 
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Table 4-6: List of candidate homozygous CNV deletions including genes and shared by one sample 
Variant ID Number of 
samples 
Chromosome del/dup Number 
of SNPs 
Start End Size Genes 
CNVHMCA15 1 6 del 7 124277388 124278017 630 NKAIN2 
CNVHMCA16 1 7 del 4 154058605 154059351 747 DPP6 
CNVHMCA31 1 19 del 6 56024079 56025050 972 KLK15 
CNVHMCA14 1 6 del 7 70747250 70753018 5,769 COL19A1 
CNVHMCA18 1 8 del 19 85425438 85431221 5,784 RALYL 
CNVHMCA32 1 20 del 5 319337 326242 6,906 TRIB3 
CNVHMCA3 1 1 del 9 102127547 102134503 6,957 DNAJA1P5, MIR548AI, OLFM3 
CNVHMCA13 1 6 del 26 66456203 66463931 7,729 EYS 
CNVHMCA22 1 10 del 13 89059776 89107280 47,505 LOC439994, LOC728190 
CNVHMCA26 1 13 del 14 51969153 52043659 74,507 TPTE2P3 
CNVHMCA19 1 10 del 108 67577247 67734756 157,510 CTNNA3 
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4.6 Creation of University of California, Santa Cruz browser tracks 
 
Rather than simply listing the rare CNVs found in this study, it is easier to visualise the CNV 
data alongside other genomic features using PLINK. PLINK generates a University of 
California, Santa Cruz (UCSC)-friendly BED file containing chromosome, start position, end 
position and type (del/dup) which can be uploaded and viewed in a browser. Figure 4-6 
shows an example of the UCSC browser track generated for each candidate CNV. The track 
illustrates the CNV deletion/duplication, the number of samples that carry the same 
deletion/duplication, whether the CNV overlaps with any genetic association studies of 
complex diseases and disorders, the DECIPHER chromosomal imbalance and phenotype, the 
human quantitative trait locus, RefSeq genes and DGV structural variants. 
Chapter Four: Contribution of Rare Copy Number Variants to Obesity Susceptibility 
192 
 
 
 
 
Figure 4-6: UCSC browser track of STXBP3 gene impacted by a CNV deletion. This deletion is in chromosome 1 with a size of 
29,628kb in sample 10DG1441 and 16,780kb in sample 10DG1412, which disrupts the imprinted gene. It overlaps with common CNV 
deletion at the 5‟ end of the gene. 
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4.7 Identification of rare CNVs which may disrupt obesity candidate genes 
 
Next, genes overlapping the prioritised CNVs described above were examined and 
considered as possible candidates for obesity. This section will examine only candidate CNV 
deletions causing obesity. 
 
4.7.1 CNVs shared between two samples including genes 
 
This section will present homozygous and heterozygous CNV deletions shared by two 
samples. As the study is of an inbred population, it is expected that there will be a tendency 
for a higher number of homozygous CNV deletions. For this reason, homozygous CNV 
deletions are prioritised for further investigation. A summary of the candidate genes 
discussed in this section can be found in Table 4-6, and clinical information on the samples 
carrying these deletions are shown in Table 4-7. 
 
4.7.1.1 Homozygous CNV deletions 
 
In general, homozygous CNV deletions are rare. In this data set no homozygous CNV 
deletions were found to be shared by two samples. 
 
4.7.1.2 Heterozygous CNV deletions 
 
One of the candidate genes within the CNV deletion on chromosome 2p16.3 contains a 
potential candidate gene Neurexin 1 (NRXN1) (Figure 4-7). Neurexins are a group of highly 
polymorphic cell surface proteins involved in cell recognition and cell adhesion, by forming 
intracellular junctions and synapse formation and signalling [301]. This is one of the largest 
known human genes and has relatively frequent disruptions, such as missense changes, 
translocation, whole gene deletion, and intragenic copy number alterations. NRXN1 has been 
associated with autism spectrum disorders and schizophrenia [301, 302]. This deletion is 
present in samples 10DG1418, 10DG1107, 11DG1442, 11DG141 and 11DG1434 with 
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moderate obesity, having BMIs of 33.7 and 34 kg/m² respectively. The deletion is of interest 
because it is highly expressed in the brain and most obesity genes are similarly expressed in 
the brain. This deletion has been found to delete exon 5 of the NRXN1 gene. The clinical data 
of the samples show that they have MR, are hyperactive, and have moderate to severe 
learning difficulties (Table 4-7). Other dysmorphic features are not present. No genes were 
found 100kb upstream or downstream of this CNV. 
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Figure 4-7: NRXN1 gene impacted by a CNV deletion on chromosome 2 with a size of 15,376kb. This deletion is found in samples 
10DG1418, 10DG1107, 11DG1442, 11DG141 and 11DG1434 shown by the red arrow. It deletes exon 5 of NRXN1 and does not contain any 
common variants. 
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Another CNV deletion in chromosome 16p11.2 was found in two samples 11DG0588 and 
11DG0572. This deletion is the same large deletion on chromosome 16p11.2 that has been 
previously seen to increase the risk of developing severe obesity. This deletion is 659,635bp 
in size, with the presence of two segmental duplications that renders this locus (Figure 4-8). 
This deletion encompasses some potential obesity-developing genes, including bolA 
homolog (BOLA), bolA homolog 2B (BOLA2B), sulfotransferase family, cytosolic, 1A, 
phenol-preferring, member 4 (SULT1A4), sulfotransferase family, cytosolic, 1A, phenol-
preferring, member 3 (SULT1A3), sialophorin (SPN), MYC-associated zinc finger protein 
(MAZ), major vault protein (MVP), potassium channel tetramerisation domain containing 13 
(KCTD13), TAO kinase 2 (TAOK2), protein phosphatase 4, catalytic subunit (PPP4C), 
glycerophosphodiester phosphodiesterase domain containing 3 (GDPD3) and mitogen-
activated protein kinase 3 (MAPK3); however, they require further investigation [303-309]. 
The two samples carrying this CNV deletion have moderate obesity with BMIs of 34.5 and 
35.1 kg/m². They also have mild MR, language delay, hyperactivity, and hyperphagia (Table 
4-7). 
 
Table 4-8 shows candidate obesity genes shared in two samples. The table also gives a 
description of each gene, its pathways and interactions and whether it is associated with 
obesity or any other disease. 
 
Other genes were found to be deleted in other CNVs in this data set but are a lower priority. 
A list of these genes and their location is given in Appendix A. 
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Figure 4-8: Heterozygous deletion in the chromosome16p11.2 region. This is a 659,635kb 
deletion encompassing many genes and is found in two samples, 11DG0588 and 11DG0572, 
shown by the red arrow. 
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Table 4-7: Clinical data of patients carrying the same CNV deletion 
Variant 
ID 
CNVHTCA31 
10DG1107  Mental retardation, hyperactive and moderate to severe learning difficulties; other dysmorphic 
features are not present 
11DG1442 Mental retardation, hyperactive and moderate to severe learning difficulties; other dysmorphic 
features are not present 
11DG1413 Mental retardation, hyperactive and moderate to severe learning difficulties; other dysmorphic 
features are not present 
11DG1434 Mental retardation, hyperactive and moderate to severe learning difficulties; other dysmorphic 
features are not present 
11DG1418 Mental retardation, hyperactive and moderate to severe learning difficulties; other dysmorphic 
features are not present 
11DG0588 Mild mental retardation, language delay, hyperactivity and hyperphagia 
11DG0572 Mild mental retardation, language delay, hyperactivity and hyperphagia 
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Table 4-8: Description of candidate obesity genes shared between two samples 
Gene and/or region Gene function Expressed in 
the brain 
Associated with 
obesity 
Associated with other disease 
NRXN1 involved in cell recognition and cell adhesion yes no no  
16p11.2: - - yes 16p11.2 del Autism 
BOLA2 and BOLA2B Cell proliferation yes - - 
SULT1A4 and 
SULT1A3 
Induced in response to fasting or as a result of a defect 
in leptin signaling 
yes no - 
SPN Activator of JNK1 and MAPK3 signaling yes no - 
MAZ Interacts with SP1 in regulating transcription of 
serotonin receptor gene HTR1A 
yes no Immune-mediated cerebral disease 
MVP Regulates cytoplasmic localization of PTEN yes no Acute Myeloid Leukemia 
KCTD13 Mediator of insulin resistance in rodent obesity models yes no - 
TAOK2 Activates JNK1 and MAPK3 pathways via the upstream 
MKK3 and MKK6 kinases 
yes no - 
PPP4C Regulates JNK1 signalling yes no - 
GDPD3 Glycerophosphodiesterase domain yes no - 
MAPK3 Proliferation and differentiation of preadipocytes yes no - 
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At this stage, genes in CNVs shared by two samples have been examined. The next stage is to 
look at candidate genes that are deleted in CNVs and found in individual samples. This 
section will discuss homozygous and heterozygous CNV deletions found in individual 
samples. As the study is of an inbred population, it is expected that there will be a tendency 
for a higher number of homozygous CNV deletions. For this reason, homozygous CNV 
deletions are prioritised for further investigation. 
 
4.7.1.3 Homozygous CNV deletions 
 
Sample 10DG1421 had a 6906 bp CNV homozygous deletion in chromosome 20p13 
containing TRIB3. The deletion includes exon 3 and exon 4 of TRIB3 (Figure 4-9). The 
sample has a BMI of 35.8 kg/m². TRIB3 is a gene that functions mainly as a 45-kDA 
peusdokinase binding to Akt, a key mediator in insulin signalling. A gain of function variant 
in this gene has been shown to be involved in shaping the risk of developing insulin 
resistance, T2D and cardiovascular disease [310]. Knockout mice for this gene have shown a 
70 per cent increase in white adipose tissue [311]. The clinical data of sample 10DG1421 
show hyperactivity, mild learning difficulties and deviated nasal spectrum. Fasting blood 
glucose is 8.6 mmol/l with triglyceride higher than 2.62 mmol/L. Some genes were found 
either upstream or downstream of this CNV, such as ring finger protein 31 (HOIL-1), RanBP-
type and C3HC4-type zinc finger containing 1 (RBCK1), neurensin 2 (NRSN2) and SRY (sex 
determining region Y)-box 12 (SOX12). None of these has previously been associated with 
obesity. 
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Figure 4-9: TRIB3 gene impacted by a CNV deletion on chromosome 20. The deletion, 
found in sample 10DG1421, is 6,906kb in size and disrupts the imprinted gene indicated by 
the red arrow. This deletion does not overlap with common CNVs found in other data sets. 
 
Catenin (Cadherin-Associated Protein), Alpha 3 (CTNNA3), a gene that is necessary for the 
formation of stretch-resistant cell-cell adhesion complexes, was impacted by a homozygous 
CNV deletion at chromosome 10q21.3 found in sample 10DG1097. This CNV deletion is 
157kb in size and is the largest of all the homozygous deletions. It appears that exon 5 is 
deleted (Figure 4-10). This gene has previously been associated with late-onset Alzheimer‟s 
disease and asthma [312-315]. Protein networks of this gene show an interaction with 
diabetes-associated genes, GATA binding protein 4 (GATA4) and transcription factor 7-like 2 
(TCF7L2). The gene is expressed in both the brain and the heart. This sample has a BMI of 
39 kg/m² and also presents with severe learning difficulties, behavioural problems (severe 
aggressiveness), rheumatic fever and atrial fibrillation. 
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Figure 4-10: CTNNA3 gene impacted by a CNV deletion on chromosome 10. The 
deletion, found in sample 10DG1097, is 157,510kb in size and disrupts the imprinted gene. 
This deletion does not overlap with common CNVs found in other databases. 
 
4.7.1.4 Heterozygous CNV deletions 
 
Disabled Homolog 1 (Drosophila) (DAB1), a gene that is highly expressed in the cerebral 
cortex and is required for normal cognitive function and brain development, was impacted by 
a CNV deletion at chromosome 1p32.1 that existed in sample 11DG-0567 [316]. Neither the 
gene nor its pathways and protein networks have previously been associated with obesity, but 
it has been previously seen to be associated with autism [316]. The deletion encompasses the 
intronic region between exon 11 and exon 12 (Figure 4-11). Sample 11DG-0567 has a BMI 
of 37.6 kg/m² as well as behavioural problems, moderate learning difficulties, multiple 
patches of partial cutis aplasia and epilepsy. 
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Figure 4-11: DAB1 gene impacted by a CNV deletion on chromosome 1. The deletion, 
found in sample 11DG-0567, is 105,626kb in size and is indicated by the red arrow. This 
deletion partially overlaps with a common CNV deletion at 58,385,034-58,388,147bp. 
 
In chromosome 1p36.33 a 174 kb CNV deletion was detected in sample 11DG-0585. This 
encompasses many genes: C1orf233, CDK11A, CDK11B, MIB2, MMP23A, MMP23B, 
SLC35E2, SLC35E2B and SSU72 (Figure 4-12). Cyclin-dependent kinase 11A (CDK11A) is 
the only gene that has previously been found to be associated with T2D [317]. This gene 
plays a role in cell cycle progression, cytokinesis, and apoptosis [317]. The clinical data show 
that the BMI of this sample is 33.8 kg/m², with developmental delays, behavioural problems, 
moderate learning difficulties, multiple skin appendages in the neck/upper back and epilepsy. 
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Figure 4-12: A CNV heterozygous deletion on chromosome 1 with a size of 174,449kb in 
sample 11DG-0585. This deletion overlaps with a common CNV duplication at 825,513-
1,691,539bp. 
 
Catenin (Cadherin-Associated Protein), Alpha 3 (CTNNA3), a gene that is necessary for the 
formation of stretch-resistant cell-cell adhesion complexes, was impacted by a homozygous 
CNV deletion at chromosome 10q21.3 found in sample 10DG1431. This CNV deletion, 
230.2 kb in size, is the largest of all the heterozygous deletions and it appears that exons 8 
and 9 are deleted (Figure 4-13). This gene has previously been associated with late-onset 
Alzheimer‟s disease and asthma [312-315]. Protein networks of this gene show an interaction 
with obesity- and diabetes-associated genes GATA4 and TCF7L2. It is expressed in both the 
brain and the heart. This sample has a BMI of 38.5 kg/m², as well as developmental delays, 
severe learning difficulties, behavioural problems, classical TS facial lesions, ash-leaf spots, 
cafe-au-lait spots, and tuberous sclerosis. This sample has a family history of obesity and MR 
in the paternal aunt and comes from a consanguineous family. 
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Other genes were found to be deleted in different CNVs in this data set but these are a lower 
priority. A list of these genes and their locations is shown in Appendix A. 
Figure 4-13: CNV heterozygous deletion at chromosome 10q21.3 in sample 10DG1431 
containing the CTNNA3 gene. The deletion is in exons 8 and 9 and partially overlaps with a 
common CNV deletion found in different data sets at 67,989,824-68,078,508. 
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4.8 Investigation and validation of rare CNVs that may disrupt obesity 
candidate genes 
 
This section will describe the investigation of the candidate multiple rare CNVs described in 
section 4.7. The priority candidates, as described in Chapter Two, section 2.4, are 
homozygous and heterozygous deleted CNVs that encompass genes and cause a loss of 
function in these genes. 
 
4.8.1 Rare homozygous deleted CNVs 
 
Two homozygous deleted CNVs that have been shown to delete TRIB3 and CTNNA3 genes 
were investigated further. This section presents the screening and validation process for these 
CNV deletions. 
4.8.1.1 Screening and identification of rare homozygous deletions through genome-
wide CNV prediction 
 
As mentioned in Chapter Two, section 2.4, genome-wide copy number prediction algorithm 
PennCNV was carried out on signal intensity data from Affymetrix 6.0 SNP arrays in a Saudi 
MR and extreme obesity cohort and normal Saudi controls of 85 cases and 72 controls. 
 
PennCNV identified a homozygous deleted region overlapping the TRIB3 at 20p13 with a 
size of 6906bp and CTNNA3 at 10q21.3 with a size of 157kb. These two deletions were only 
found in cases and not in controls. Figure 4-14 and 4-15 illustrates the signal intensity of both 
deletions in obesity cases. 
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Figure 4-14: Signal intensity of TRIB3 and CTNNA3 homozygous deletions. PennCNV CNV prediction showing a. Log R Ratio and b. B 
Allele Frequency for TRIB3 aberration. 
 
  
a. b. 
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Figure 4-15: Signal intensity of TRIB3 and CTNNA3 homozygous deletions. PennCNV CNV prediction showing a. Log R Ratio and b. B 
Allele Frequency for CTNNA3 aberration.
a. b. 
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4.8.1.2 Genotyping analysis at TRIB3 6906bp and CTNNA3 157kb deletion 
 
In order further to investigate the role of both TRIB3 and CTNNA3 variants in obesity 
susceptibility, the TRIB3 and CTNNA3 deletions were genotyped for the cases carrying these 
deletions (Table 4-5) and for 100 Saudi controls. The genotyping of the deletion was carried 
out using a direct PCR assay. As described in Chapter Two, section 2.4.7.2, the PCR 
designed for genotyping TRIB3 and CTNNA3 deletions consists of two PCR assays, one 
employing a primer pair positioned within the boundaries of the deletion and a second primer 
pair located outside the deletion boundaries. Using this PCR primer design, a PCR only for 
the internal primer pair will be produced for samples with a copy number of two at the 
deletion. PCR products for both internal and external primer pairs will be produced only for 
samples with heterozygous deletion, and a PCR product for the external primer pair will be 
produced in the case of homozygous samples for TRIB3 and CTNNA3 deletions. 
 
This analysis confirmed the TRIB3 6906bp homozygous deletion using the two PCR assays 
(Figure 4-16). However, the CTNNA3 PCR assay did not confirm the deletion. The PCR 
products appeared within the internal and external PCR primers, which suggests a false-
positive call generated by PennCNV for this deletion. 
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Figure 4-16: PCR based genotyping assay of TRIB3 6,906bp deletion within exons 3and 4. The different products are labeled in red. The gel 
shows that the affected sample has external product with no internal product. In the control sample, only internal products are seen with no 
external products. All primers are of expected size. A blue arrow denotes external at 539bp and green denotes internal at 605bp. 
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4.8.1.3 Sequence analysis of TRIB3 6,906bp deletion 
 
The 6,906bp deletion, which deletes exons 3 and 4 of the TRIB3 gene, was sequenced in the 
sample carrying the deletion and in ten Saudi controls to establish the breakpoints. As shown 
in Figure 4-17, the sequence analysis of the 6906bp deletion was the correct size, with the 
breakpoints exactly matching the CNV deletion detected by PennCNV. The deletion was 
visible only in the sample with the deletion and was not present in the ten Saudi controls 
sequenced. 
 
The deletions observed in the TRIB3 and CTNNA3 genes do not have a high frequency in 
publicly-available genomic variant databases. No CNV deletions were detected within this 
gene (Figures 4-9 and 4-10). 
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Figure 4-17: Upstream and downstream breakpoints of 6,906bp deletion that deletes 
exons 3 and 4 of the TRIB3 gene. The red arrow indicates the location of the upstream and 
downstream breakpoints of the deletion showing sequences of both the case and the reference 
sample. 
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4.8.2 Rare heterozygous 16p11.2 CNV deletion previously associated with obesity 
 
This section describes the investigation of the rare ~600kb deletion at chromosome 16p11.2 
that has been shown to be associated with a highly increased risk of obesity [185]. This 
deletion was found in two samples, as described in section 4.7.1.2, and was identified using 
PennCNV. The process of direct copy number determination by MLPA will be presented, as 
well as the application of this method to identify this deletion in other subjects with no MR 
from a cohort of Saudi, Sudanese and Yemeni samples with obesity. 
 
4.8.2.1 Confirmation of chromosome 16p11.2 deletion carriers by Multiplex Ligation-
Dependent Probe Amplification (MLPA) 
 
The two samples carrying the chromosome 16p11.2 heterozygous deletion, identified by 
PennCNV and located within the known chromosome 16p11.2 boundaries, were genotyped 
using MLPA assay-containing probes specifically interrogating sequences within the deleted 
segments. The two samples carrying this deletion were found to be heterozygous for this 
deletion at 16p11.2 (Figure 4-18). 
 
The identification of two 16p11.2 deletion carriers among 85 subjects with extreme obesity 
and MR suggests that the deletion is present in 2.35 per cent of subjects in this cohort. 
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Figure 4-18: MLPA results for samples found to carry a heterozygous deletion at chromosome 16p11.2. MLPA probes are listed 
according to their genomic location. Two probes flank the 16p11.2 region and nine probes are within the deleted region. Figures a. and b. show 
two samples carrying this deletion; these are compared with the control in c. and d.
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4.8.2.2 Characterisation of chromosome 16p11.2 deletion carriers in the Saudi mental 
retardation extreme obesity cohort 
 
Two samples in the Saudi MR extreme obesity cohort were found to carry chromosome 
16p11.2. Both have a BMI of almost 35 kg/m². No yearly BMI data was available. Both 
subjects have mild MR, language delay, hyperactivity, and hyperphagia. Fasting blood 
glucose is in the normal range at 5.3 mmol/l in both samples. 
 
4.8.2.3 Replication of the chromosome 16p11.2 heterozygous deletion in obese Saudi, 
Sudanese and Yemeni samples with no mental retardation 
 
The MLPA assay was also employed on a total of 185 replication samples from three Arab 
populations – Saudi, Sudanese and Yemeni (see Chapter Two, section 2.1.4). These samples 
have obesity with no MR. 
 
The assay showed three samples carrying duplication within the chromosome 16p11.2 
deletion region (Figure 4-19). The three samples are of Saudi origin and are obese. The 
duplication was between the MAZ gene probe and the HIRIP3 gene probe. None of the other 
seven probes covering the chromosome 16p11.2 deletion region were duplicated. 
 
This result suggests that the obesity-causing gene in the chromosome 16p11.2 heterozygous 
deletion may be within the genes flanking the duplicated region (Table 4-8). 
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Figure 4-19: MLPA results for samples found to carry a heterozygous duplication at chromosome 16p11.2. MLPA probes are listed 
according to their genomic location. Two probes flank the 16p11.2 region and nine probes are within the 16p11.2 region. Figures a., b. and c. 
give three samples carrying duplication in the region between MAZ probe 2 and HIRIP3 probe 1. The red line shows that all duplicated probes 
have a signal intensity ratio of 1.3 and above. 
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4.9 Genome-wide analysis of large CNVs from the Saudi mental retardation 
and extreme obesity cohort 
 
Several studies have investigated the contribution of large CNVs to bodyweight regulation 
and obesity susceptibility. Some of these study specific CNVs such as chromosome 16p11.2 
deletion and duplication in the development of obesity [185, 186, 290]. Others have also 
analysed the global CNV load to determine whether obese subjects have a higher burden of 
large CNVs compared with normal controls [190, 290]. 
 
This section will examine whether large rare CNVs contribute to susceptibility to obesity in 
the Saudi extreme obesity and MR cohort. In this study, large CNVs are defined as those 
larger than 500kb and are present in less than 1 per cent of subjects. 
 
4.9.1 Merging of large CNVs predicted by PennCNV prediction algorithm 
 
PennCNV was used to call large CNVs in both cases and controls (see Chapter Two, section 
2.6). From the analysis, it appeared that large CNVs were split into multiple small CNV calls, 
making it difficult to estimate the total number of large CNVs in the Saudi extreme obesity 
and MR cohort. In order to merge the adjacent small calls generated by PennCNV, the 
clean_cnv.pl Perl script was used. It appeared that when using only the raw CNV prediction 
generated by PennCNV, large CNVs were difficult to detect. This phenomenon was also 
observed in raw CNV calls predicted by other algorithms (CNVPartition and cnvHap), and 
confirmed that the prediction of large CNVs by these algorithms is frequently difficult 
(Figure 4-20) [318]. 
 
In order to avoid biasing this analysis, a criterion of a minimum of 20 probes within the given 
merged calls was employed for the identification of large CNVs. The CNVs were also 
filtered to exclude variants in centromeric and telomeric regions. 
 
Among the variants larger than 500kb identified in the extreme obesity and MR cohort, three 
subjects were found to carry gross structural variants larger than 4Mb (Figure 4-21). Two of 
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the subjects carried a 5Mb deletion in chromosome 1 and one carried another 5Mb deletion in 
chromosome 15. The chromosome 1 deletion was consistent with a deletion in published 
samples carrying chromosome 1q36 deletion syndrome and with obesity [319]. 
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Figure 4-20: Large copy-number variants artificially split by the PennCNV algorithm. UCSC tracks with split 700kb and 1.5Mb 
deletions are shown in a. and c. respectively. After using the PennCNV clean_cnv.pl perl script, small CNV predictions were merged into one 
CNV call, as shown in b. and d.  
a. b. 
c. 
 
d.  
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Figure 4-21: Gross aberrations above 4Mb detected in Saudi extreme obesity and mental retardation cohort, showing a 5Mb deletion in 
the q arm of chromosome 1. LRR pattern and BAF are both seen on a. and b. The breakpoint of this aberration is indicated by the red line. 
a. 
b. 
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4.9.2 Large copy number variants identified in Saudi extreme obesity and mental 
retardation cohort 
 
After merging the large CNV calls, a total of 155 large copy number variants above 500kb 
were identified in the Saudi extreme obesity and MR cohort. The numbers of deletions and 
duplications in cases compared with controls are presented in Table 4-9. The full list of large 
CNV deletions is presented in Table 4-10. Expanded tables listing CNVs and genes 
encompassing these CNVs are attached at Appendix A. All the CNV deletions reported in 
this section were in heterozygous state. No homozygous deletions above 500kb were 
detected. From this analysis, it is also notable that CNV duplications above 500kb were 
present more frequently than heterozygous deleted CNVs in the Saudi extreme obesity and 
MR cohort. 
 
Table 4-9: Number of copy number variants above 500kb detected in Saudi extreme 
obesity and mental retardation cases and controls 
Copy Number Variants Cases (N=85) Controls (N=72) 
Above 500kb Deletions 15 7 
Duplications 49 19 
All 63 26 
Above 1Mb Deletions 10 15 
Duplications 37 4 
All 47 19 
 
Table 4-10: Copy number variation above 500kb detected by PennCNV in Saudi 
extreme obesity and mental retardation case control samples 
Chromosome Start genomic 
coordinate 
(hg18) 
End genomic 
coordinate 
(hg18) 
Length (bp) CNV Type Phenotype 
chr1 51598 758656 707,059 Duplication Case 
chr1 147159969 147703466 543,498 Deletion Control 
chr2 87191480 87833445 641,966 Deletion Control 
chr2 87214683 87777487 562,805 Duplication Control 
chr2 87214683 87805782 591,100 Deletion Control 
chr2 87325354 87833445 508,092 Duplication Control 
chr2 89278610 91202791 1,924,182 Duplication Case 
chr2 89281588 89958702 677,115 Duplication Case 
chr2 89281588 91233073 1,951,486 Duplication Case 
chr2 89334354 91255279 1,920,926 Duplication Case 
chr2 89365022 89912071 547,050 Duplication Case 
chr2 89395525 91255279 1,859,755 Duplication Case 
chr2 89648439 91017673 1,369,235 Deletion Case 
chr2 89938569 91068463 1,129,895 Deletion Case 
chr2 110212024 110854188 642,165 Duplication Control 
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Chromosome Start genomic 
coordinate 
(hg18) 
End genomic 
coordinate 
(hg18) 
Length (bp) CNV Type Phenotype 
chr2 110227488 110854188 626,701 Duplication Case 
chr3 75195065 75740799 545,735 Duplication Case 
chr4 188933689 189628106 694,418 Duplication Case 
chr5 21025215 21656087 630,873 Deletion Case 
chr5 69110733 70290662 1,179,930 Deletion Case 
chr7 57275061 57910659 635,599 Duplication Control 
chr7 61686865 62343851 656,987 Duplication Case 
chr8 21254 11101968 11,080,715 Duplication Case 
chr8 7141477 7670832 529,356 Deletion Case 
chr8 7141477 7836800 695,324 Duplication Case 
chr8 7202021 7836800 634,780 Duplication Case 
chr8 7202021 7836800 634,780 Duplication Case 
chr8 7202021 7836800 634,780 Duplication Case 
chr8 7202021 7836800 634,780 Duplication Case 
chr8 7202021 7847316 645,296 Duplication Control 
chr8 7202021 7847316 645,296 Duplication Control 
chr8 7202021 7847316 645,296 Duplication Control 
chr8 7202021 7869464 667,444 Duplication Case 
chr8 7202021 7869464 667,444 Duplication Case 
chr8 7202021 7869464 667,444 Duplication Case 
chr8 7225313 7825372 600,060 Deletion Case 
chr8 7225313 7847316 622,004 Deletion Case 
chr8 7237790 7825372 587,583 Deletion Case 
chr8 7237790 7825372 587,583 Duplication Control 
chr8 7237790 7836800 599,011 Deletion Control 
chr8 7237790 7836800 599,011 Deletion Control 
chr8 7237790 7836800 599,011 Duplication Case 
chr8 7237790 7836800 599,011 Duplication Case 
chr8 7237790 7836800 599,011 Duplication Case 
chr8 7237790 7836800 599,011 Duplication Case 
chr8 7237790 7847316 609,527 Deletion Control 
chr8 7237790 7847316 609,527 Duplication Case 
chr8 7237790 7847316 609,527 Duplication Case 
chr8 7237790 7869464 631,675 Duplication Case 
chr8 7254775 7869464 614,690 Duplication Case 
chr8 7267308 7836800 569,493 Duplication Case 
chr8 7358888 7869464 510,577 Deletion Control 
chr9 40085483 45953932 5,868,450 Duplication Control 
chr9 42986072 44213237 1,227,166 Duplication Case 
chr9 43575109 44729459 1,154,351 Deletion Case 
chr9 44181813 44795733 613,921 Duplication Case 
chr9 44569219 45071919 502,701 Duplication Case 
chr9 44569219 45071919 502,701 Duplication Case 
chr9 45805240 46744084 938,845 Deletion Control 
chr9 67772966 69205261 1,432,296 Duplication Case 
chr9 68055004 68985820 930,817 Duplication Case 
chr9 68055004 69205261 1,150,258 Duplication Case 
chr9 68055004 69205261 1,150,258 Duplication Case 
chr9 68114141 68822858 708,718 Duplication Case 
chr9 68285054 69215560 930,507 Duplication Case 
chr9 68285054 69248021 962,968 Deletion Control 
chr9 68312776 69256653 943,878 Deletion Control 
chr9 68352250 68857687 505,438 Duplication Case 
chr9 68352250 69220052 867,803 Deletion Control 
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Chromosome Start genomic 
coordinate 
(hg18) 
End genomic 
coordinate 
(hg18) 
Length (bp) CNV Type Phenotype 
chr10 45905767 47241036 1,335,270 Duplication Control 
chr10 45905767 47433407 1,527,641 Duplication Case 
chr10 46094186 47063139 968,954 Duplication Case 
chr10 46094186 47067933 973,748 Duplication Case 
chr10 46094186 47174643 1,080,458 Duplication Case 
chr10 46094186 47174643 1,080,458 Duplication Case 
chr10 46337321 46839717 502,397 Duplication Case 
chr10 46337321 47020102 682,782 Deletion Control 
chr10 46337321 47241036 903,716 Duplication Control 
chr10 46401209 47132778 731,570 Duplication Control 
chr10 46409098 47174643 765,546 Duplication Case 
chr10 46478798 47174643 695,846 Duplication Case 
chr10 46482317 47170483 688,167 Duplication Case 
chr10 46482317 47174643 692,327 Duplication Case 
chr10 46482317 47174643 692,327 Duplication Case 
chr10 46482317 47241036 758,720 Duplication Case 
chr13 93319769 93892399 572,631 Duplication Control 
chr14 18521076 19493212 972,137 Duplication Case 
chr14 18611714 19213349 601,636 Deletion Case 
chr14 18611714 19227683 615,970 Deletion Case 
chr14 18670435 19329803 659,369 Deletion Case 
chr14 18842018 19439731 597,714 Duplication Case 
chr14 18842018 19439731 597,714 Duplication Case 
chr14 18914107 19490079 575,973 Deletion Case 
chr15 18276341 19566875 1,290,535 Duplication Control 
chr15 18276341 19566875 1,290,535 Duplication Control 
chr15 18476969 20089383 1,612,415 Duplication Case 
chr15 18491920 20232614 1,740,695 Duplication Case 
chr15 18491920 21038987 2,547,068 Duplication Case 
chr15 18506386 19462019 955,634 Duplication Case 
chr15 18506386 20232614 1,726,229 Duplication Case 
chr15 18522250 20089383 1,567,134 Duplication Case 
chr15 18652835 19406927 754,093 Duplication Case 
chr15 18652835 19566875 914,041 Duplication Case 
chr15 18652835 19835526 1,182,692 Deletion Control 
chr15 18652835 20089383 1,436,549 Duplication Case 
chr15 18652835 20089383 1,436,549 Duplication Case 
chr15 18652835 20089383 1,436,549 Duplication Case 
chr15 18652835 20232614 1,579,780 Duplication Case 
chr15 18700552 20089383 1,388,832 Duplication Case 
chr15 18700552 20089383 1,388,832 Duplication Case 
chr15 18700552 20089383 1,388,832 Duplication Case 
chr15 18700552 20089383 1,388,832 Duplication Case 
chr15 18706152 20089383 1,383,232 Deletion Case 
chr15 18728578 19931449 1,202,872 Duplication Case 
chr15 18728578 20089383 1,360,806 Deletion Control 
chr15 18824589 19422452 597,864 Duplication Case 
chr15 18824589 19566875 742,287 Deletion Control 
chr15 18850041 20089383 1,239,343 Duplication Case 
chr15 18861568 20089383 1,227,816 Duplication Case 
chr15 18977400 19548935 571,536 Duplication Control 
chr15 19055354 19566875 511,522 Deletion Case 
chr15 19090388 19951021 860,634 Deletion Control 
chr15 19334428 20089383 754,956 Duplication Case 
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Chromosome Start genomic 
coordinate 
(hg18) 
End genomic 
coordinate 
(hg18) 
Length (bp) CNV Type Phenotype 
chr15 19406842 20089383 682,542 Duplication Control 
chr15 19412503 20051723 639,221 Duplication Control 
chr15 19412503 20089383 676,881 Deletion Case 
chr15 19412503 20089383 676,881 Duplication Control 
chr15 19412503 20089383 676,881 Duplication Control 
chr15 19412503 21038987 1,626,485 Duplication Control 
chr15 19414814 20089383 674,570 Duplication Control 
chr15 19523446 20089383 565,938 Deletion Case 
chr15 19523446 20089383 565,938 Deletion Case 
chr15 19548935 20232614 683,680 Duplication Case 
chr15 20224763 20852214 627,452 Deletion Control 
chr15 30557401 32459378 1,901,978 Duplication Case 
chr16 15389435 18221734 2,832,300 Duplication Case 
chr16 29474810 30134444 659,635 Deletion Case 
chr16 31882199 33588602 1,706,404 Duplication Case 
chr16 31901431 32823606 922,176 Deletion Case 
chr16 32021183 33149454 1,128,272 Deletion Case 
chr16 32136481 33517284 1,380,804 Duplication Case 
chr16 32136481 33683586 1,547,106 Duplication Case 
chr16 32151974 33588602 1,436,629 Duplication Case 
chr16 32302430 33009105 706,676 Deletion Case 
chr16 32365901 33562041 1,196,141 Duplication Case 
chr16 32461678 33683586 1,221,909 Duplication Case 
chr16 32746359 33618281 871,923 Deletion Control 
chr17 28984749 29936217 951,469 Duplication Control 
chr17 41536766 42107479 570,714 Duplication Case 
chr18 14887155 15392408 505,254 Duplication Control 
 
4.9.3 Assessment of global burden of large CNVs in obesity cases and controls in the 
Saudi extreme obesity mental retardation cohort 
 
To assess the enrichment of CNVs above 500kp in obesity cases compared with controls, the 
global burden of large CNVs in extreme obesity cases was compared to normal-weight 
controls. A one-sided permutation test (100,000 permutations) was used, with analyses 
stratified by CNV size and type. 
 
Obesity cases were found to be enriched for CNVs above 500kb (p-value 0.014). Stratified 
analyses of deletions and duplications above 500kb revealed that enrichment in cases with 
obesity for CNVs above 500kb was driven by duplications. There is also no evidence for 
enrichment of deletions above 500kb in (p-value = 0.6). CNVs above 1Mb were found to 
marginally enriched in cases compared with controls, with duplications once again driving 
the association observed in the analysis (p-value 0.012).  
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4.10 Discussion 
 
GWAS studies have identified a few obesity genes that collectively only explain a fraction of 
inter-individual differences in obesity and are very unlikely to account for a significant 
proportion of genetic risk [1, 3]. In recent years, it has been found that CNVs play a wider 
role in human health. Recent studies have found several diseases to be associated with CNVs, 
including autism, schizophrenia, bipolar disorder and host response to Human 
immunodeficiency virus [284, 286, 288]. 
 
The Affymetrix 6.0 platform was used in this study, with 1 million probes located in all 
genomic regions. This allowed the detection of small as well as larger CNVs, which enabled 
a systematic investigation into the size distributions of a large number of both previously 
identified and novel CNVs in more detail than in many previous studies. The median size of 
CNVs discovered was 20kb for heterozygous deletions and 6.35kb for homozygous deletions, 
which are larger than those found in studies of other populations. Homozygous deletions 
were more frequent in the controls (14.4%) than in the cases (13%). On the other hand, 
heterozygous deletions were more frequent in cases than in controls (22.7% and 13.4% 
respectively). In addition, large variations of over 100kb found in this study account for only 
24% of the CNVs identified in cases and 18% in the controls (Figure 4-3 and 4-4) compared 
with 45% of variations reported in the TCAG Database. The results of this study suggest that 
the frequency of larger CNVs (<100kb) is higher in cases than in controls. An overall higher 
percentage of CNVs <100kb was found in this study compared with other databases, and 
many of the variant regions in this database may be smaller than has been reported by studies 
using lower-resolution techniques [320]. 
 
In the current study, after applying different filtration processes on the samples, 365 rare 
CNVs were identified in this data set. Array-based technologies such as PennCNV have been 
found to detect copy number changes in higher resolution using CNV calling algorithms 
[178]. The use of CNV calling algorithms is an error-prone process as it may generate either 
false-positive or false-negative CNVs. It was necessary to carry out more than one procedure 
in order to ensure that the CNVs detected were in fact de novo [156]. CNV regions detected 
in the samples were considered if they involved a minimum of 10 consecutive probes. Data 
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from both sets of parents is also very important, as it enables the filtering out of any CNVs 
present in the parents and the elimination of common polymorphic loci that would incorrectly 
appear to be de novo. Unfortunately, it was very difficult to collect data on parents, especially 
those with mentally retarded children, owing to socio-cultural difficulties. 
 
Each candidate variant that may disrupt obesity candidate genes was further examined 
through a more careful assessment. Interestingly, none of the CNVs detected had been 
previously seen to be associated with obesity, with the exception of the chromosome 16p11.2 
heterozygous deletion. This may explain that obesity high-risk loci found in certain 
populations are not necessarily found in the Saudi population owing to the difference in their 
genetic structure. It was also noticed that some candidate variants occurred in more than one 
sample, which may point to a shared mechanistic basis for developing this disease [185, 290]. 
Most carriers of recurrent candidate variants carry similar phenotypes. One sample has been 
found to share more than one candidate variant with other samples. This sample may either 
have been falsely called owing to poor CNV calling using PennCNV or it may actually carry 
multiple CNV deletions which must be validated using other CNV calling algorithms such as 
cnvHap. 
 
By looking at genes overlapping the CNVs prioritised as described above, it was established 
that none of these CNVs encompass known obesity genes but may encompass potential 
obesity genes. Most candidate genes detected in this study are expressed in the brain. This is 
important because it is clear from studying rare obesity syndromes that the majority of 
molecular defects discovered so far are neuroendocrine in nature, which has profound effects 
on feeding behaviour resulting in severe early-onset obesity [1]. CNVs may affect genes in a 
variety of ways. Whole genes vary in CNV as a result of either gains or losses leading to 
increasing or decreasing effects on gene expression [284]. It is also important to note that 
CNV deletions and duplications lying outside the coding region may also affect gene 
expression [284] and will cause changes in the location or efficiency of important regulatory 
elements [285]. 
 
Given the large number of genes that overlapped with CNVs in this study, a significant 
proportion of obesity-relevant genes are likely to be affected. It has been determined that 
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many of these overlapping genes are involved in various cell functions such as cell growth, 
cell recognition, cell adhesion and intracellular transport e.g. ANKRD28, RBP2, SENP7 and 
CTNNA3. It is important to note that two genes that affect cell functions in the nervous 
system were affected: NRXN1 and DAB1. Some genes have also been associated with autism 
and late-onset Alzheimer‟s, e.g. CTNNA3 and DAB1 [312-315, 317]. This is interesting 
because de novo obesity-related CNV deletions have previously been found to encompass a 
known autism-associated locus [185, 290]. Other genes that play a critical role in regulating 
many cellular functions, including development, differentiation, and proliferation in the 
insulin signalling pathway, such as TRIB3, are also of interest [310]. 
 
In this study with large numbers of interesting genes, one homozygous deleted CNV 
encompassing the TRIB3 gene was investigated, as well as a heterozygous CNV deletion in 
the chromosome 16p11.2 region that has previously been shown to be associated with obesity 
[185]. 
 
As mentioned in section 4.7.1.3, the TRIB3 gene functions as a 45-kDA peusdokinase 
binding to Akt, a key mediator in insulin signalling that is highly expressed in the liver. 
TRIB3 has been suggested to play an inhibitory role in insulin signal transduction as it has 
been shown to bind to the pleckstrin homology domain of the insulin-responsive Ser-Thr 
kinase, v-akt murine thymoma viral oncogene homologue 1 (AKT1). Therefore, it will 
prevent membrane association with Thr308 phosphorylation and activation via upstream 
kinases [321, 322]. In a rodent model of Type 2 diabetes db/db mice, Trib3 expression was 
found to be increased in the liver [321]. It has recently been found that a protein known as an 
adaptor protein, which mediates adiponectin signalling (phospho-tyrosine interaction), 
enhances insulin-stimulated activation of AKT1 and suppresses gluconeogenesis by blocking 
the interaction of AKT1 with TRIB3 through direct competition [323]. In humans, a gain-of-
function association of TRIB3 Glu84Arg missense polymorphism with insulin resistance-
related phenotypes has been shown [324]. An over-expression of the variant Arg84 allele has 
also been found to enhance the inhibition of insulin-mediated AKT1 phosphorylation in 
HepG2 cells [324], and TRIB3 has been associated with impaired insulin signalling in 
endothelium cells [310]. In this study, the 6,909bp deletion that deletes exons 3 and 4 of the 
TRIB3 gene was validated through a PCR assay and sequencing run on the affected sample 
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and on the Saudi controls mentioned in section 4.8.1.3. The subject carrying this deletion 
shows insulin resistance, with a fasting blood glucose level of 8.6 mmol/l and a BMI of 35.8 
kg/m². This deletion has also been replicated in other populations in Singapore, France, and 
Switzerland, and no CNV deletions have been found within this gene. 
 
The identification of rare variants that have a strong association with common disease is very 
difficult, as reflected by the need to screen a large number of affected samples. In recent 
years, the role of large CNVs in susceptibility to obesity has been increasingly recognised, as 
well as the contribution of individually rare CNVs to obesity pathogenesis that may help to 
explain the missing heritability of obesity [325]. Chromosome 16p11.2 heterozygous 
deletion, which is a highly penetrant form of obesity, was initially observed in 31 subjects 
with cognitive defects [185]. Another 19 subjects out of 16,053 individuals of European 
descent were found to carry this deletion, accounting for 0.7% of morbid obesity cases [185]. 
In this study, two samples in the Saudi extreme obesity and MR cohort carried this deletion, 
confirmed by MLPA, suggesting that the deletion is present in 2.35% of subjects in this 
cohort. This may allow the hypothesis that observed differences in frequency may lie in 
differences in the nature of the cohorts investigated. 
 
When replicating this deletion using MLPA on 150 samples from three different populations 
(Saudi, Yemeni and Sudanese) that have obesity with no MR, no deletion was present. Only a 
duplication within a certain region of the known chromosome 16p11.2 region was present. 
This result is of particular interest because, in a study published by Jacquemont et al. in 2011, 
reduced head circumference and BMI were found to be associated with duplication in the 
chromosome 16p11.2 region [186]. The duplication found in this study was between the MAZ 
gene probe and the HIRIP3 gene probe (Figure 4-19), suggesting that the obesity-causing 
gene lies outside this duplicated region. 
 
Two genes within the chromosome 16p11.2 region were investigated for autism and 
microcephaly. A study using zebrafish for an unbiased screening of individual genes within 
the chromosome 16p11.2 region found that over-expression of the potassium channel 
tetramerisation domain containing gene (KCTD13) in zebrafish leads to a 20 per cent 
decrease in head size [326]. In another study conducted on zebrafish it was found that the 
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majority of genes in the 16p11.2 region affect brain development [327]. In most genes, 
expression must be lowered by at least 75 per cent for any effect to be seen [327]. However, 
in the case of the ALDOA and KIF22 genes, cutting the expression in half, which mirrors the 
loss of a single copy in humans, has been shown to lead to abnormal brain and body shapes 
[327]. In this study, the duplication region included the KCTD13 gene but did not include the 
aldolase A, aructose-bisphosphate (ALDOA) and kinesin family member 22 (KIF22) genes 
(Figure 4-22). The three samples carrying this duplication were all found to have obese 
phenotypes with marginally smaller head circumference compared with the other 147 
samples. This result may show that more than one gene within this region affects head 
circumference and that the obesity gene probably lies outside this duplication region and 
requires further investigation. 
 
 
Figure 4-22: Genes within the duplicated region (shown between the red dashed lines). 
The duplicated region is between the MAZ and HIRIP3 genes. 
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Finally, the results of the investigation of large CNVs above 500kb in the same Saudi 
extreme obesity and MR cohort were reported. No homozygous deletions above 500kb were 
found. It was also noticed that CNV duplications above 500kb were present more frequently 
than heterozygous deleted CNVs. Analysis of the global burden of large CNVs in the Saudi 
extreme obesity and MR control cohort showed that CNVs above 500kb were enriched in 
cases compared with the controls. This finding was driven by a higher number of large 
duplications in cases than in controls, with no significant number of large CNV deletions in 
obesity cases. This result is of particular interest as two previous studies that examined the 
global CNV burden of large CNVs in obese subjects found that there was a significant 
enrichment of large deletions among cases compared with controls, with no reported 
enrichment for duplications [189, 290]. Additional replication studies should be carried out to 
confirm these findings as this study uses a smaller data set than the other studies. 
 
4.11 Summary 
 
CNVs may play a wider than previously expected role in human health as susceptible loci for 
common diseases, such as cancer, neuropsychiatric diseases, obesity, and diabetes. This study 
has identified rare CNVs that may represent major risk factors for obesity. None of these 
CNVs encompasses known obesity genes but may encompass potential obesity genes that 
will be investigated further. Additional genes were found to be deleted in different CNVs and 
should also be investigated further (Tables 4-4, 4-5 and 4-6). In order to gain a more 
comprehensive understanding of the extent of variation between the genomes of obesity cases 
compared with controls, copy number variation should be investigated using larger sample 
sets. Enrichment analysis should also be conducted to see whether there would be a 
significant enrichment of genes associated with obesity within the duplicated regions found 
in these samples. Further investigation should also be carried out to elucidate the role of large 
CNVs, in particular duplications, in obesity susceptibility. 
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4.12 Limitations 
 
This study has a number of limitations: 
 
 Lack of parental DNA, which is important in order to detect whether CNVs are inherited 
from one or both the parents or are de novo. 
 The size of the cohort is small. PennCNV will generate better CNV calls (e.g. fewer 
false-positive calls) with larger sample sizes. 
 Some of the DNA replication samples were of low quality. Better replication DNA 
samples should be collected 
 
4.13 Future work 
 
4.13.1 Samples 
 
More samples of both adults and children meeting the inclusion criteria mentioned above will 
be collected. More normal Saudi controls will also be analysed. This will help to identify 
common CNVs found in the Saudi population and will also help in the detection of rare 
variants occurring in the population. 
 
4.13.2 Use of other CNV detection algorithms 
 
Other CNV detection algorithms will be used to establish whether rare CNVs detected by 
PennCNV are genuine. This will be done by developing the use of cvnHap, an algorithm 
developed by the Department of Genomics of Common Disease at Imperial College, London, 
on Affymetrix data. CnvHap is an integrated approach to CNV detection and genotyping, 
using signal intensity data from genotyping arrays to model the copy number at each 
genotype probe position, and a hidden Markov model simultaneously to build a spatial model 
of copy-number variation across the genome and population models of the signal intensities 
at each probe position [179]. The model is constructed at the level of single chromosomes. It 
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thereby reflects joint haplotypic structure between GSVs and SNPs, resulting in a flagging of 
the majority of genuine GSV calls by the presence of an LD structure that extends beyond the 
limits of the presumed GSV. 
 
4.13.3 Replication in other Cohorts 
 
To assess whether each GSV is associated only with obesity in Saudi obesity patients, the 
GSVs identified will be compared with other GSV data from adult and child obesity, such as 
TCAG, DECIPHER and Genome Sequencing Data (e.g. 1,000 genomes). GWAS data from 
different cohorts of the general population and from specific population groups could also be 
used, e.g. DESIR, NFBC1966, NFBC1986. Arabs, Chinese, Malay, African, etc. will also be 
assessed for evidence of the GSVs. This will help to determine whether there is an overlap in 
the GSVs between these datasets and will also result in significant increases in statistical 
power. 
4.13.4 Validation of 16p11.2 obesity-associated GSVs 
 
Having identified rare small duplications within known 16p11.2 obesity-associated 
heterozygous deletion, further experimental validation should be carried out with qPCR or 
Sequenom-based homozygosity mapping [237, 291]. 
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5 Conclusion 
 
Obesity is a complex disease that involves interplay between many genetic variants and 
environmental exposure. There is clear evidence of a strong genetic influence on both 
childhood and adult adiposity, regardless of the obesogenic environment [35]. It is also clear 
that there are certain genetic variants that make individuals more susceptible to weight gain, 
especially when they are exposed to an unhealthy lifestyle [71, 328]. Although there is 
evidence that genetics affects the development of adiposity, pinning down the underlying 
genes that modulate the risk of developing obesity has proved difficult, with much success 
coming specifically from early onset extreme obesity disorders.  
 
Most of the extreme obesity phenotypes are caused by mutations of single genes that encode 
effectors and/or receptors in the leptin-melanocortin-pathway [58, 272]. These mutations are 
very rare and only account for 2% of extremely obese cases. It is still unclear how rare forms 
of obesity contribute to more common forms of obesity.  Different studies have found that 
there are a number of SNPs frequently found in the same genes, which cause monogenic 
forms of obesity that specifically modulate BMI in all ages in the general population [71, 
328].  
 
Another approach based on extreme obesity has also proved successful. It involves the 
investigation of the physiology of obesity through the investigation of syndromic forms of 
obesity. As discussed in Chapter One: Introduction, there are more than 20 syndromic 
forms of obesity alongside other abnormalities, especially MR [83]. It is important to note 
that individuals carrying these syndromes might have other risk factors that could contribute 
to the development of obesity, such as differences in life-style, e.g. impaired mobility. In 
some cases, there are genetic factors that play a role in the development of obesity. For 
example, looking at WAGR syndrome, genes that are responsible for MR (e.g. the BDNF 
gene) may also act on the brain or elsewhere, either to increase food intake or to decrease 
energy expenditure, [98]. This was investigated by comparing the extent of the chromosomal 
aberration carried by different patients and it was clearly found that patients carrying 
chromosomal deletions that encompass the BDNF gene had a BMI above the 95
th
 percentile 
[98]. 
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In this thesis, I used this approach to look at extreme obesity cases in small well-phenotyped 
cohorts then replicating the findings in larger cohorts studies that appears to be a promising 
strategy for identifying missing heritability in obesity [185]. This study is the first obesity 
study conducted in Saudi Arabia and in the Middle East that looks at both monogenic and 
syndromic forms of obesity in this population.  
 
The first aspect of the project was the investigation of Saudi consanguineous families with 
extreme obesity to yield new obesity genes and loci, the implications of which will then be 
assessed in more common forms of obesity by analysis of large-scale population cohorts. 
From the analysis of 10 Saudi consanguineous families with extreme obesity, it was clear that 
recessive forms of obesity were present in this population. A first report of its sort for this 
population found, in family 8 (a family with extreme obesity), a novel MC4R gene mutation 
(p.S85G), with carriers of this mutation having a BMI above the 95
th
 percentile. Within the 
same family, another gene mutation was found in the exon 4 of LPIN3 gene (p.G110R). This 
mutation is a heterozygous mutation that was found in two out of three heterozygous carriers 
of MC4R mutation. The two carrying both heterozygous MC4R and LPIN3 mutation are of 
normal weight. On the other hand, the third carrier of only the MC4R heterozygous mutation 
was found to be morbidly obese. LPIN3 gene belongs to the LPIN family of genes, e.g. 
LPIN1 and LPIN2, which are mainly required for normal adipose tissue development and 
have provided a candidate gene for human lipodystrophy [266]. This result could explain the 
co-dominant mode of inheritance, with heterozygous MC4R mutation fluctuating in BMI and 
having either severe or normal phenotypes [262].  I am currently in the process of doing some 
functional work on this gene in collaboration with a group in UCLA, California, to 
investigate the effect of this mutation on the functionality of the gene. This will be 
approached by the expression of the mutant protein in adipose tissue and evaluation of its 
function experimentally.  
 
Another gene of interest was found in family 6. A nucleotide C deletion at p.126 in CHRNA7 
gene was found in two obese children within this family. This gene could be a candidate 
obesity-causing gene, as it is highly expressed in the brain, especially in the lateral 
hypothalamus that has a key role in regulating food appetite, food consumption and body 
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mass [283]. In addition, nicotine acting on alpha7 nAChRs is important for modulating 
inflammation and regulating body weight [279]. Further investigation of how CHRNA7 gene 
might play a role in the development of obesity is essential and will be undertaken in the 
future.  
 
Linkage analysis of these families also generated important results. Two linkage regions from 
genome-wide linkage scans of BMI and obesity were found to replicate in my data set. These 
regions are found in 11q14 and 20q13 [115, 120, 122, 259]. Unfortunately, no variants from 
WES were found within this region.  
 
In the first aspect of this thesis, I had problems with either obtaining the right linkage peaks, 
when I knew that I had a gene mutation with a recessive form of inheritance in that region, or 
(vice versa) having a good linkage peak in a certain locus and not finding the corresponding 
variant from WES data.  There are several ways to tackle this problem. First, in the case of 
linkage analysis, it is essential to properly curate phenotypes, particularly in monogenic 
forms of obesity. In this study, it seems that some families had poorly defined familial 
phenotypes that are rare or unique; this was seen specifically in the analysis of family 8 that 
had the MC4R mutation. A misdiagnosis of one of the affected individuals caused the loss of 
a linkage peak within the MC4R chromosomal region. Second, in the case of WES data, one 
of two approaches should be used: either improved statistical and bioinformatics methods for 
reducing the rate of false-positive and false-negative variant calls, and predicting and 
annotating the potential functional impact for disease genes, or improved wet-lab capture 
protocols. I feel that in this thesis the quality of the WES data is low due to poor coverage 
that is most likely caused by the low capture of genes. This may be due largely to uneven 
target enrichment. 
 
The second aspect of the project is to identify causative loci for novel syndromic forms of 
obesity by investigation of Saudi adults/children with severe obesity, developmental delay and 
dysmorphic features. The sample size of this study was very small due to the rarity of these 
cases. All known syndromic forms of obesity were excluded to help identify new loci. Even 
though the numbers of samples are low, interesting results were found from this study. Three 
hundred and sixty-five rare CNVs were identified with the different filtering processes used 
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and explained in Chapter Two. Each one of these CNVs was examined for its association 
with obesity. Only one CNV deletion in chromosome 16p11.2, previously associated with 
obesity, was found in 2 out of 85 cases. That suggests that this deletion is present in 2.35% of 
subjects in this cohort compared to 0.7% in other larger cohorts [185]. Replicating this 
deletion in other obesity-only cohorts from Saudi, Yemen and Sudan has led to an interesting 
result. Within the Saudi replication samples, three individuals carried a small duplication 
within the known region of chromosome 16p11.2 deletion. This result suggests that the region 
that is associated with the development of obesity in chromosome 16p11.2 is most probably 
outside this duplication region. Due to the low DNA stores, the only validation method that 
was used to detect the duplication was MLPA. I am working on tracking down the samples 
that were collected in 2005 to carry out further examination of the candidate obesity region 
within chromosome 16p11.2 deletion region. To follow up this result, I will run genome-wide 
array chips on these samples in order to detect this duplication, using CNV calling algorithms, 
e.g. PennCNV. I will also run WES on these samples to look for any genomic variants within 
the candidate obesity region. 
 
TRIB3 homozygous CNV deletion was also found in 1 out of 85 cases. TRIB3 gene is a key 
mediator in insulin signalling and is highly expressed in the liver [310]. In humans, a gain-of-
function association of TRIB3 Glu84Arg missense polymorphism with insulin resistance-
related phenotypes has been shown [324]. Knockout mice for this gene have shown a 70% 
increase of white adipose tissue [311]. The subject carrying this deletion has insulin 
resistance, which is a promising result that needs further investigation. This deletion was not 
found in the 150 obesity replication sample and will be further investigated; by both running 
functional work and replicating this deletion in other cohorts that we have in the department. 
 
Given the large number of genes that overlapped with CNVs in this study, a significant 
proportion of obesity-relevant genes are likely to be affected. From examination of all the rare 
CNVs detected, it appears that many of the genes that encompass these CNVs are involved 
with cell functions, e.g. NRXN1 and DAB1. Further investigation of these CNVs will be 
undertaken, especially large CNVs that have been shown to be slightly enriched within cases 
versus controls. 
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In order to gain a more comprehensive understanding of the extent of variation between the 
genomes of obesity cases in this study compared with controls, copy number variation should 
be investigated using larger sample sets. Enrichment analysis should also be conducted to see 
whether there would be a significant enrichment of genes associated with obesity within the 
duplicated regions found in these samples. Further investigation should also be carried out to 
elucidate the role of large CNVs, in particular duplications, in obesity susceptibility. 
Collecting parental DNA from samples carrying candidate deletions is also essential to help 
identify if these deletions are de novo.  
 
Much research has been done to elucidate the complex aetiology of obesity. Although many 
genetic loci have been identified, this still does not explain the disease onset. When 
considering future research in the field of genetics of obesity, it will be interesting to witness 
how epigenetic modifications increase the susceptibility of development obesity by providing 
greater insight into the molecular basis of obesity. This is done by investigating the 
modifications to gene expression patterns that result from different mechanisms such as 
methylation patterns and histone modifications [329]. There is increasing evidence that the 
exposure to different factors, e.g. maternal nutrition in the gestational period, may contribute 
to the modification of fetal epigenetic programming [330, 331]. This phenomenon may 
contribute to the increased risk of obesity in later life and may represent a missing link 
between environmental exposure factors and long-term risk of obesity.   
 
From this study, it appears that genetics has a considerable role in the susceptibility to obesity 
in this population. The study of monogenic obesity has revealed that in the Saudi population 
there is evidence that the genes in the leptin-melanocortin pathway may have an integral role 
in the development of obesity. Novel possible obesity-causing genes are also found and need 
further investigation. Furthermore, with several rare CNVs detected in this study, detailed 
investigation into the effect of these CNVs should be carried out. It is also essential to 
perform functional studies to determine the role of the genes identified in obesity.  
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Table A1: Copy number variants shared between two samples and including genes. All genetic coordinates given in hg18. 
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CNVHTCA4 1 15167612 15180443 15 12,832 Heterozygous 
Deletion 
cases KAZN 
CNVHTCA24 1 246798656 246863836 37 65,181 Heterozygous 
Deletion 
cases OR2T10, OR2T11, OR2T34 
CNVHTCA44 2 193089962 193350783 124 260,822 Heterozygous 
Deletion 
cases PCGEM1 
CNVHTCA74 4 69211554 69512426 11 300,873 Heterozygous 
Deletion 
cases TMPRSS11E, UGT2B15 
CNVHTCA97 5 69110733 70290662 16 1,179,930 Heterozygous 
Deletion 
cases GTF2H2B, GTF2H2C, GTF2H2D, GUSBP9, LOC100170939, 
SERF1A, SERF1B, SMA5, SMN1, SMN2 
CNVHTCA188 10 47011195 47122809 108 111,615 Heterozygous 
Deletion 
cases ANTXRL, ANXA8L2 
CNVHTCA238 15 21192955 26203954 3455 5,011,000 Heterozygous 
Deletion 
cases ATP10A, C15orf2, GABRA5, GABRB3, GABRG3 ,HBII-52-27, 
HBII-52-28, HBII-52-45, HBII-52-46, HERC2, IPW, LOC503519, 
MAGEL2, MIR450, MIR4715, MKRN3, NDN, OCA2, PARSN, 
PAR1, PAR4, PAR5, PWRN1, PWRN2, SNORD107, SNORD108, 
SNORD109A, SNORD109B, SNORD115-1, SNORD115-10, 
SNORD115-11, SNORD115-12, SNORD115-13, SNORD115-14, 
SNORD115-15, SNORD115-16, SNORD115-17, SNORD115-18, 
SNORD115-19, SNORD115-2, SNORD115-20, SNORD115-21, 
SNORD115-22, SNORD115-23, SNORD115-24, SNORD115-25, 
SNORD115-26, SNORD115-29, SNORD115-3, SNORD115-30, 
SNORD115-31, SNORD115-32, SNORD115-33, SNORD115-34, 
SNORD115-35, SNORD115-36, SNORD115-37, SNORD115-38, 
SNORD115-39, SNORD115-4, SNORD115-40, SNORD115-41 
,SNORD115-42,SNORD115-43,SNORD115-44,SNORD115-48 
,SNORD115-5,SNORD115-6,SNORD115-7,SNORD115-8 
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,SNORD115-9,SNORD116-1,SNORD116-10,SNORD116-11 
,SNORD116-12,SNORD116-13,SNORD116-14,SNORD116-15 
,SNORD116-16,SNORD116-17,SNORD116-18,SNORD116-19 
,SNORD116-2,SNORD116-20,SNORD116-21,SNORD116-22 
,SNORD116-23,SNORD116-24,SNORD116-25,SNORD116-26 
,SNORD116-27,SNORD116-28,SNORD116-29,SNORD116-3 
,SNORD116-4,SNORD116-5,SNORD116-6,SNORD116-7 
,SNORD116-8,SNORD116-9,SNORD64,SNRPN,SNURF 
,UBE3A 
CNVHTCA285 19 20367573 20508229 86 140,657 Heterozygous 
Deletion 
cases MIR1270-1,MIR1270-2,ZNF826P 
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Table A2: Copy number variants found in one samples and including genes. All genetic coordinates given in hg18. 
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CNVHTCA2 1 1488015 1662463 174,449 Heterozygous 
Deletion 
cases C1orf233, CDK11A, CDK11B, MIB2, MMP23A, MMP23B, 
SLC35E2, SLC35E2B, SSU72 
CNVHTCA3 1 12768450 12790553 22,104 Heterozygous 
Deletion 
cases PRAMEF1 
CNVHTCA8 1 94212693 94251183 38,491 Heterozygous 
Deletion 
cases ABCA4 
CNVHTCA9 1 95089932 95102112 12,181 Heterozygous 
Deletion 
cases SLC44A3 
CNVHTCA10 1 102385750 102420682 34,933 Heterozygous 
Deletion 
cases MIR548AI 
CNVHTCA14 1 153455784 153467688 11,905 Heterozygous 
Deletion 
cases GBAP1 
CNVHTCA15 1 170249712 170291151 41,440 Heterozygous 
Deletion 
cases DNM3 
CNVHTCA16 1 173960984 173978862 17,879 Heterozygous 
Deletion 
cases TNR 
CNVHTCA21 1 211081076 211136186 55,111 Heterozygous 
Deletion 
cases C1orf227, FLVCR1, FLVCR1-AS1 
CNVHTCA23 1 246764014 246841722 77,709 Heterozygous 
Deletion 
cases OR2T10, OR2T29, OR2T34 
CNVHTCA28 2 40057400 40079607 22,208 Heterozygous 
Deletion 
cases LOC100128590 
CNVHTCA35 2 106512087 106541715 29,629 Heterozygous 
Deletion 
cases LIMS3-LOC440895, LINC00116, LOC100288570, LOC151009, 
LOC440894, MALL, NPHP1 
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CNVHTCA36 2 110212024 110340970 128,947 Heterozygous 
Deletion 
cases LINC00116, MALL, NPHP1 
CNVHTCA37 2 115252384 115259260 6,877 Heterozygous 
Deletion 
cases DPP10 
CNVHTCA40 2 137761562 137782241 20,680 Heterozygous 
Deletion 
cases THSD7B 
CNVHTCA41 2 167653198 167657754 4,557 Heterozygous 
Deletion 
cases XIRP2 
CNVHTCA42 2 170078758 170181039 102,282 Heterozygous 
Deletion 
cases FASTKD1, KBTBD10, PPIG 
CNVHTCA45 2 203004020 203020446 16,427 Heterozygous 
Deletion 
cases BMPR2 
CNVHTCA49 3 4113369 4427039 313,671 Heterozygous 
Deletion 
cases SETMAR, SUMF1 
CNVHTCA50 3 196868323 196987753 119,431 Heterozygous 
Deletion 
cases but extension 
of above 
MIR570, MUC20, MUC4, SDHAP2 
CNVHTCA106 5 133543411 133802067 258,657 Heterozygous 
Deletion 
cases CDKL3, CDKN2AIPNL, MIR3661, PPP2CA, UBE2B 
CNVHTCA117 6 45144428 45333739 189,312 Heterozygous 
Deletion 
cases MIR586, SUPT3H 
CNVHTCA144 7 143623463 143720412 96,950 Heterozygous 
Deletion 
cases ARHGEF5, OR2A1, OR2A20P, OR2A42, OR2A9P 
CNVHTCA165 9 36587 1481796 1,445,210 Heterozygous 
Deletion 
cases C9orf66, CBWD1, DMRT1, DMRT2, DMRT3, DOCK8, 
FOXD4, KANK1 
CNVHTCA186 1
0 
45613625 46010237 396,613 Heterozygous 
Deletion 
cases AGAP4, PTPN20A, PTPN20B 
CNVHTCA189 1
0 
48871826 49067492 195,667 Heterozygous 
Deletion 
cases FAM25B, FAM25C, FAM25G, FRMPD2, LOC399753 
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CNVHTCA193 1
0 
81497207 81588035 90,829 Heterozygous 
Deletion 
cases LOC642361 
CNVHTCA196 1
0 
135237230 135356694 119,465 Heterozygous 
Deletion 
cases DUX2, DUX4, DUX4L2, DUX4L3, DUX4L5, DUX4L6, 
DUX4L7, FRG2B 
CNVHTCA199 1
1 
9209445 9317826 108,382 Heterozygous 
Deletion 
cases DENND5A, TMEM41B 
CNVHTCA253 1
6 
1152524 1444150 291,627 Heterozygous 
Deletion 
cases BAIAP3, C16orf42, C16orf91, CACNA1H, CCDC154, CLCN7, 
GNPTG, TPSAB1, TPSB2, TPSD1, TPSG1, UBE2I, UNKL 
CNVHTCA255 1
6 
15148795 15324011 175,217 Heterozygous 
Deletion 
cases MIR3180-4 
CNVHTCA256 1
6 
29474810 30134444 659,635 Heterozygous 
Deletion 
cases ALDOA, ASPHD1, BOLA2, BOLA2B, C16orf53, C16orf54, 
C16orf92, CDIPT, CORO1A, DOC2A, FAM57B, GDPD3, 
HIRIP3, INO80E, KCTD13, LOC100271831, LOC388242, 
LOC440354, LOC440356, LOC606724, LOC613038, MAPK3, 
MAZ, MVP, PPP4C, PRRT2, QPRT, SEZ6L2, SLC7A5P1, 
SLX1A, SLX1A, SULT1A3, SLX1B, SLX1BSULT1A4, SPN, 
SULT1A3, SULT1A4, TAOK2, TBX6, TMEM219, YPEL3, ZG16 
CNVHTCA257 1
6 
31901431 32823606 922,176 Heterozygous 
Deletion 
cases HERC2P4, LOC390705, LOC653550, SLC6A10P, TP53TG3, 
TP53TG3B 
CNVHTCA258 1
6 
32021183 33149454 1,128,272 Heterozygous 
Deletion 
cases HERC2P4, LOC390705, LOC653550, SLC6A10P, TP53TG3, 
TP53TG3B 
CNVHTCA259 1
6 
32302430 33009105 706,676 Heterozygous 
Deletion 
cases LOC653550, SLC6A10P, TP53TG3, TP53TG3B 
CNVHTCA271 1
8 
35266187 35524132 257,946 Heterozygous 
Deletion 
cases LOC647946 
CNVHTCA284 1
9 
15507051 15626362 119,312 Heterozygous 
Deletion 
cases CYP4F22, CYP4F3, CYP4F8 
CNVHTCA287 1 22045513 22145212 99,700 Heterozygous cases ZNF257 
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9 Deletion 
CNVHTCA295 2
0 
14771144 14889584 118,441 Heterozygous 
Deletion 
cases MACROD2, MACROD2-AS1 
CNVHTCA306 2
2 
17256428 17384899 128,472 Heterozygous 
Deletion 
cases DGCR5, DGCR6, PRODH 
CNVHMCA15 6 124277388 124278017 630 Homozygous 
Deletion 
case NKAIN2 
CNVHMCA16 7 154058605 154059351 747 Homozygous 
Deletion 
case DPP6 
CNVHMCA31 1
9 
56024079 56025050 972 Homozygous 
Deletion 
case KLK15 
CNVHMCA14 6 70747250 70753018 5,769 Homozygous 
Deletion 
case COL19A1 
CNVHMCA18 8 85425438 85431221 5,784 Homozygous 
Deletion 
case RALYL 
CNVHMCA3 1 102127547 102134503 6,957 Homozygous 
Deletion 
case DNAJA1P5, MIR548AI, OLFM3 
CNVHMCA13 6 66456203 66463931 7,729 Homozygous 
Deletion 
case EYS 
CNVHMCA22 1
0 
89059776 89107280 47,505 Homozygous 
Deletion 
case LOC439994, LOC728190 
CNVHMCA26 1
3 
51969153 52043659 74,507 Homozygous 
Deletion 
case TPTE2P3 
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Table A3: Copy number variants shared between two samples and not including genes. All genetic coordinates given in hg18. 
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CNVHTCA1 22 37693565 37705253 11,689 Heterozygous Deletion cases no genes 
CNVHTCA6 1 34875241 34877078 1,838 Heterozygous Deletion cases no genes 
CNVHTCA13 1 151028881 151034587 5,707 Heterozygous Deletion cases no genes 
CNVHTCA20 1 193198583 193210277 11,695 Heterozygous Deletion cases no genes 
CNVHTCA29 2 41091947 41099391 7,445 Heterozygous Deletion cases no genes 
CNVHTCA43 2 184802770 184845163 42,394 Heterozygous Deletion cases no genes 
CNVHTCA50 3 7878856 7889996 11,141 Heterozygous Deletion cases no genes 
CNVHTCA57 3 68814718 68830103 15,386 Heterozygous Deletion cases no genes 
CNVHTCA73 4 34455255 34497735 42,481 Heterozygous Deletion cases no genes 
CNVHTCA76 4 104426263 104464197 37,935 Heterozygous Deletion cases no genes 
CNVHTCA84 5 5731997 5733901 1,905 Heterozygous Deletion cases no genes 
CNVHTCA85 5 8542452 8548442 5,991 Heterozygous Deletion cases no genes 
CNVHTCA88 5 12722547 12792608 70,062 Heterozygous Deletion cases no genes 
CNVHTCA89 5 13415776 13435543 19,768 Heterozygous Deletion cases no genes 
CNVHTCA91 5 17687887 17720599 32,713 Heterozygous Deletion cases no genes 
CNVHTCA96 5 57992583 57994594 2,012 Heterozygous Deletion cases no genes 
CNVHTCA109 6 20358686 20363094 4,409 Heterozygous Deletion cases no genes 
CNVHTCA113 6 32959485 32979514 20,030 Heterozygous Deletion cases no genes 
CNVHTCA119 6 55457609 55519247 61,639 Heterozygous Deletion cases no genes 
CNVHTCA122 6 93630519 93635351 4,833 Heterozygous Deletion cases no genes 
CNVHTCA140 7 109220983 109228159 7,177 Heterozygous Deletion cases no genes 
Appendix A: Supplementary Tables 
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CNVHTCA147 8 2242045 2246765 4,721 Heterozygous Deletion cases no genes 
CNVHTCA148 8 3771595 3777514 5,920 Heterozygous Deletion cases no genes 
CNVHTCA150 8 13720460 13735593 15,134 Heterozygous Deletion cases no genes 
CNVHTCA152 8 16306606 16319032 12,427 Heterozygous Deletion cases no genes 
CNVHTCA159 8 107927695 107929502 1,808 Heterozygous Deletion cases no genes 
CNVHTCA161 8 115703663 115719963 16,301 Heterozygous Deletion cases no genes 
CNVHTCA162 8 120419684 120434830 15,147 Heterozygous Deletion cases no genes 
CNVHTCA163 8 120986952 121010979 24,028 Heterozygous Deletion cases no genes 
CNVHTCA167 9 581967 598808 16,842 Heterozygous Deletion cases no genes 
CNVHTCA172 9 11068875 11088891 20,017 Heterozygous Deletion cases no genes 
CNVHTCA185 10 15966304 15971078 4,775 Heterozygous Deletion cases no genes 
CNVHTCA187 10 46401209 46479827 78,619 Heterozygous Deletion cases no genes 
CNVHTCA197 11 4206589 4293105 86,517 Heterozygous Deletion cases no genes 
CNVHTCA204 11 79650581 79663289 12,709 Heterozygous Deletion cases no genes 
CNVHTCA205 11 81130698 81212834 82,137 Heterozygous Deletion cases no genes 
CNVHTCA207 11 126705569 126709193 3,625 Heterozygous Deletion cases no genes 
CNVHTCA208 12 734094 755455 21,362 Heterozygous Deletion cases no genes 
CNVHTCA209 12 739370 744290 4,921 Heterozygous Deletion cases no genes 
CNVHTCA211 12 30126546 30134989 8,444 Heterozygous Deletion cases no genes 
CNVHTCA212 12 33192673 33198641 5,969 Heterozygous Deletion cases no genes 
CNVHTCA214 12 57508241 57513990 5,750 Heterozygous Deletion cases no genes 
CNVHTCA217 12 98319424 98322865 3,442 Heterozygous Deletion cases no genes 
Appendix A: Supplementary Tables 
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CNVHTCA219 12 118473270 118475144 1,875 Heterozygous Deletion cases no genes 
CNVHTCA221 12 128433673 128443503 9,831 Heterozygous Deletion cases no genes 
CNVHTCA222 13 23990781 24031358 40,578 Heterozygous Deletion cases no genes 
CNVHTCA223 13 36968044 36982757 14,714 Heterozygous Deletion cases no genes 
CNVHTCA232 14 39784957 39970545 185,589 Heterozygous Deletion cases no genes 
CNVHTCA244 15 54574968 54600698 25,731 Heterozygous Deletion cases no genes 
CNVHTCA248 15 85631534 85671737 40,204 Heterozygous Deletion cases no genes 
CNVHTCA261 16 64633936 64650059 16,124 Heterozygous Deletion cases no genes 
CNVHTCA267 17 19438482 19479350 40,869 Heterozygous Deletion cases no genes 
CNVHTCA272 18 36514418 36519387 4,970 Heterozygous Deletion cases no genes 
CNVHTCA274 18 38305676 38312393 6,718 Heterozygous Deletion cases no genes 
CNVHTCA276 18 56268102 56272211 4,110 Heterozygous Deletion cases no genes 
CNVHTCA277 18 63110187 63117452 7,266 Heterozygous Deletion cases no genes 
CNVHTCA288 19 23119056 23149732 30,677 Heterozygous Deletion cases no genes 
CNVHTCA289 19 24170942 24256797 85,856 Heterozygous Deletion cases no genes 
CNVHTCA294 20 6368595 6375219 6,625 Heterozygous Deletion cases no genes 
CNVHTCA296 20 15259370 15265978 6,609 Heterozygous Deletion cases no genes 
CNVHTCA301 21 22573005 22586529 13,525 Heterozygous Deletion cases no genes 
CNVHMCA5 2 14622400 14627543 5,144 Homozygous Deletion cases no genes 
CNVHMCA10 4 122501918 122504585 2,668 Homozygous Deletion cases no genes 
CNVHMCA12 5 150185693 150198797 13,105 Homozygous Deletion cases no genes 
CNVHMCA28 14 40680246 40727099 46,854 Homozygous Deletion cases no genes 
Appendix A: Supplementary Tables 
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CNVHMCA30 18 61878472 61879320 849 Homozygous Deletion cases no genes 
 
Table A4: Copy number variants found in one samples and not including genes. All genetic coordinates given in hg18. 
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CNVHTCA5 1 20766552 20768461 1,910 1 cases no genes 
CNVHTCA11 1 108729983 108787720 57,738 1 cases no genes 
CNVHTCA12 1 119793685 119819508 25,824 1 cases no genes 
CNVHTCA17 1 186208846 186417684 208,839 1 cases no genes 
CNVHTCA18 1 187623137 187725642 102,506 1 cases no genes 
CNVHTCA19 1 190685431 190691410 5,980 1 cases no genes 
CNVHTCA22 1 215625537 215630208 4,672 1 cases no genes 
CNVHTCA25 2 33896393 34039265 142,873 1 cases no genes 
CNVHTCA26 2 35494598 35602427 107,830 1 cases no genes 
CNVHTCA27 2 36092524 36118503 25,980 1 cases no genes 
CNVHTCA30 2 46505128 46552968 47,841 1 cases no genes 
CNVHTCA33 2 51151390 51239120 87,731 1 cases no genes 
Appendix A: Supplementary Tables 
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CNVHTCA34 2 52908857 52911698 2,842 1 cases no genes 
CNVHTCA38 2 118109694 118121322 11,629 1 cases no genes 
CNVHTCA39 2 123985854 124014721 28,868 1 cases no genes 
CNVHTCA46 2 226665007 226678094 13,088 1 cases no genes 
CNVHTCA47 2 229467723 229468463 741 1 cases no genes 
CNVHTCA48 3 1747109 1753669 6,561 1 cases no genes 
CNVHTCA51 3 21656097 21660093 3,997 1 cases no genes 
CNVHTCA52 3 34839494 34852317 12,824 1 cases no genes 
CNVHTCA53 3 39332078 39382940 50,863 1 cases no genes 
CNVHTCA54 3 39714115 39748551 34,437 1 cases no genes 
CNVHTCA55 3 60281931 60313046 31,116 1 cases no genes 
CNVHTCA56 3 68527391 68546854 19,464 1 cases no genes 
CNVHTCA58 3 85603605 85751857 148,253 1 cases no genes 
CNVHTCA59 3 100234073 100288093 54,021 1 cases no genes 
CNVHTCA60 3 125554790 125576487 21,698 1 cases no genes 
CNVHTCA61 3 146709335 146739025 29,691 1 cases no genes 
CNVHTCA62 3 153829784 153836590 6,807 1 cases no genes 
CNVHTCA63 3 154660135 154671572 11,438 1 cases no genes 
CNVHTCA64 3 155290329 155329171 38,843 1 cases no genes 
CNVHTCA65 3 173364393 173393134 28,742 1 cases no genes 
CNVHTCA66 3 180365866 180370859 4,994 1 cases no genes 
CNVHTCA67 3 192268446 192272420 3,975 1 cases no genes 
CNVHTCA69 4 18815649 19062097 246,449 1 cases no genes 
Appendix A: Supplementary Tables 
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CNVHTCA70 4 20981101 20985949 4,849 1 cases no genes 
CNVHTCA71 4 29060101 29067635 7,535 1 cases no genes 
CNVHTCA72 4 33055531 33065475 9,945 1 cases no genes 
CNVHTCA75 4 96465761 96468118 2,358 1 cases no genes 
CNVHTCA76 4 104426263 104464197 37,935 1 cases no genes 
CNVHTCA77 4 104426263 104467383 41,121 1 
 
no genes 
CNVHTCA77 4 104961839 104980713 18,875 1 cases no genes 
CNVHTCA78 4 108285200 108295007 9,808 1 cases no genes 
CNVHTCA79 4 114085534 114090719 5,186 1 cases no genes 
CNVHTCA80 4 133146375 133168141 21,767 1 cases no genes 
CNVHTCA81 4 138302088 138314571 12,484 1 cases no genes 
CNVHTCA82 4 172611459 172618528 7,070 1 cases no genes 
CNVHTCA83 4 183789294 183801140 11,847 1 cases no genes 
CNVHTCA86 5 8755522 8800142 44,621 1 cases no genes 
CNVHTCA87 5 12212947 12218272 5,326 1 cases no genes 
CNVHTCA90 5 15769127 15776485 7,359 1 cases no genes 
CNVHTCA91 5 17687887 17720599 32,713 1 cases no genes 
CNVHTCA92 5 21025215 21656087 630,873 1 cases no genes 
CNVHTCA93 5 27823711 27831846 8,136 1 cases no genes 
CNVHTCA94 5 36371148 36382779 11,632 1 cases no genes 
CNVHTCA95 5 51380747 51513270 132,524 1 cases no genes 
CNVHTCA98 5 83228587 83240720 12,134 1 cases no genes 
CNVHTCA99 5 106812528 106865451 52,924 1 cases no genes 
Appendix A: Supplementary Tables 
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CNVHTCA100 5 108936579 109024122 87,544 1 cases no genes 
CNVHTCA101 5 109460856 109607426 146,571 1 cases no genes 
CNVHTCA103 5 119035954 119058324 22,371 1 cases no genes 
CNVHTCA104 5 120188471 120296471 108,001 1 cases no genes 
CNVHTCA105 5 121790162 121848002 57,841 1 cases no genes 
CNVHTCA107 5 155409350 155415307 5,958 1 cases no genes 
CNVHTCA108 5 165699952 165712491 12,540 1 cases no genes 
CNVHTCA110 6 26517830 26549786 31,957 1 cases no genes 
CNVHTCA111 6 30491391 30590972 99,582 1 cases no genes 
CNVHTCA112 6 32731255 32766288 35,034 1 cases no genes 
CNVHTCA114 6 40170146 40211285 41,140 1 cases no genes 
CNVHTCA115 6 42952980 42990474 37,495 1 cases no genes 
CNVHTCA116 6 43329699 43343791 14,093 1 cases no genes 
CNVHTCA118 6 53964539 53972482 7,944 1 cases no genes 
CNVHTCA120 6 69616314 69617993 1,680 1 cases no genes 
CNVHTCA121 6 87442867 87467837 24,971 1 cases no genes 
CNVHTCA123 6 115843475 115872450 28,976 1 cases no genes 
CNVHTCA124 6 136316537 136373208 56,672 1 cases no genes 
CNVHTCA125 6 136344485 136370638 26,154 1 cases no genes 
CNVHTCA126 6 139667342 139693451 26,110 1 cases no genes 
CNVHTCA127 6 154676473 154703008 26,536 1 cases no genes 
CNVHTCA128 6 160488987 160532249 43,263 1 cases no genes 
CNVHTCA129 7 3133925 3225174 91,250 1 cases no genes 
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CNVHTCA130 7 12279766 12296780 17,015 1 cases no genes 
CNVHTCA131 7 13069427 13089933 20,507 1 cases no genes 
CNVHTCA132 7 13957468 13964653 7,186 1 cases no genes 
CNVHTCA133 7 14937047 14976338 39,292 1 cases no genes 
CNVHTCA134 7 17133099 17237360 104,262 1 cases no genes 
CNVHTCA135 7 38260626 38315464 54,839 1 cases no genes 
CNVHTCA136 7 54528635 54532006 3,372 1 cases no genes 
CNVHTCA137 7 61624608 61718176 93,569 1 cases no genes 
CNVHTCA138 7 96519238 96559881 40,644 1 cases no genes 
CNVHTCA139 7 105892810 105919887 27,078 1 cases no genes 
CNVHTCA141 7 116178589 116178830 242 1 cases no genes 
CNVHTCA142 7 117922977 117948608 25,632 1 cases no genes 
CNVHTCA143 7 141969864 142004707 34,844 1 cases no genes 
CNVHTCA145 7 155995613 156003709 8,097 1 cases no genes 
CNVHTCA146 7 158743495 158753806 10,312 1 cases no genes 
CNVHTCA149 8 4704907 4742185 37,279 1 cases no genes 
CNVHTCA151 8 15467641 15478054 10,414 1 cases no genes 
CNVHTCA153 8 25034409 25040250 5,842 1 cases no genes 
CNVHTCA154 8 39894911 39918350 23,440 1 cases no genes 
CNVHTCA155 8 39945623 39950804 5,182 1 cases no genes 
CNVHTCA156 8 73171747 73173784 2,038 1 cases no genes 
CNVHTCA157 8 85398428 85431221 32,794 1 cases no genes 
CNVHTCA158 8 89947240 90138831 191,592 1 cases no genes 
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CNVHTCA160 8 115386857 115445017 58,161 1 cases no genes 
CNVHTCA164 8 135123971 135144856 20,886 1 cases no genes 
CNVHTCA166 9 334508 345299 10,792 1 cases no genes 
CNVHTCA168 9 2782552 2810784 28,233 1 cases no genes 
CNVHTCA169 9 8229423 8235496 6,074 1 cases no genes 
CNVHTCA170 9 9809724 9822730 13,007 1 cases no genes 
CNVHTCA171 9 9927577 9936835 9,259 1 cases no genes 
CNVHTCA173 9 11895556 11977651 82,096 1 cases no genes 
CNVHTCA174 9 11931913 12061398 129,486 1 cases no genes 
CNVHTCA175 9 28670869 28688479 17,611 1 cases no genes 
CNVHTCA176 9 29738024 29752235 14,212 1 cases no genes 
CNVHTCA177 9 45258766 45506515 247,750 1 cases no genes 
CNVHTCA178 9 78849906 78875018 25,113 1 cases no genes 
CNVHTCA179 9 80628359 80658849 30,491 1 cases no genes 
CNVHTCA180 9 102615558 102623589 8,032 1 cases no genes 
CNVHTCA181 10 6877057 6906048 28,992 1 cases no genes 
CNVHTCA182 10 8715411 8785608 70,198 1 cases no genes 
CNVHTCA183 10 9821733 9848720 26,988 1 cases no genes 
CNVHTCA184 10 10058972 10215130 156,159 1 cases no genes 
CNVHTCA190 10 54599860 54611407 11,548 1 cases no genes 
CNVHTCA191 10 57545161 57568918 23,758 1 cases no genes 
CNVHTCA194 10 107974310 108009334 35,025 1 cases no genes 
CNVHTCA195 10 110747661 110774964 27,304 1 cases no genes 
Appendix A: Supplementary Tables 
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CNVHTCA198 11 5768936 5783893 14,958 1 cases no genes 
CNVHTCA200 11 17470139 17475101 4,963 1 cases no genes 
CNVHTCA201 11 25663542 25680654 17,113 1 cases no genes 
CNVHTCA202 11 49664951 49703344 38,394 1 cases no genes 
CNVHTCA203 11 55130608 55198894 68,287 1 cases no genes 
CNVHTCA206 11 91508153 91535229 27,077 1 cases no genes 
CNVHTCA210 12 9521823 9619559 97,737 1 cases no genes 
CNVHTCA213 12 38589772 38603910 14,139 1 cases no genes 
CNVHTCA215 12 86287460 86315675 28,216 1 cases no genes 
CNVHTCA216 12 88972574 89018327 45,754 1 cases no genes 
CNVHTCA218 12 111424319 111424706 388 1 cases no genes 
CNVHTCA220 12 126158640 126170367 11,728 1 cases no genes 
CNVHTCA224 13 77558005 77588848 30,844 1 cases no genes 
CNVHTCA225 13 84526679 84676741 150,063 1 cases no genes 
CNVHTCA226 13 93938965 93948241 9,277 1 cases no genes 
CNVHTCA227 13 103422502 103426642 4,141 1 cases no genes 
CNVHTCA228 14 21696788 21717343 20,556 1 cases no genes 
CNVHTCA229 14 21983834 22030672 46,839 1 cases no genes 
CNVHTCA230 14 23359319 23377938 18,620 1 cases no genes 
CNVHTCA231 14 37869205 37895994 26,790 1 cases no genes 
CNVHTCA233 14 41363532 41396683 33,152 1 cases no genes 
CNVHTCA234 14 44895806 45085468 189,663 1 cases no genes 
CNVHTCA235 14 47301717 47347201 45,485 1 cases no genes 
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CNVHTCA236 14 56250532 56267699 17,168 1 cases no genes 
CNVHTCA237 14 98247896 98262655 14,760 1 cases no genes 
CNVHTCA239 15 22063128 22192755 129,628 1 cases no genes 
CNVHTCA240 15 22122442 22329984 207,543 1 cases no genes 
CNVHTCA241 15 39896905 39966716 69,812 1 cases no genes 
CNVHTCA242 15 44021607 44023757 2,151 1 cases no genes 
CNVHTCA243 15 52917264 52924898 7,635 1 cases no genes 
CNVHTCA245 15 59475461 59485273 9,813 1 cases no genes 
CNVHTCA246 15 62945987 62989056 43,070 1 cases no genes 
CNVHTCA247 15 84137214 84151043 13,830 1 cases no genes 
CNVHTCA249 15 85706849 85714553 7,705 1 cases no genes 
CNVHTCA250 15 88444608 88465058 20,451 1 cases no genes 
CNVHTCA251 15 98422157 98461893 39,737 1 cases no genes 
CNVHTCA252 16 347327 381810 34,484 1 cases no genes 
CNVHTCA254 16 12218249 12258482 40,234 1 cases no genes 
CNVHTCA260 16 32445730 32563024 117,295 1 cases no genes 
CNVHTCA262 16 77618863 77620657 1,795 1 cases no genes 
CNVHTCA263 16 78807555 78823265 15,711 1 cases no genes 
CNVHTCA264 16 81753452 81766799 13,348 1 cases no genes 
CNVHTCA265 17 3054237 3059727 5,491 1 cases no genes 
CNVHTCA266 17 14256378 14267302 10,925 1 cases no genes 
CNVHTCA268 17 32213734 32220784 7,051 1 cases no genes 
CNVHTCA269 17 41465321 41495480 30,160 1 cases no genes 
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CNVHTCA270 17 45666057 45675114 9,058 1 cases no genes 
CNVHTCA273 18 37172282 37193949 21,668 1 cases no genes 
CNVHTCA275 18 43688215 43692750 4,536 1 cases no genes 
CNVHTCA278 18 67590053 67775134 185,082 1 cases no genes 
CNVHTCA279 19 1833762 1873939 40,178 1 cases no genes 
CNVHTCA280 19 6217778 6307520 89,743 1 cases no genes 
CNVHTCA281 19 6908877 6966047 57,171 1 cases no genes 
CNVHTCA282 19 12447385 12480453 33,069 1 cases no genes 
CNVHTCA283 19 14766086 14813347 47,262 1 cases no genes 
CNVHTCA286 19 21179648 21191982 12,335 1 cases no genes 
CNVHTCA290 19 37786292 37805898 19,607 1 cases no genes 
CNVHTCA291 19 51103796 51133831 30,036 1 cases no genes 
CNVHTCA292 19 58010916 58048997 38,082 1 cases no genes 
CNVHTCA293 20 4712629 4742989 30,361 1 cases no genes 
CNVHTCA297 20 16516062 16534634 18,573 1 cases no genes 
CNVHTCA298 20 20740180 20751798 11,619 1 cases no genes 
CNVHTCA299 21 18438410 18447089 8,680 1 cases no genes 
CNVHTCA300 21 20724844 20757493 32,650 1 cases no genes 
CNVHTCA302 21 37243671 37306935 63,265 1 cases no genes 
CNVHTCA303 21 39677877 39709953 32,077 1 cases no genes 
CNVHTCA304 21 40094036 40136215 42,180 1 cases no genes 
CNVHTCA305 21 44431971 44440345 8,375 1 cases no genes 
CNVHTCA307 22 37170970 37204173 33,204 1 cases no genes 
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CNVHTCA308 22 37681412 37705253 23,842 1 cases no genes 
CNVHMCA2 1 61886594 61890775 4,182 0 case no genes 
CNVHMCA4 1 147291426 147496467 205,042 0 case no genes 
CNVHMCA6 2 55177792 55183854 6,063 0 case no genes 
CNVHMCA7 2 89609986 89912071 302,086 0 case no genes 
CNVHMCA8 3 97790348 97801614 11,267 0 case no genes 
CNVHMCA9 3 194363167 194365597 2,431 0 case no genes 
CNVHMCA11 5 117416321 117416862 542 0 cases no genes 
CNVHMCA20 10 81475459 81487784 12,326 0 case no genes 
CNVHMCA21 10 83288423 83300342 11,920 0 case no genes 
CNVHMCA23 12 11402844 11434673 31,830 0 case no genes 
CNVHMCA24 12 30128764 30135217 6,454 0 case no genes 
CNVHMCA27 14 37869205 37870125 921 0 case no genes 
CNVHMCA29 17 6047210 6073536 26,327 0 case no genes 
CNVHMCA33 20 16610745 16615772 5,028 0 case no genes 
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Table A5: Copy number variants above 500kb detected in study objects for Saudi extreme obesity and mental retardation control 
cohort. All genetic coordinates given in hg18. 
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chr1 51598 758656 707,059 Duplication Case 
LINC00115, LOC100132062, LOC100132287, LOC100133331, LOC100288069, 
LOC643837, LOC729737, OR4F16, OR4F29, OR4F3, OR4F5 
chr1 147159969 147703466 543,498 Deletion Control FCGR1C, LOC388692, LOC645166 
chr2 87191480 87833445 641,966 Deletion Control LINC00152, MIR4435-1, MIR4435-2, MIR4771-1, MIR4771-2, PLGLB1, PLGLB2 
chr2 87214683 87777487 562,805 Duplication Control LINC00152, MIR4435-1, MIR4435-2, MIR4771-1, MIR4771-2 
chr2 87214683 87805782 591,100 Deletion Control LINC00152, MIR4435-1, MIR4435-2, MIR4771-1, MIR4771-2 
chr2 87325354 87833445 508,092 Duplication Control LINC00152, MIR4435-1, MIR4435-2, PLGLB1, PLGLB2 
chr2 89278610 91202791 1,924,182 Duplication Case LOC654342 
chr2 89281588 91233073 1,951,486 Duplication Case LOC654342 
chr2 89334354 91255279 1,920,926 Duplication Case LOC654342 
chr2 89395525 91255279 1,859,755 Duplication Case LOC654342 
chr2 110212024 110854188 642,165 Duplication Control 
LIMS3, LIMS3LOC440895, LIMS3L, LINC00116, LOC10028857, LOC151009, 
LOC440894, MALL, NPHP1, RGPD5, RGPD6, RGPD8 
chr2 110227488 110854188 626,701 Duplication Case 
LIMS3, LIMS3-LOC440895, LIMS3L, LINC00116, LOC100288570, LOC151009, 
LOC440894, MALL, NPHP1, RGPD5, RGPD6, RGPD8 
chr3 75195065 75740799 545,735 Duplication Case FAM86DP, MIR4444-1 
chr4 188933689 189628106 694,418 Duplication Case LOC401164, TRIML1, TRIML2, ZFP42 
chr5 21025215 21656087 630,873 Deletion Case GUSBP1 
chr5 69110733 70290662 1,179,930 Deletion Case 
GTF2H2B, GTF2H2C, GTF2H2D, GUSBP9, LOC100170939, SERF1A, SERF1B, 
SMA4, SMA5, SMN1, SMN2 
chr7 57275061 57910659 635,599 Duplication Control MIR3147, ZNF716 
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chr8 21254 11101968 11,080,715 Duplication Case 
AGPAT5, ANGPT2, ARHGEF10, C8orf42, C8orf74, CLDN23, CLN8, CSMD1, 
DEFA1, DEFA10P, DEFA1B, DEFA3, DEFA4, DEFA5, DEFA6, DEFB1, 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB109P1B, DEFB4A, 
DEFB4B, DEFT1P, DEFT1P2, DLGAP2, ERI1, ERICH1, FAM66B, FAM66E, 
FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
FAM90A20, FAM90A5, FAM90A7, FAM90A7P, FAM90A8, FAM90A9, FBXO25, 
FLJ10661, KBTBD11, LOC100132396, LOC100287015, LOC100652791, 
LOC157273, LOC157627, LOC286083, LOC349196, MCPH1, MFHAS1, MIR124-
1, MIR1322, MIR4286, MIR4659A, MIR4659B, MIR4660, MIR548I3, MIR596, 
MIR597, MIR598, MSRA, MYOM2, OR4F21, PINX1, PPP1R3B, PRSS55, RP1L1, 
RPL23AP53, SGK223, SOX7, SPAG11A, SPAG11B, TNKS, XKR5, XKR6, ZNF596, 
ZNF705G 
chr8 7141477 7670832 529,356 Deletion Case 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB109P1B, DEFB4B, 
FAM66B, FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, 
FAM90A19, FAM90A20, FAM90A7, FAM90A7P, FAM90A8, FAM90A9, 
SPAG11B, ZNF705G 
chr8 7141477 7836800 695,324 Duplication Case 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB109P1B, DEFB4A, 
DEFB4B, FAM66B, FAM90A10, FAM90A10P, FAM90A13, FAM90A14, 
FAM90A18, FAM90A19, FAM90A20, FAM90A7, FAM90A7P, FAM90A8, 
FAM90A9, LOC100132396, SPAG11A, SPAG11B, ZNF705G 
chr8 7202021 7836800 634,780 Duplication Case 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4A, DEFB4B, 
FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
FAM90A7, FAM90A7P, FAM90A8, FAM90A9, LOC100132396, SPAG11A, 
SPAG11B, ZNF705G 
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chr8 7202021 7836800 634,780 Duplication Case 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4A, DEFB4B, 
FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
FAM90A7, FAM90A7P, FAM90A8, FAM90A9, LOC100132396, SPAG11A, 
SPAG11B, ZNF705G 
chr8 7202021 7836800 634,780 Duplication Case 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4A, DEFB4B, 
FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
FAM90A7, FAM90A7P, FAM90A8, FAM90A9, LOC100132396, SPAG11A, 
SPAG11B, ZNF705G 
chr8 7202021 7836800 634,780 Duplication Case 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4A, DEFB4B, 
FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
FAM90A7, FAM90A7P, FAM90A8, FAM90A9, LOC100132396, SPAG11A, 
SPAG11B, ZNF705G 
chr8 7202021 7847316 645,296 Duplication Control 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4A, DEFB4B, 
FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
FAM90A7, FAM90A7P, FAM90A8, FAM90A9, LOC100132396, SPAG11A, 
SPAG11B, ZNF705G 
chr8 7202021 7847316 645,296 Duplication Control 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4A, DEFB4B, 
FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
FAM90A7, FAM90A7P, FAM90A8, FAM90A9, LOC100132396, SPAG11A, 
SPAG11B, ZNF705G 
chr8 7202021 7847316 645,296 Duplication Control 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4A, DEFB4B, 
FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
Appendix A: Supplementary Tables 
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FAM90A7, FAM90A7P, FAM90A8, FAM90A9, LOC100132396, SPAG11A, 
SPAG11B, ZNF705G 
chr8 7202021 7869464 667,444 Duplication Case 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4A, DEFB4B, FAM66E, 
FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
FAM90A7, FAM90A7P, FAM90A8, FAM90A9, LOC100132396, SPAG11A, 
SPAG11B, ZNF705G 
chr8 7202021 7869464 667,444 Duplication Case 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4A, DEFB4B, FAM66E, 
FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
FAM90A7, FAM90A7P, FAM90A8, FAM90A9, LOC100132396, SPAG11A, 
SPAG11B, ZNF705G 
chr8 7202021 7869464 667,444 Duplication Case 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4A, DEFB4B, FAM66E, 
FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
FAM90A7, FAM90A7P, FAM90A8, FAM90A9, LOC100132396, SPAG11A, 
SPAG11B, ZNF705G 
chr8 7225313 7825372 600,060 Deletion Case 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4A, DEFB4B, 
FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
FAM90A7, FAM90A7P, FAM90A8, FAM90A9, LOC100132396, SPAG11A, 
SPAG11B 
chr8 7225313 7847316 622,004 Deletion Case 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4A, DEFB4B, 
FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
FAM90A7, FAM90A7P, FAM90A8, FAM90A9, LOC100132396, SPAG11A, 
SPAG11B 
chr8 7237790 7825372 587,583 Deletion Case DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
Appendix A: Supplementary Tables 
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DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4A, DEFB4B, 
FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
FAM90A7, FAM90A7P, FAM90A8, FAM90A9, LOC100132396, SPAG11A, 
SPAG11B 
chr8 7237790 7825372 587,583 Duplication Control 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4A, DEFB4B, 
FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
FAM90A7, FAM90A7P, FAM90A8, FAM90A9, LOC100132396, SPAG11A, 
SPAG11B 
chr8 7237790 7836800 599,011 Deletion Control 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4A, DEFB4B, 
FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
FAM90A7, FAM90A7P, FAM90A8, FAM90A9, LOC100132396, SPAG11A, 
SPAG11B 
chr8 7237790 7836800 599,011 Deletion Control 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4A, DEFB4B, 
FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
FAM90A7, FAM90A7P, FAM90A8, FAM90A9, LOC100132396, SPAG11A, 
SPAG11B 
chr8 7237790 7836800 599,011 Duplication Case 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4A, DEFB4B, 
FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
FAM90A7, FAM90A7P, FAM90A8, FAM90A9, LOC100132396, SPAG11A, 
SPAG11B 
chr8 7237790 7836800 599,011 Duplication Case 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4A, DEFB4B, 
FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
FAM90A7,FAM90A7P, FAM90A8, FAM90A9, LOC100132396, SPAG11A, 
Appendix A: Supplementary Tables 
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SPAG11B 
chr8 7237790 7836800 599,011 Duplication Case 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4A, DEFB4B, 
FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
FAM90A7, FAM90A7P, FAM90A8, FAM90A9, LOC100132396, SPAG11A, 
SPAG11B 
chr8 7237790 7836800 599,011 Duplication Case 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4A, DEFB4B, 
FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
FAM90A7, FAM90A7P, FAM90A8, FAM90A9, LOC100132396, SPAG11A, 
SPAG11B 
chr8 7237790 7847316 609,527 Deletion Control 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4A, DEFB4B, 
FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
FAM90A7, FAM90A7P, FAM90A8, FAM90A9, LOC100132396, SPAG11A, 
SPAG11B 
chr8 7237790 7847316 609,527 Duplication Case 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4A, DEFB4B, 
FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
FAM90A7, FAM90A7P, FAM90A8, FAM90A9, LOC100132396, SPAG11A, 
SPAG11B 
chr8 7237790 7847316 609,527 Duplication Case 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4A, DEFB4B, 
FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
FAM90A7, FAM90A7P, FAM90A8, FAM90A9, LOC100132396, SPAG11A, 
SPAG11B 
chr8 7237790 7869464 631,675 Duplication Case 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4A, DEFB4B, FAM66E, 
Appendix A: Supplementary Tables 
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FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
FAM90A7, FAM90A7P, FAM90A8, FAM90A9, LOC100132396, SPAG11A, 
SPAG11B 
chr8 7254775 7869464 614,690 Duplication Case 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4A, DEFB4B, FAM66E, 
FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
FAM90A7, FAM90A7P, FAM90A8, FAM90A9, LOC100132396, SPAG11A, 
SPAG11B 
chr8 7267308 7836800 569,493 Duplication Case 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4A, FAM90A10, 
FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, FAM90A7, 
FAM90A7P, FAM90A8, FAM90A9, LOC100132396, SPAG11A, SPAG11B 
chr8 7358888 7869464 510,577 Deletion Control 
DEFB103A, DEFB103B, DEFB104A, DEFB104B, DEFB105A, DEFB105B, 
DEFB106A, DEFB106B, DEFB107A, DEFB107B, DEFB4A, FAM66E, 
FAM90A10, FAM90A10P, FAM90A13, FAM90A14, FAM90A18, FAM90A19, 
FAM90A7, FAM90A7P, FAM90A8, FAM90A9, LOC100132396, SPAG11A, 
SPAG11B 
chr9 40085483 45953932 5,868,450 Duplication Control 
ANKRD20A2, ANKRD20A3, AQP7P3, CNTNAP3B, FAM27A, FAM27C, 
FAM74A3, FAM75A3, FAM75A4, FAM75A5, FAM75A6, FAM75A7, FAM95B1, 
FOXD4L2, FOXD4L4, KGFLP1, KGFLP2, LOC286297, LOC642929, 
LOC643648,LOC653501, MGC21881, ZNF658, ZNF658B 
chr9 42986072 44213237 1,227,166 Duplication Case 
ANKRD20A2, ANKRD20A3, CNTNAP3B, FAM75A6, FAM95B1, KGFLP1, 
LOC642929 
chr9 43575109 44729459 1,154,351 Deletion Case CNTNAP3B, KGFLP1, LOC643648 
chr9 44181813 44795733 613,921 Duplication Case KGFLP1, LOC643648 
chr9 44569219 45071919 502,701 Duplication Case FAM27C 
chr9 44569219 45071919 502,701 Duplication Case FAM27C 
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chr9 45805240 46744084 938,845 Deletion Control KGFLP1, LOC643648 
chr9 67772966 69205261 1,432,296 Duplication Case 
ANKRD20A4, CBWD6, FOXD4L6, LOC100132352, LOC100133920, LOC440896, 
LOC642236, PGM5P2 
chr9 68055004 68985820 930,817 Duplication Case 
ANKRD20A4, CBWD6, FOXD4L6, LOC100132352, LOC100133920, LOC440896, 
PGM5P2 
chr9 68055004 69205261 1,150,258 Duplication Case 
ANKRD20A4, CBWD6, FOXD4L6, LOC100132352, LOC100133920, LOC440896, 
PGM5P2 
chr9 68055004 69205261 1,150,258 Duplication Case 
ANKRD20A4, CBWD6, FOXD4L6, LOC100132352, LOC100133920, LOC440896, 
PGM5P2 
chr9 68114141 68822858 708,718 Duplication Case ANKRD20A4, CBWD6, FOXD4L6, LOC100132352, LOC440896, PGM5P2 
chr9 68285054 69215560 930,507 Duplication Case ANKRD20A4, CBWD6, FOXD4L6, LOC100133920, LOC440896, PGM5P2 
chr9 68285054 69248021 962,968 Deletion Control ANKRD20A4, CBWD6, FOXD4L6, LOC100133920, LOC440896, PGM5P2 
chr9 68312776 69256653 943,878 Deletion Control ANKRD20A4, CBWD6, FOXD4L6, LOC100133920, LOC440896, PGM5P2 
chr9 68352250 68857687 505,438 Duplication Case ANKRD20A4, CBWD6, FOXD4L6, LOC440896, PGM5P2 
chr9 68352250 69220052 867,803 Deletion Control ANKRD20A4, CBWD6, FOXD4L6, LOC100133920, LOC440896, PGM5P2 
chr10 45905767 47241036 1,335,270 Duplication Control 
AGAP9, ANTXRL, ANXA8, ANXA8L1, ANXA8L2, BMS1P1, BMS1P5, FAM25B, 
FAM25C, FAM25G, FAM35B, FAM35B2, FRMPD2P1, GPRIN2, LOC642826, 
LOC643650, LOC728643, PPYR1, PTPN20A, PTPN20B, SYT15 
chr10 45905767 47433407 1,527,641 Duplication Case 
AGAP9, ANTXRL, ANXA8, ANXA8L1, ANXA8L2, BMS1P1, BMS1P5, FAM21B, 
FAM25B, FAM25C, FAM25G, FAM35B, FAM35B2, FRMPD2P1, GPRIN2, 
LOC642826, LOC643650, LOC728643, PPYR1, PTPN20A, PTPN20B, SYT15 
chr10 46094186 47063139 968,954 Duplication Case 
AGAP9, ANXA8, ANXA8L1, BMS1P1, BMS1P5, FAM25B, FAM25C, FAM25G, 
FAM35B, FAM35B2, FRMPD2P1, GPRIN2, LOC642826, LOC643650, 
LOC728643, PPYR1, SYT15 
chr10 46094186 47067933 973,748 Duplication Case 
AGAP9, ANXA8, ANXA8L1, BMS1P1, BMS1P5, FAM25B, FAM25C, FAM25G, 
FAM35B, FAM35B2, FRMPD2P1, GPRIN2, LOC642826, LOC643650, 
Appendix A: Supplementary Tables 
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LOC728643, PPYR1, SYT15 
chr10 46094186 47174643 1,080,458 Duplication Case 
AGAP9, ANTXRL, ANXA8, ANXA8L1, BMS1P1, BMS1P5, FAM25B, FAM25C, 
FAM25G, FAM35B, FAM35B2, FRMPD2P1, GPRIN2, LOC642826, LOC643650, 
LOC728643, PPYR1, SYT15 
chr10 46094186 47174643 1,080,458 Duplication Case 
AGAP9, ANTXRL, ANXA8, ANXA8L1, BMS1P1, BMS1P5, FAM25B, FAM25C, 
FAM25G, FAM35B, FAM35B2, FRMPD2P1, GPRIN2, LOC642826, LOC643650, 
LOC728643, PPYR1, SYT15 
chr10 46337321 46839717 502,397 Duplication Case 
AGAP9, ANXA8, ANXA8L1, FAM25B, FAM25C, FAM25G, FAM35B, FAM35B2, 
GPRIN2, LOC642826, LOC643650, LOC728643, PPYR1, SYT15 
chr10 46337321 47020102 682,782 Deletion Control 
AGAP9, ANXA8, ANXA8L1, FAM25B, FAM25C, FAM25G, FAM35B, FAM35B2, 
GPRIN2, LOC642826, LOC643650, LOC728643, PPYR1, SYT15 
chr10 46337321 47241036 903,716 Duplication Control 
AGAP9, ANTXRL, ANXA8, ANXA8L1, ANXA8L2, FAM25B, FAM25C, FAM25G, 
FAM35B, FAM35B2, GPRIN2, LOC642826, LOC643650, LOC728643, PPYR1, 
SYT15 
chr10 46401209 47132778 731,570 Duplication Control 
AGAP9, ANTXRL, ANXA8, ANXA8L1, FAM25B, FAM25C, FAM25G, FAM35B2, 
GPRIN2, LOC642826, LOC643650, LOC728643, PPYR1 
chr10 46409098 47174643 765,546 Duplication Case 
AGAP9, ANTXRL, ANXA8, ANXA8L1, FAM25B, FAM25C, FAM25G, FAM35B2, 
GPRIN2, LOC642826, LOC643650, LOC728643, PPYR1 
chr10 46478798 47174643 695,846 Duplication Case 
AGAP9, ANTXRL, ANXA8, ANXA8L1, FAM25B, FAM25C, FAM25G, FAM35B2, 
LOC642826, LOC643650, LOC728643, PPYR1 
chr10 46482317 47170483 688,167 Duplication Case 
AGAP9, ANTXRL, ANXA8, ANXA8L1, FAM25B, FAM25C, FAM25G, FAM35B2, 
LOC642826, LOC643650, LOC728643, PPYR1 
chr10 46482317 47174643 692,327 Duplication Case 
AGAP9, ANTXRL, ANXA8, ANXA8L1, FAM25B, FAM25C, FAM25G, FAM35B2, 
LOC642826, LOC643650, LOC728643, PPYR1 
chr10 46482317 47174643 692,327 Duplication Case 
AGAP9, ANTXRL, ANXA8, ANXA8L1, FAM25B, FAM25C, FAM25G, FAM35B2, 
LOC642826, LOC643650, LOC728643, PPYR1 
chr10 46482317 47241036 758,720 Duplication Case 
AGAP9, ANTXRL, ANXA8, ANXA8L1, ANXA8L2, FAM25B, FAM25C, FAM25G, 
FAM35B2, LOC642826, LOC643650, LOC728643, PPYR1 
Appendix A: Supplementary Tables 
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chr13 93319769 93892399 572,631 Duplication Control DCT, GPC6 
chr14 18521076 19493212 972,137 Duplication Case OR11H2, OR4K1, OR4K2, OR4K5, OR4M1, OR4N2, OR4Q3, POTEG, POTEM 
chr14 18611714 19213349 601,636 Deletion Case POTEG, POTEM 
chr14 18611714 19227683 615,970 Deletion Case POTEG, POTEM 
chr14 18670435 19329803 659,369 Deletion Case OR11H2, OR4M1, OR4Q3, POTEM 
chr14 18842018 19439731 597,714 Duplication Case OR11H2, OR4K2, OR4M1, OR4N2, OR4Q3, POTEM 
chr14 18842018 19439731 597,714 Duplication Case OR11H2, OR4K2, OR4M1, OR4N2, OR4Q3, POTEM 
chr14 18914107 19490079 575,973 Deletion Case OR11H2, OR4K1, OR4K2, OR4K5, OR4M1, OR4N2, OR4Q3, POTEM 
chr15 18276341 19566875 1,290,535 Duplication Control 
CHEK2P2, CXADRP2, GOLGA6L6, GOLGA8C, HERC2P3, LOC348120, 
LOC646214, NBEAP1, NF1P2, POTEB 
chr15 18276341 19566875 1,290,535 Duplication Control 
CHEK2P2, CXADRP2, GOLGA6L6, GOLGA8C, HERC2P3, LOC348120, 
LOC646214, NBEAP1, NF1P2, POTEB 
chr15 18476969 20089383 1,612,415 Duplication Case 
CHEK2P2, CXADRP2, GOLGA6L6, GOLGA8C, HERC2P3, LOC348120, 
LOC646214, LOC727924, NBEAP1, NF1P2, OR4M2, OR4N3P, OR4N4, POTEB, 
REREP3 
chr15 18491920 20232614 1,740,695 Duplication Case 
CHEK2P2, CXADRP2, GOLGA6L6, GOLGA8C, HERC2P3, LOC348120, 
LOC646214, LOC727924, MIR4509-1, MIR4509-2, MIR4509-3, NBEAP1, NF1P2, 
OR4M2, OR4N3P, OR4N4, POTEB, REREP3 
chr15 18491920 21038987 2,547,068 Duplication Case 
CHEK2P2, CXADRP2, CYFIP1, GOLGA6L1, GOLGA6L6, GOLGA8C, 
GOLGA8DP, GOLGA8E, GOLGA8IP, HERC2P2, HERC2P3, HERC2P7, 
LOC283683, LOC348120, LOC646214, LOC727924, MIR4509-1, MIR4509-2, 
MIR4509-3, NBEAP1, NF1P2, NIPA1, NIPA2, OR4M2, OR4N3P, OR4N4, 
POTEB, REREP3, TUBGCP5, WHAMMP3 
chr15 18506386 19462019 955,634 Duplication Case 
CHEK2P2, CXADRP2, GOLGA6L6, GOLGA8C, HERC2P3, LOC348120, 
LOC646214, NBEAP1, NF1P2, POTEB 
Appendix A: Supplementary Tables 
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chr15 18506386 20232614 1,726,229 Duplication Case 
CHEK2P2, CXADRP2, GOLGA6L6, GOLGA8C, HERC2P3, LOC348120, 
LOC646214, LOC727924, MIR4509-1, MIR4509-2, MIR4509-3, NBEAP1, NF1P2, 
OR4M2, OR4N3P, OR4N4, POTEB, REREP3 
chr15 18522250 20089383 1,567,134 Duplication Case 
CHEK2P2, CXADRP2, GOLGA6L6, GOLGA8C, HERC2P3, LOC348120, 
LOC646214, LOC727924, NBEAP1, NF1P2, OR4M2, OR4N3P, OR4N4, POTEB, 
REREP3 
chr15 18652835 19406927 754,093 Duplication Case 
CHEK2P2, CXADRP2, GOLGA6L6 ,GOLGA8C, HERC2P3, LOC646214, 
NBEAP1, NF1P2, POTEB 
chr15 18652835 19566875 914,041 Duplication Case 
CHEK2P2, CXADRP2, GOLGA6L6, GOLGA8C, HERC2P3, LOC348120, 
LOC646214, NBEAP1, NF1P2, POTEB 
chr15 18652835 19835526 1,182,692 Deletion Control 
CHEK2P2, CXADRP2, GOLGA6L6, GOLGA8C, HERC2P3, LOC348120, 
LOC646214, LOC727924, NBEAP1, NF1P2, POTEB 
chr15 18652835 20089383 1,436,549 Duplication Case 
CHEK2P2, CXADRP2, GOLGA6L6, GOLGA8C, HERC2P3, LOC348120, 
LOC646214, LOC727924, NBEAP1, NF1P2, OR4M2, OR4N3P, OR4N4, POTEB, 
REREP3 
chr15 18652835 20089383 1,436,549 Duplication Case 
CHEK2P2, CXADRP2, GOLGA6L6, GOLGA8C, HERC2P3, LOC348120, 
LOC646214, LOC727924, NBEAP1, NF1P2, OR4M2, OR4N3P, OR4N4, POTEB, 
REREP3 
chr15 18652835 20089383 1,436,549 Duplication Case 
CHEK2P2, CXADRP2, GOLGA6L6, GOLGA8C, HERC2P3, LOC348120, 
LOC646214, LOC727924, NBEAP1, NF1P2, OR4M2, OR4N3P, OR4N4, POTEB, 
REREP3 
chr15 18652835 20232614 1,579,780 Duplication Case 
CHEK2P2, CXADRP2, GOLGA6L6, GOLGA8C, HERC2P3, LOC348120, 
LOC646214, LOC727924, MIR4509-1, MIR4509-2, MIR4509-3, NBEAP1, NF1P2, 
OR4M2, OR4N3P, OR4N4, POTEB, REREP3 
chr15 18700552 20089383 1,388,832 Duplication Case 
CHEK2P2, CXADRP2, GOLGA6L6, GOLGA8C, HERC2P3, LOC348120, 
LOC646214, LOC727924, NBEAP1, NF1P2, OR4M2, OR4N3P, OR4N4, POTEB, 
REREP3 
chr15 18700552 20089383 1,388,832 Duplication Case CHEK2P2, CXADRP2, GOLGA6L6, GOLGA8C, HERC2P3, LOC348120, 
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LOC646214, LOC727924, NBEAP1, NF1P2, OR4M2, OR4N3P, OR4N4, POTEB, 
REREP3 
chr15 18700552 20089383 1,388,832 Duplication Case 
CHEK2P2, CXADRP2, GOLGA6L6, GOLGA8C, HERC2P3, LOC348120, 
LOC646214, LOC727924, NBEAP1, NF1P2, OR4M2, OR4N3P, OR4N4, POTEB, 
REREP3 
chr15 18700552 20089383 1,388,832 Duplication Case 
CHEK2P2, CXADRP2, GOLGA6L6, GOLGA8C, HERC2P3, LOC348120, 
LOC646214, LOC727924, NBEAP1, NF1P2, OR4M2, OR4N3P, OR4N4, POTEB, 
REREP3 
chr15 18706152 20089383 1,383,232 Deletion Case 
CHEK2P2, CXADRP2, GOLGA6L6, GOLGA8C, HERC2P3, LOC348120, 
LOC646214, LOC727924, NBEAP1, NF1P2, OR4M2, OR4N3P, OR4N4, POTEB, 
REREP3 
chr15 18728578 19931449 1,202,872 Duplication Case 
CHEK2P2, CXADRP2, GOLGA6L6, GOLGA8C, HERC2P3, LOC348120, 
LOC646214, LOC727924, NBEAP1, NF1P2, OR4M2, OR4N3P, OR4N4, POTEB 
chr15 18728578 20089383 1,360,806 Deletion Control 
CHEK2P2, CXADRP2, GOLGA6L6, GOLGA8C, HERC2P3, LOC348120, 
LOC646214, LOC727924, NBEAP1, NF1P2, OR4M2, OR4N3P, OR4N4, POTEB, 
REREP3 
chr15 18824589 19422452 597,864 Duplication Case 
CXADRP2, GOLGA6L6, GOLGA8C, HERC2P3, LOC348120, LOC646214, 
NBEAP1, NF1P2, POTEB 
chr15 18824589 19566875 742,287 Deletion Control 
CXADRP2, GOLGA6L6, GOLGA8C, HERC2P3, LOC348120, LOC646214, 
NBEAP1, NF1P2, POTEB 
chr15 18850041 20089383 1,239,343 Duplication Case 
CXADRP2, GOLGA6L6, GOLGA8C, HERC2P3, LOC348120, LOC646214, 
LOC727924, NBEAP1, NF1P2, OR4M2, OR4N3P, OR4N4, POTEB, REREP3 
chr15 18861568 20089383 1,227,816 Duplication Case 
CXADRP2, GOLGA6L6, GOLGA8C, HERC2P3, LOC348120, LOC646214, 
LOC727924, NBEAP1, NF1P2, OR4M2, OR4N3P, OR4N4, POTEB, REREP3 
chr15 18977400 19548935 571,536 Duplication Control 
CXADRP2, GOLGA6L6, GOLGA8C, LOC348120, LOC646214, NBEAP1, NF1P2, 
POTEB 
chr15 19055354 19566875 511,522 Deletion Case CXADRP2, LOC348120, LOC646214, NBEAP1, NF1P2, POTEB 
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chr15 19090388 19951021 860,634 Deletion Control 
CXADRP2, LOC348120, LOC646214, LOC727924, NBEAP1, NF1P2, OR4M2, 
OR4N3P, OR4N4, POTEB 
chr15 19334428 20089383 754,956 Duplication Case LOC348120, LOC727924, NF1P2, OR4M2, OR4N3P, OR4N4, POTEB, REREP3 
chr15 19406842 20089383 682,542 Duplication Control LOC348120, LOC727924, OR4M2, OR4N3P, OR4N4, REREP3 
chr15 19412503 20051723 639,221 Duplication Control LOC348120, LOC727924, OR4M2, OR4N3P, OR4N4, REREP3 
chr15 19412503 20089383 676,881 Deletion Case LOC348120, LOC727924, OR4M2, OR4N3P, OR4N4, REREP3 
chr15 19412503 20089383 676,881 Duplication Control LOC348120, LOC727924, OR4M2, OR4N3P, OR4N4, REREP3 
chr15 19412503 20089383 676,881 Duplication Control LOC348120, LOC727924, OR4M2, OR4N3P, OR4N4, REREP3 
chr15 19412503 21038987 1,626,485 Duplication Control 
CYFIP1, GOLGA6L1, GOLGA8DP, GOLGA8E, GOLGA8IP, HERC2P2, 
HERC2P7, LOC283683, LOC348120, LOC727924, MIR4509-1, MIR4509-2, 
MIR4509-3, NIPA1, NIPA2, OR4M2, OR4N3P, OR4N4, REREP3, TUBGCP5, 
WHAMMP3 
chr15 19414814 20089383 674,570 Duplication Control LOC348120, LOC727924, OR4M2, OR4N3P, OR4N4, REREP3 
chr15 19523446 20089383 565,938 Deletion Case LOC727924, OR4M2, OR4N3P, OR4N4, REREP3 
chr15 19523446 20089383 565,938 Deletion Case LOC727924, OR4M2, OR4N3P, OR4N4, REREP3 
chr15 19548935 20232614 683,680 Duplication Case 
LOC727924, MIR4509-1, MIR4509-2, MIR4509-3, OR4M2, OR4N3P, OR4N4, 
REREP3 
chr15 20224763 20852214 627,452 Deletion Control 
CYFIP1, GOLGA6L1, GOLGA8DP, GOLGA8IP, HERC2P2, LOC283683, 
MIR4509-1, MIR4509-2, MIR4509-3, NIPA1, NIPA2, TUBGCP5, WHAMMP3 
chr15 30557401 32459378 1,901,978 Duplication Case 
ARHGAP11A, AVEN, C15orf24, C15orf29, C15orf55, CHRM5, FMN1, GOLGA8A, 
GREM1, LOC100288615, LPCAT4, NOP10, PGBD4, RYR3, SCG5, SLC12A6, 
TMCO5B, TMEM85 
chr16 15389435 18221734 2,832,300 Duplication Case 
ABCC1, ABCC6, C16orf45, FOPNL, KIAA0430, MIR3179-1, MIR3179-2, 
MIR3179-3, MIR3180-1, MIR3180-2, MIR3180-3, MIR484, MPV17L, MYH11, 
NDE1, NOMO3, PKD1P1, XYLT1 
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chr16 29474810 30134444 659,635 Deletion Case 
ALDOA, ASPHD1, BOLA2, BOLA2B, C16orf53, C16orf54, C16orf92, CDIPT, 
CORO1A, DOC2A, FAM57B, GDPD3, HIRIP3, INO80E, KCTD13, KIF22, 
LOC388242, LOC440354, LOC440356, LOC606724, LOC613038, MAPK3, MAZ, 
MVP, PPP4C, PRRT2, QPRT, SEZ6L2, SLC7A5P1, SLX1A, SLX1A-SULT1A3, 
SLX1B, SLX1B-SULT1A4, SPN,SULT1A3, SULT1A4, TAOK2, TBX6, TMEM219, 
YPEL3, ZG16 
chr16 31882199 33588602 1,706,404 Duplication Case 
HERC2P4, LOC390705, LOC729264, SLC6A10P, TP53TG3, TP53TG3B, 
TP53TG3C 
chr16 31901431 32823606 922,176 Deletion Case 
HERC2P4, LOC390705, LOC729264, SLC6A10P, TP53TG3, TP53TG3B, 
TP53TG3C 
chr16 32021183 33149454 1,128,272 Deletion Case 
HERC2P4, LOC390705, LOC729264, SLC6A10P, TP53TG3, TP53TG3B, 
TP53TG3C 
chr16 32136481 33517284 1,380,804 Duplication Case LOC390705, LOC729264, SLC6A10P, TP53TG3, TP53TG3B, TP53TG3C 
chr16 32136481 33683586 1,547,106 Duplication Case LOC390705, LOC729264, SLC6A10P, TP53TG3, TP53TG3B, TP53TG3C 
chr16 32151974 33588602 1,436,629 Duplication Case LOC390705, LOC729264, SLC6A10P, TP53TG3, TP53TG3B, TP53TG3C 
chr16 32302430 33009105 706,676 Deletion Case SLC6A10P, TP53TG3, TP53TG3B, TP53TG3C 
chr16 32365901 33562041 1,196,141 Duplication Case LOC390705, SLC6A10P, TP53TG3, TP53TG3B, TP53TG3C 
chr16 32461678 33683586 1,221,909 Duplication Case LOC390705, SLC6A10P, TP53TG3, TP53TG3B, TP53TG3C 
chr16 32746359 33618281 871,923 Deletion Control LOC390705, SLC6A10P, TP53TG3, TP53TG3B, TP53TG3C 
chr17 28984749 29936217 951,469 Duplication Control ACCN1, C17orf102, CCL1, CCL11, CCL13, CCL2, CCL7, CCL8, TMEM132E 
chr17 41536766 42107479 570,714 Duplication Case ARL17A, ARL17B, KANSL1, KANSL1-AS1, LRRC37A, LRRC37A2, NSF, NSFP1 
chr18 14887155 15392408 505,254 Duplication Control LOC644669 
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Figure B1: Homozygosity mapping for Family 1, chromosome 1 using autoSNP and 
PLINK 
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Figure B2: Homozygosity mapping for Family 1, chromosome 11 using autoSNP and 
PLINK 
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Figure B3: Homozygosity mapping for Family 1, chromosome 17 using autoSNP and 
PLINK 
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Figure B4: Homozygosity mapping for Family 2, chromosome 10 using autoSNP and 
PLINK 
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Figure B5: Homozygosity mapping for Family 4, chromosome 2 using autoSNP and 
PLINK 
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Figure B6: Homozygosity mapping for Family 4, chromosome 7 using autoSNP and 
PLINK 
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Figure B7: Homozygosity mapping for Family 5, chromosome 3 using autoSNP and 
PLINK 
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Figure B8: Homozygosity mapping for Family 7, chromosome 3 using autoSNP and 
PLINK 
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Figure B9: Homozygosity mapping for Family 7, chromosome 15 using autoSNP and 
PLINK 
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Clinical details of Patient for array CGH Obesity 
Project 
 
Form number       
Patient 
code…………
…… 
Patient name 
     Date of Birth 
     Pedigree number 
     
Patient number 
   
Consultant…
……………… 
Age at assessment 
     Ethnicity 
     Most Impo to collect : Birth weight, Gestation /postnatal feeding porblems, Age of onset of hyperphagie & clinical 
pictures if present  
 General 
     
Obesity 
>97%centile     yes     no   
……………………………. 
 
 
age of onset of 
obesity……………………… 
Current 
weight...……
…….. 
 
birth weight (include 
%centile)……………………………………… 
Gestation………………………………………………………………………… 
  Feeding…………………………………………………………………………… 
  Tone………………………………………………………………………………. 
  
Developmental delay yes no 
……………………
……………….. 
 
Behavioural problems yes no 
……………………
……………….. 
 
Mental retardation /learning yes no 
……………………
……………….. 
                           difficulties mild moderate severe  
  
      
Height (include %centile) 
………………………..……………………
……………….. 
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OFC,%centile 
………………………………………………
…………….. 
 
Pubertal development normal abnormal 
……………………
……………….. 
 
      Craniofacial 
     
Head shape normal abnormal 
……………………
……………….. 
 
      Eyes 
     
position abnormality yes no 
……………………
……………….. 
 
Shape abnormality yes no 
……………………
……………….. 
 
Congenital abnormality yes no 
……………………
……………….. 
 
Other / eye sight problems 
  
……………………
……………….. 
 
      Nose 
     
Shape abnomality yes no 
……………………
……………….. 
 
      Mouth abnormality yes no 
   
Abnormal palate yes no 
……………………
……………….. 
 
Mandibular abnormality yes no 
……………………
……………….. 
 
Dental abnormaities yes no 
……………………
……………….. 
 Upper resp. tract  
     
abnormality yes no 
……………………
……………….. 
 
Other 
  
……………………
……………….. 
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Ears abnormality yes no 
   
Shape abnormality yes no 
……………………
……………….. 
 
hearing yes no 
……………………
……………….. 
 Other 
     
      Heart 
     
abnormalities yes no 
……………………
……………….. 
 
      
      Urogenital 
     
Renal abnormalities yes no 
……………………
……………….. 
 
External genitial abnormalites yes no 
……………………
……………….. 
 
Internal genital abnormalities yes no 
……………………
……………….. 
 Other  
     
      Gastrointestinal abnormality yes no 
   
Omphalocele yes no 
……………………
……………….. 
 
Anal atresia yes no 
……………………
……………….. 
 
Other  
  
……………………
……………….. 
 
      Skeletal abnormality yes no 
   
Arthritis yes no 
……………………
……………….. 
 
Arthrogryposis yes no 
……………………
……………….. 
 
Vertebral Abnormality yes no 
……………………
……………….. 
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Abnormal thorax yes no 
……………………
……………….. 
 
Limb defects yes no 
……………………
……………….. 
 
Other 
  
……………………
……………….. 
 
      Skin abnormality yes no 
   Eczema yes no 
   Lymph oedema yes no 
   Cutis laxa yes no 
   Hair abnormalties yes no 
   
Abnormal pigmentation yes no 
……………………
……………….. 
 
Other 
  
……………………
……………….. 
 
      Endocrine / haematology 
     Endrocrine abnormality yes no …………………………… 
Metabolic abnormality yes no …………………………… 
Blood abnormality yes no 
……………………
……………….. 
 
Immune system abnormality yes no 
……………………
……………….. 
 Other 
     
      
Family History yes no 
……………………
……………….. 
 
Obesity yes no 
……………………
……………….. 
 
Mental retardation yes no 
……………………
……………….. 
 
Congenital abnormalities yes no 
……………………
……………….. 
 Recurrent miscarriage yes no ……………………
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……………….. 
Consanguinity yes no 
……………………
……………….. 
 Other  
     
      Possible diagnosis 
     
      
Tests undertaken yes no 
test method / 
result 
  Fra(X) -  
     PWS 
     karyotype 
     telomere studies 
     FISH 22q 
     Smith Magenis Syndrome 
     Other tests eg scans, imaging 
     
      Other relevant details 
      bone age 
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Appendix: summary of permission for third party copyright works  
Please read the e-theses advice and guidance web pages, especially the section on clearing third party copyright works and  complete the 
table below for all third party copyright works not covered by the fair dealing exception of criticism and review. 
Where you have ticked: 
 Permission to reuse - make sure you include proof of permission in this appendix  
 Permission requested - make sure you include a copy of the request letter or email  
 Orphan work - you include evidence that you have tried to locate the author 
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